<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k_030816p.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
     <TITLE></TITLE>
</HEAD><BODY STYLE="font: 10pt Times New Roman, Times, Serif">





<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: #7F0000 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->
<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>
<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: #7F0000 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->


<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>UNITED STATES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Washington, D.C. 20549</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>FORM 10-K</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>(Mark One)</b></font></td>
    <td style="width: 91%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><font style="font-family: Wingdings; font-size: 10pt">x</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><font style="font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934</b></font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-align: center; text-indent: -19.8pt; margin: 0pt 0"><b>For the fiscal year ended December&nbsp;31,
        2015</b></p>
        <p style="font-size: 10pt; text-align: center; text-indent: -19.8pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><font style="font-family: Wingdings; font-size: 10pt">o</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><font style="font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15 (d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934</b></font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Commission File Number&nbsp;000-21326</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Anika Therapeutics,&nbsp;Inc.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><i>(Exact Name of Registrant as Specified in Its Charter)</i></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-align: center; text-indent: -19.8pt; margin: 0pt 0"><b>Massachusetts</b></p>
        <p style="font-size: 10pt; text-align: center; text-indent: -19.8pt; margin: 0pt 0"><i>(State or Other Jurisdiction of
Incorporation or Organization)</i></p></td>
    <td style="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>04-3145961</b></p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0"><i>(IRS Employer Identification No.)</i></p></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>32 Wiggins Avenue, Bedford, Massachusetts 01730</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><i>(Address of Principal Executive Offices) (Zip Code)</i></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(781)&nbsp;457-9000</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><i>(Registrant&#8217;s Telephone Number, Including Area Code)</i></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Securities registered pursuant to Section&nbsp;12(b) of the Act:</b>
Common stock, par value $.01 per share</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">Preferred Stock Purchase Rights</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Name of Each Exchange on Which Registered:</b> NASDAQ Global Select
Market</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Securities registered pursuant to Section&nbsp;12(g) of the Act:</b>
None</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule&nbsp;405 of the Securities Act.&nbsp;Yes&nbsp;<font style="font-family: Wingdings"> o</font> &nbsp;No&nbsp;<font style="font-family: Wingdings">
x</font></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">Indicate by check mark if the registrant is not required to file
reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;Yes&nbsp;<font style="font-family: Wingdings"> o</font>
&nbsp;No&nbsp;<font style="font-family: Wingdings"> x</font></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0pt 0">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15 (d)&nbsp;of the Securities Exchange Act of 1934 during
the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has
been subject to such filing requirements for the past 90&nbsp;days.&nbsp;Yes&nbsp;<font style="font-family: Wingdings"> x</font>
&nbsp;No&nbsp;<font style="font-family: Wingdings"> o</font></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0pt 0">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). Yes&nbsp;<font style="font-family: Wingdings">
x</font> &nbsp;No&nbsp;<font style="font-family: Wingdings"> o</font></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0pt 0">Indicate by check mark if disclosure of delinquent
filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s
knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this Form&nbsp;10-K or any
amendment to this Form&nbsp;10-K.&nbsp;<font style="font-family: Wingdings"> x</font></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0pt 0">&nbsp;</p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: #7F0000 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; text-align: center; text-indent: 0.55in; margin: 0pt 0">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&nbsp;12b-2
of the Exchange Act. (Check one)</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><font style="font-size: 10pt">Large accelerated filer&nbsp;<font style="font-family: Wingdings">o</font></font></td>
    <td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><font style="font-size: 10pt">Accelerated filer&nbsp;<font style="font-family: Wingdings">x</font></font></td>
    <td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0">Non-accelerated filer&nbsp;<font style="font-family: Wingdings">o</font></p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0">(Do not check if a smaller&nbsp;</p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0">reporting company)&nbsp;</p></td>
    <td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><font style="font-size: 10pt">Smaller reporting company&nbsp;<font style="font-family: Wingdings">o</font></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.55in; margin: 0pt 0">Indicate by check mark whether the registrant
is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act). Yes<font style="font-family: Wingdings"> o</font> No<font style="font-family: Wingdings">
x</font></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.55in; margin: 0pt 0">The aggregate market value of voting and
non-voting equity held by non-affiliates of the Registrant (without admitting that any person whose shares are not included
in such calculation is an affiliate) as of June&nbsp;30, 2015, the last day of the Registrant&#8217;s most recently completed
second fiscal quarter, was $483,203,467 based on the close price per share of common stock of $33.03 as of such date as
reported on the NASDAQ Global Select Market. At March&nbsp;4, 2016, there were issued and outstanding 14,330,207 shares of
common stock, par value $.01 per share.</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Documents Incorporated By Reference</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.55in; margin: 0pt 0">The registrant intends to file&nbsp;a proxy
statement pursuant to Regulation&nbsp;14A within 120&nbsp;days of the end of the fiscal year ended December&nbsp;31, 2015. Portions
of such proxy statement are incorporated by reference into Part&nbsp;III of this Annual Report on Form&nbsp;10-K.</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: #7F0000 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>ANIKA THERAPEUTICS,&nbsp;INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>TABLE OF CONTENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>Page</b></td></tr>
<tr style="vertical-align: top">
    <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="width: 78%"><a href="#cautionary">Cautionary Note
                                         Regarding Forward-Looking Statements</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 7%"><a href="#cautionary">

        3</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#p1">Part&nbsp;I</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i1">Item&nbsp;1.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i1"><font style="font-size: 10pt">Business</font></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i1">5</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i1a">Item&nbsp;1A.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i1a">Risk Factors</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i1a">12</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i1b">Item&nbsp;1B.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i1b">Unresolved Staff Comments</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i1b">23</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i2">Item&nbsp;2.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i2">Properties</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i2">23</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i3">Item&nbsp;3.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i3">Legal Proceedings</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i3">23</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i4">Item&nbsp;4.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i4">Mine Safety Disclosures</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i4">24</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#p2">Part&nbsp;II</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i5">Item&nbsp;5.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i5">Market for Registrant&#8217;s Common Equity,
    Related Stockholder Matters and Issuer Purchases of Equity Securities</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i5">24</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i6">Item&nbsp;6.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i6">Selected Financial Data</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i6">26</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i7">Item&nbsp;7.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i7">Management&#8217;s Discussion and Analysis
    of Financial Condition and Results of Operations</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i7">26</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i7a">Item&nbsp;7A.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i7a">Quantitative and Qualitative Disclosures
    About Market Risk</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i7a">39</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i8">Item&nbsp;8.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i8">Financial Statements and Supplementary Data</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i8">40</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i9">Item&nbsp;9.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i9">Changes in and Disagreements with Accountants
    on Accounting and Financial Disclosure</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i9">65</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i9a">Item&nbsp;9A.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i9a">Controls and Procedures</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i9a">65</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i9b">Item&nbsp;9B.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i9b">Other Information</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i9b">65</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#p3">Part&nbsp;III</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i10">Item&nbsp;10.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i10">Directors, Executive Officers and Corporate
    Governance</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i10">66</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i11">Item&nbsp;11.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i11">Executive Compensation</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i11">66</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i12">Item&nbsp;12.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i12">Security Ownership of Certain Beneficial
    Owners and Management and Related Stockholder Matters</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i12">66</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i13">Item&nbsp;13.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i13">Certain Relationships and Related Transactions,
    and Director Independence</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i13">66</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i14">Item&nbsp;14.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i14">Principal Accounting Fees and Services</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i14">66</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#p4">Part&nbsp;IV</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; margin: 0pt 0; padding-left: 10pt"><a href="#i15">Item&nbsp;15.</a></td>
    <td style="font-size: 10pt; margin: 0pt 0"><a href="#i15">Exhibits and Financial Statement Schedules</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#i15">66</a></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt; margin: 0pt 0"><a href="#sign">Signatures</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="#sign">70</a></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">References in this Annual Report on Form 10-K to &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; and other similar references refer to Anika Therapeutics, Inc.
and its subsidiaries unless the context otherwise indicates.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">ANIKA, ANIKA THERAPEUTICS, ANIKAVISC, CINGAL, HYAFF, HYDRELLE, HYVISC,
INCERT, MONOVISC, and ORTHOVISC are our registered trademarks, and HYALOSS, OPTIVISC, and SHELLGEL are our trademarks. This Annual
Report on Form 10-K also contains registered marks, trademarks, and trade names that are the property of other companies and licensed
to us.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>FORM 10-K</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>ANIKA THERAPEUTICS,&nbsp;INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>For Fiscal Year Ended December&nbsp;31, 2015</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="cautionary"></a><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>This Annual Report on Form&nbsp;10-K, including the documents
incorporated by reference into this Annual Report on Form&nbsp;10-K, contains forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934, including, without
limitation, statements regarding:</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our future sales and product revenue, including geographic expansions, possible retroactive price adjustments, and expectations
of unit volumes or other offsets to price reductions;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our manufacturing capacity, efficiency gains, and  manufacturing operations;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The timing, scope, and rate of patient enrollment for clinical trials;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The development of possible line extensions and new products;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our ability to achieve and/or maintain compliance with laws and regulations;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The timing of and/or receipt of Food and Drug Administration (&#8220;FDA&#8221;), foreign, or other regulatory approvals, clearances,
and/or reimbursement approvals of current, new, or potential products, and any limitations on such approvals;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our intention to seek patent protection for our products and processes, and to protect our intellectual property;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our ability to effectively compete against current and future competitors;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Negotiations with potential and existing partners, including our performance under any of our existing and future distribution,
license, or supply agreements or our expectations with respect to sales and sales threshold milestones pursuant to such agreements;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The level of our revenue or sales in particular geographic areas and/or for particular products, and the market share for any
of our products;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our current strategy, including our corporate objectives, research and development activities, and collaboration activities;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our expectations regarding our orthobiologics products, including expectations related to our existing products, our new products,
including CINGAL, expanded uses of existing products, new distribution and sales models and partnerships, and revenue growth;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our intention to increase our market share for orthobiologics products in international and domestic markets or otherwise penetrate
growing markets for osteoarthritis of the knee and other joints;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our expectations regarding next generation osteoarthritis product development, clinical trials, regulatory approvals,
and commercial launches;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></p>



<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></p>



<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our expectations regarding dermal, surgical, ophthalmic, and veterinary sales;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>





<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our expectations regarding product gross margin;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our expectations regarding CINGAL, including our ability to obtain regulatory approvals and commercialize this product ourselves
in the United States and with distribution partners in other territories;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our expectations regarding HYALOFAST, including the expenses associated therewith, and our ability to obtain regulatory approvals
for the product in the United States and other international markets outside of the European Union;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our expectations for changes in operating expenses, including research and development and selling, general, and administrative
expenses;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The rate at which we use cash, the amounts used and generated by operations, and our expectations regarding the adequacy and
usage of such cash;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our expectation for capital expenditures spending and future amounts of interest income and expense;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Possible negotiations or re-negotiations with existing or new distribution or collaboration partners;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The strength of the economies in which we operate or will operate, as well as the political stability of any of those geographic
areas;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our ability to effectively prioritize the many research and development projects underway;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our ability to obtain U.S. approval for our orthopedic and other product franchises, including the timing and potential success
of such efforts, and to expand sales of these products in the United States, including the impact such efforts may have on our
revenue;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to successfully manage the implementation of our direct sales model for CINGAL, and other future products, in the
United States initially through a contract sales organization, and our ability to successfully transition the direct sales function
into our organization as part of a broader buildout of our commercial capabilities;</TD></TR></TABLE>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our ability to successfully manage the transfer of manufacturing responsibilities related to Anika S.r.l.&#8217;s HYAFF
                                                                                                            products from the current contract manufacturer to Anika&#8217;s Bedford, Massachusetts facility, and our ability to achieve
                                                                                                            planned results from this transfer; and</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our expectations related to, and our ability to manage, the physical move of our Italian subsidiary from its current facility
to its newly-leased facility.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><i>Furthermore, statements identified by words
such as &#8220;will,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221;
&#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;designed,&#8221; &#8220;develop,&#8221; &#8220;would,&#8221; &#8220;future,&#8221;
&#8220;can,&#8221; &#8220;could,&#8221; and other expressions that are predictions of or indicate future events and trends and
which do not relate to historical matters, also identify forward-looking statements.</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Forward-looking statements involve known and unknown risks, uncertainties,
and other factors, some of which are beyond our control, including those factors described in the section titled &#8220;Risk Factors&#8221;
in this Annual Report on Form&nbsp;10-K or elsewhere in this report. These risks, uncertainties, and other factors may cause our
actual results, performance or achievement to be materially different from the anticipated future results, performance, or achievement,
expressed or implied by the forward-looking statements. These forward-looking statements are based upon the current assumptions
of our management and are only expectations of future results. You should carefully review all of these factors, and you should
be aware that there may be other factors that could cause these differences, including those factors discussed in the sections
titled &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
elsewhere in this Annual Report on Form&nbsp;10-K. We undertake no obligation to publicly update or revise any forward-looking
statement to reflect changes in underlying assumptions or factors, new information, future events, or other changes.</i>&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="p1"></a><b>PART I</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i1"></a><b>ITEM 1. BUSINESS</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Overview</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We are a global, integrated orthopedic medicines company committed
to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing innovative and differentiated
therapeutic pain management solutions along the continuum of care, from palliative care to regenerative medicine. We have over
two decades of expertise developing, manufacturing and commercializing more than 20 products, in markets across the globe, based
on our proprietary hyaluronic acid (&#8220;HA&#8221;) technology. Our orthopedic medicine portfolio is comprised of marketed (ORTHOVISC
and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by
replenishing depleted HA and aiding cartilage repair and regeneration.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our therapeutic offerings consist of products in the following areas:
Orthobiologics, Dermal, Surgical, Ophthalmic, and Veterinary. All of our products are based on HA, a naturally occurring, biocompatible
polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number
of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural
integrity of tissues, and the transport of molecules to and within cells.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our proprietary technologies for modifying the HA molecule allow
product properties to be tailored specifically to therapeutic use. Our patented technology chemically modifies HA to allow for
longer residence time in the body. We also offer products made from HA based on two other technologies: HYAFF, which is a solid
form of HA, and ACP gel, an autocross-linked polymer of HA.&nbsp;Our technologies are protected by an extensive portfolio of owned
and licensed patents.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Since our inception in 1992, we have utilized a commercial partnership model for the distribution of our products
to end users. Our strong, worldwide network of distributors has historically provided, and continues to provide, a solid foundation
for our revenue growth and territorial expansion. In 2015, we made the strategic decision to commercialize our next generation
viscosupplementation product, CINGAL, in the United States by utilizing a direct sales model, initially through the engagement
of a contract sales organization. Ultimately, we intend to transition the direct sales function into our company as part of a broader
buildout of our commercial capabilities. We believe that the combination of the direct and distribution commercial models will
maximize the revenue potential from our current and future product portfolio.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We began a strategic project in 2015 to move the manufacturing of
our HYAFF-based products, which currently are manufactured by a third party in Italy, to our Bedford, Massachusetts facility. Our
main purposes behind this strategic move are to improve the efficiency of our manufacturing process and to enhance our research
and development capabilities, with the aim of accelerating future product development. We expect to expend approximately $15 million
on this project over the course of the next 12 to 18 months.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following sections provide more specific information about our
products and related activities:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Orthobiologics</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our orthobiologics products primarily consist of viscosupplementation
and regenerative orthopedics products. These products are used in a wide range of treatments, from providing pain relief from osteoarthritis,
to regenerating damaged tissue such as cartilage. Osteoarthritis is a debilitating disease causing pain, swelling, and restricted
movement in joints. It occurs when the cartilage in a joint gradually deteriorates due to the effects of mechanical stress, which
can be caused by a variety of factors, including the normal aging process. In an osteoarthritic joint, particular regions of articulating
surfaces are exposed to irregular forces, which results in the remodeling of tissue surfaces that disrupt the normal equilibrium
or mechanical function. As osteoarthritis advances, the joint gradually loses its ability to regenerate cartilage tissue, and the
cartilage layer attached to the bone deteriorates to the point where eventually the bone becomes exposed. Advanced osteoarthritis
often requires surgery and the possible implantation of artificial joints. The current treatment options for osteoarthritis, before
joint replacement surgery, include viscosupplementation, analgesics, non-steroidal anti-inflammatory drugs, and steroid injections.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our viscosupplementation franchise includes ORTHOVISC, ORTHOVISC<i>
mini</i>, MONOVISC, and CINGAL. ORTHOVISC is available in the United States, Canada, and other international markets for the treatment
of osteoarthritis of the knee, and in Europe and certain international markets for the treatment of osteoarthritis in all joints.
In the U.S. market, ORTHOVISC is the lead product in the multi-injection segment, and the number two viscosupplementation product
overall. ORTHOVISC<i> mini</i> is available in Europe, and it is designed for the treatment of osteoarthritis in small joints.
MONOVISC is our single injection osteoarthritis treatment indicated for all joints in Europe and certain international markets,
and for the knee in the United States, Turkey, and Canada. ORTHOVISC has been marketed by us internationally since 1996. ORTHOVISC<i>
mini</i> and MONOVISC became available in certain international markets in the second quarter of 2008. MONOVISC was approved by
the FDA for sale in the United States in February 2014, and the related U.S. commercial introduction of the product occurred in
April 2014. CINGAL, our second single-injection osteoarthritis product, received regulatory approval from Health Canada in November
2015, and we expect the related commercial introduction of CINGAL in Canada to occur in the second quarter of 2016. We are currently
seeking regulatory approval of CINGAL in the United States and the European Union. Upon achievement, if any, of such regulatory
approval in the United States, we plan to commercialize the product through a direct sales model, initially through the engagement
of a contract sales organization, with the ultimate goal of transitioning the direct sales function into our company as part of
a broader buildout of our commercial capabilities.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In the United States, ORTHOVISC is indicated for the treatment of
pain caused by osteoarthritis of the knee in patients who have failed to respond adequately to conservative, non-pharmacologic
therapy and to simple analgesics, such as acetaminophen. ORTHOVISC is a sterile, clear, viscous solution of hyaluronan dissolved
in physiological saline and dispensed in a single-use syringe. A complex sugar of the glycosaminoglycan family, hyaluronan is a
high molecular weight polysaccharide composed of repeating disaccharide units of sodium glucuronate and N-acetyl glucosamine. ORTHOVISC
is injected into joints in a series of three intra-articular injections one week apart. ORTHOVISC became available for sale in
the United States on March&nbsp;1, 2004, and it is marketed by DePuy Synthes Mitek Sports Medicine (&#8220;Mitek&#8221;) under
the terms of a ten-year licensing, distribution, supply, and marketing agreement which was entered into in December 2003 and was
extended for an additional 5 years in November 2012 (the &#8220;Mitek ORTHOVISC Agreement&#8221;). Outside of the U.S., we have
a number of distribution relationships servicing international markets including Canada, Europe, the Middle East, Latin America,
and Asia. We will continue to seek to establish distribution relationships in other key markets. See the sections captioned &#8220;<i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8212;Management Overview</i>&#8221; and &#8220;<i>Risk
Factors.</i>&#8221;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In the United States, MONOVISC is also indicated for the treatment
of pain caused by osteoarthritis of the knee in patients who have failed to respond adequately to conservative, non-pharmacologic
therapy and to simple analgesics, such as acetaminophen. MONOVISC is a sterile, clear, viscous solution of partially cross-linked
sodium hyaluronate in a phosphate buffered saline solution. A treatment of MONOVISC is comprised of one injection of the product
delivered directly into the affected joint. MONOVISC became available for sale in the United States in April 2014, and it is also
marketed by Mitek under the terms of a fifteen-year licensing, distribution, supply, and marketing agreement, which was entered
into on December 21, 2011 (the &#8220;Mitek MONOVISC Agreement&#8221;). Outside of the United States, we have a number of distribution
relationships servicing international markets including Canada, Europe, Latin America, Asia, and certain other international countries.
We continue to seek to establish distribution relationships in other key markets. See the sections captioned &#8220;<i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8212;Management Overview</i>&#8221; and &#8220;<i>Risk
Factors.</i>&#8221;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">In addition to the four viscosupplementation products discussed above,
we also offer several additional products used in connection with orthopedic regenerative medicine.&nbsp;These products are based
on the HYAFF technology and are currently available in Europe, South America, and Asia. They include HYALOFAST, a biodegradable
support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery;
HYALONECT, a woven gauze used as a graft wrap; and HYALOSS<SUP> </SUP> MATRIX, HYAFF fibers used to mix blood/bone grafts to form
a paste for bone regeneration.&nbsp;We also offer HYALOGLIDE, an ACP gel used in tenolysis treatment, with the potential for use
in flexor tendon adhesion prevention and for use in the shoulder for prevention of adhesive capsulitis with additional clinical
data.&nbsp;These products are commercialized through a network of distributors, primarily in Europe, the Middle East, and Korea.
In total, orthobiologics products accounted for 84%, 82%, and 78% of our product revenue in 2015, 2014, and 2013 respectively.&nbsp;</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><i>Dermal</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our dermal products consist of advanced wound care products, based
on the HYAFF technology, and aesthetic dermal fillers, based on our proprietary chemically modified cross-linked HA technology,
BCDI. Products utilizing our HYAFF technology are used for the treatment of skin wounds, ranging from burns to diabetic ulcers.&nbsp;The
products cover a variety of wound treatment solutions including debridement agents, advanced therapies to aid healing, and scaffolds
used as skin substitutes. Leading products include HYALOMATRIX and HYALOFILL, for the treatment of complex wounds such as burns
and ulcers.&nbsp;The dermal products are commercialized through a network of distributors, primarily in the United States, Europe,
Latin America, and the Middle East.&nbsp;Several of the products are also cleared for sale in the United States including HYALOMATRIX,
HYALOFILL, HYALOGRAN, and HYALOMATRIX 3D. We previously entered into a distribution agreement for the sale of advanced wound care
products in nine South American countries, including Argentina, Brazil, Mexico, and Chile, on an exclusive basis through 2018.
We have also entered into an agreement with Medline Industries, Inc. to commercialize HYALOMATRIX in the United States on an exclusive
basis through 2019.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our aesthetic dermatology product is a dermal filler based on our proprietary, chemically
modified, cross-linked HA, and it is commercialized in certain European Union countries, Canada, the United States, and Korea.
Internationally, this product is marketed under the ELEVESS name. In the United States, the trade name is HYDRELLE, although the
product is not currently marketed in the United States.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Surgical</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our surgical business consists of products used to prevent post-surgical
adhesions after abdominal-pelvic, spinal, and ear, nose, and throat (&#8220;ENT&#8221;) surgeries. HYALOBARRIER is a clinically
proven post-operative adhesion barrier for use in the abdominopelvic area.&nbsp;The product is currently commercialized in Europe,
the Middle East, and certain Asian countries through a distribution network, but it is not approved for sale in the United States.
HYALOSPINE, a product designed to prevent post-surgical adhesions following spinal surgery, was CE Mark approved in January 2015
for sale in Europe. INCERT, approved for sale and commercialized through a network of distributors in Europe, Turkey, and Malaysia,
is a chemically modified, cross-linked HA product, for the prevention of spinal post-surgical adhesions. There are currently no
plans at this time to distribute INCERT in the United States. We co-own issued U.S. patents covering the use of INCERT for adhesion
prevention. See the section captioned &#8220;<i>Patent and Proprietary Rights.&#8221;</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Surgical adhesions occur when fibrous bands of tissues form between
adjacent tissue layers during the wound healing process. Although surgeons attempt to minimize the formation of adhesions, they
nevertheless occur quite frequently after surgery. Adhesions in the abdominal and pelvic cavity can cause particularly serious
problems such as intestinal blockage following abdominal surgery and infertility following pelvic surgery. Fibrosis following spinal
surgery can complicate re-operation and may cause pain.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">We offer several products used in connection with the treatment of ENT
disorders.&nbsp;The lead products are MEROGEL, a woven fleece nasal packing, and MEROGEL INJECTABLE, a thick, viscous hydrogel
composed of cross-linked hyaluronic acid&mdash;a biocompatible agent that creates a moist wound-healing environment.&nbsp;We have
partnered with Medtronic XoMed, Inc. (&ldquo;Medtronic&rdquo;) for worldwide distribution of these ENT products.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Ophthalmic </i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our ophthalmic business includes HA viscoelastic products used in
ophthalmic surgery. The ophthalmic products we manufacture include STAARVISC-II, OPTIVISC (formerly ShellGel), ANIKAVISC, and NUVISC.
They are injectable, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures such as cataract
extraction and intraocular lens implantation. These products coat, lubricate, and protect sensitive tissue such as the endothelium,
and they function to maintain the shape of the eye, thereby facilitating ophthalmic surgical procedures.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We previously manufactured the AMVISC product line for Bausch&nbsp;&amp;
Lomb (&#8220;B&amp;L&#8221;) under the terms of an exclusive supply agreement that expired on December&nbsp;31, 2010 (the &#8220;2004
B&amp;L Agreement&#8221;) for viscoelastic products used in ophthalmic surgery. Effective January 1, 2011, we entered into a non-exclusive,
two year contract with B&amp;L intended to transition the manufacture of AMVISC and AMVISC Plus to an alternative, low-cost supplier
formerly affiliated with B&amp;L, and continued to supply B&amp;L with these products during 2011.&nbsp;Effective January 1, 2012,
the parties agreed to a three year contract for us to continue to supply these products to B&amp;L as a second supplier with committed
annual volumes through year-end 2014, and the contract was not renewed upon expiration.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><i>Veterinary</i></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">HYVISC is a high molecular weight injectable&nbsp;HA product for the
treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis. HYVISC has viscoelastic
properties that lubricate and protect the tissues in horse joints. HYVISC is distributed by Boehringer Ingelheim Vetmedica,&nbsp;Inc.
(&ldquo;Boehringer&rdquo;) in the United States and in selected countries in the Middle East.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">See Note&nbsp;16 <i>&#8220;Revenue by Product Group, by Significant
Customer and by Geographic Region; Geographic Information&#8221;</i> to our consolidated financial statements included elsewhere
in this Annual Report on Form 10-K for a discussion regarding our segments and geographic sales.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">See also the section captioned &#8220;<i>Risk Factors&#8212;Risks
Related to Our Business and Industry&#8212;We experience quarterly sales volume variation, which makes our future results difficult
to predict and makes period-to-period comparisons potentially not meaningful</i>&#8221; for a discussion regarding the effect that
quarterly sales volume variation could have on our business and financial performance.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">See also the section captioned &#8220;<i>Risk Factors</i> <i>&#8212;Risks
Related to Our Business and Industry&#8212;A significant portion of our revenues are derived from a small number of customers,
the loss of which could materially adversely affect our business, financial condition and results of operations</i>&#8221; for
a discussion regarding our dependence on large-volume customers and the effects that the loss of any such customer could have on
our business and financial performance.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">See also the section captioned &#8220;<i>Risk Factors&#8212;Risks
Related to Our Business and Industry&#8212;Our manufacturing processes involve inherent risks, and disruption could materially
adversely affect our business, financial condition and results of operations</i>&#8221; for a discussion of the sources and availability
of raw materials related to the manufacture of our products.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Research and Development of Potential Products</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our research and development efforts primarily consist of the development
of new medical applications for our HA-based technology, the management of clinical trials for certain product candidates, the
preparation and processing of applications for regulatory approvals or clearances at all relevant stages of product development,
and process development and scale-up manufacturing activities for our existing and new products. Our development focus includes
products for tissue protection, repair, and regeneration. For the years ended December&nbsp;31, 2015, 2014 and 2013, these expenses
were $9.0 million, $8.1&nbsp;million, and $7.1&nbsp;million, respectively. We anticipate that we will continue to commit significant
resources to research and development, including in relation to clinical trials, in the future.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our second single-injection osteoarthritis
product under development is CINGAL, which is composed of our proprietary cross-linked HA material combined with an approved steroid
and is designed to provide both short- and long-term pain relief to patients. We completed the CINGAL phase III clinical trial
and associated statistical analysis during the fourth quarter of 2014. During the first half of 2015, we completed a CINGAL retreatment
study with patients who had participated in the phase III clinical trial and reported safety data related to the retreatment study.
On the regulatory front, we submitted an application for CE Mark approval of the product in December 2014, and we expect to achieve
approval by the end of April 2016. In May 2015, we also submitted an application for regulatory approval of CINGAL to Health Canada,
and we received notification of approval for CINGAL from Health Canada in early November 2015. After discussion with the FDA related
to the regulatory pathway for CINGAL in the United States, we conducted a formal meeting with the FDA&rsquo;s Office of Combination
Products (&ldquo;OCP&rdquo;) to present and discuss our data in September 2015, and we submitted a formal request for designation
with OCP a month later. In its response to our formal request for designation, OCP assigned the product to the Center for Drug
Evaluation and Research (&ldquo;CDER&rdquo;) as the lead agency center for premarket review and regulation. Since then, we have
been in ongoing discussions with CDER to understand the requirements for submitting a New Drug Application (&ldquo;NDA&rdquo;)
for CINGAL, and preliminary indications from the FDA suggest that additional clinical work may be required. We will meet with the
FDA to collaboratively discuss this topic.</P>


<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We have research and development programs underway for new products
including for HYALOFAST, an innovative product for cartilage tissue repair, HYALOBONE, a bone void filler, and other early stage
regenerative medicine development programs. HYALOFAST received CE Mark approval in September 2009, and it is commercially available
in Europe and certain international countries. During the first quarter of 2015, we submitted an Investigational Device Exemption
(&#8220;IDE&#8221;) to the FDA, which was approved in July 2015. We are in the early stages of the phase III clinical trial for
HYALOFAST, and we enrolled our first patient in December 2015. Another of our products, HYALOSPINE, is an innovative adhesion prevention
gel for use after spinal surgery. We completed a HYALOSPINE pilot clinical study in 2012, submitted the CE Mark application in
September 2013, and received the CE Mark approval in January 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">In June 2015, we entered into an agreement with the Institute for Applied
Life Sciences at the University of Massachusetts Amherst to collaborate on research to develop a therapy for rheumatoid arthritis.
The purpose of this research is to develop a novel modality for the treatment of rheumatoid arthritis, and if successful, it is
expected to yield a potential product candidate that we could begin to move towards commercialization as early as 2017.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our research and development efforts may not be successful in (1)&nbsp;developing
our existing product candidates, (2)&nbsp;expanding the therapeutic applications of our existing products, or (3)&nbsp;resulting
in new applications for our HA technology. There is also a risk that we may choose not to pursue development of potential product
candidates. We may not be able to obtain regulatory approval for any new applications we develop. Furthermore, even if all regulatory
approvals are obtained, there can be no assurances that we will achieve meaningful sales of such products or applications.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Patent and Proprietary Rights</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our products and trademarks, including our Company name, product
names, and logos, are proprietary. We rely on a combination of patent protection, trade secrets and trademark laws, license agreements,
and confidentiality and other contractual provisions to protect our proprietary information.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have a policy of seeking patent protection
for patentable aspects of our proprietary technology. In the United States, we own 26 patents, 2 of which are co-owned with other
parties, license 18 patents, and have 2 patent applications currently pending. These U.S. patents have expiration dates through
2030. Internationally, we own 190 patents, 7 of which are co-owned with other parties, license 88 patents, and have 10 patent applications
currently pending. Outside of the United States, we own, co-own, license, or have filed for patents in 38 jurisdictions. Our international
patents have expiration dates through 2032. Many of these patents, including all licensed patents, belong to the Anika S.r.l. patent
estate, which is extensive and partly intertwined with its former parent company, Fidia Farmaceutici S.p.A. (&ldquo;Fidia&rdquo;),
through a patent licensing agreement that provides Anika S.r.l. with access to certain of Fidia&rsquo;s patents to the extent required
to support Anika S.r.l.&rsquo;s products. We intend to seek patent protection for products and processes developed in the course
of our activities when we believe such protection is in our best interests and when the cost of seeking such protection is not
inordinate relative to the potential benefits.</P>


<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Other entities have filed patent applications for, or have been issued
patents concerning, various aspects of HA-related products or processes. In addition, the products or processes we develop may
infringe the patent rights of others in the future. Any such infringement may have a material adverse effect on our business, financial
condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We rely upon trade secrets and proprietary know-how for certain non-patented
aspects of our technology. To protect such information, we require certain customers and vendors, and all employees, consultants,
and licensees to enter into confidentiality agreements limiting the disclosure and use of such information. These agreements, however,
may not provide adequate protection.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">See also the section captioned &#8220;<i>Risk Factors&#8212;Risks
Related to Our Intellectual Property.</i>&#8221;&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We have granted Mitek an exclusive and non-transferable royalty bearing
license to develop, commercialize, and sell ORTHOVISC and MONOVISC in the United States pursuant to the Mitek ORTHOVISC Agreement
and the Mitek MONOVISC Agreement. These agreements include a license to manufacture, and have manufactured, such products in the
event that we are unable to supply Mitek with ORTHOVISC or MONOVISC in accordance with the terms of the relevant agreement. We
have also granted Mitek the exclusive, royalty free right to use the trademarks ORTHOVISC and MONOVISC in connection with the marketing,
distribution, and sale of the licensed products within the United States.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Government Regulation</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The clinical development, manufacturing, and marketing of our products
are subject to governmental regulation in the United States, the European Union and other territories worldwide. Various statutes,
regulations, directives, and guidelines, including the Food, Drug, and Cosmetics Act in the United States, govern the development,
design, non-clinical and clinical research, testing, manufacture, safety, efficacy, labeling, packaging, storage, record keeping,
premarket clearance or approval, adverse event reporting, advertising, and promotion of our products. Product development and approval
within these various regulatory frameworks takes a number of years and involves the expenditure of substantial resources. Pharmaceutical
and medical device manufacturers are also inspected regularly by the FDA and other applicable regulatory bodies.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Medical products regulated by the FDA are generally classified as
drugs, biologics, or medical devices. Medical devices intended for human use are classified into three categories (Class&nbsp;I,
II or III) on the basis of the controls deemed reasonably necessary by the FDA to assure their safety and effectiveness. Class&nbsp;II
devices are cleared for marketing under the premarket notification 510(k) regulatory pathway, which may include clinical testing.
Class&nbsp;III devices require pre-market approval based on valid scientific evidence of safety and effectiveness, including evidence
elicited through appropriate clinical testing. Drugs and biologic products undergo rigorous preclinical testing prior to beginning
clinical trials. Clinical trials for new drugs or biologic products include Phase I trials in healthy volunteers to understand
safety, dosage tolerance, and pharmacokinetics, Phase II trials in a limited patient population to identify initial efficacy and
side effects, and Phase III pivotal trials to statistically evaluate the safety and efficacy of the product. The failure to demonstrate
adequately the quality, safety, and efficacy of a product under development can delay or prevent regulatory approval of the product.
In order to gain marketing approval, we must submit to the relevant regulatory authority for review information on the quality
aspects of the product as well as the non-clinical and clinical data. The FDA undertakes this review in the United States.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In the European Union, medical devices must be CE Marked in order
to be marketed. CE marking a device involves working with a Notified Body, and in some cases a Competent Authority, to demonstrate
that the device meets all applicable requirements of the Medical Devices Directive and that our Quality Management System is compliant.
Drug approval in the European Union follows one of several possible processes: (i) a centralized procedure involving members of
the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use; (ii) a &#8220;mutual recognition procedure&#8221;
in which an individual country's regulatory agency approves the product followed by &#8220;mutual recognition&#8221; of this review
by regulatory agencies of other countries; or (iii) a decentralized procedure in which the approval is sought through the regulatory
agencies of multiple countries at the same time.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Approval timelines can range from several months to several years,
or applications can be denied entirely. The approval process can be affected by a number of factors. For example, additional studies
or clinical trials may be requested during the review, which may delay marketing approval and involve unbudgeted costs. As a condition
of approval, the regulatory agency may require post-marketing surveillance to monitor for adverse effects, and may require other
additional studies, as it deems appropriate. After approval for an initial indication, further clinical studies are generally necessary
to gain approval for any additional indications. The terms of any approval, including labeling content, may be more restrictive
than expected and could affect the marketability of a product.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As a condition of approval, the relevant regulatory agency requires
that the product continues to meet applicable regulatory requirements related to quality, safety, and efficacy, and it requires
strict procedures to monitor and report any adverse effects. Where adverse effects occur or may occur, the regulatory agency may
require additional studies or changes to the labeling. Compelling new &#8220;adverse&#8221; data may result in a product approval
being withdrawn at any stage following review by an agency and discussion with product manufacturer.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The branch of the FDA responsible for product marketing oversight
routinely reviews company marketing practices and also may impose pre-clearance requirements on materials intended for use in marketing
of approved drug products. We are also subject to various U.S. federal and state laws pertaining to healthcare fraud and abuse,
including anti-kickback and false claims laws. Similar review and regulation of advertising and marketing practices exists in the
other geographic areas where the company operates.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The FDA has broad regulatory compliance and enforcement powers. If
the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement
actions, such as issuing an FDA Form 483 notice of inspectional observations, a warning letter, an untitled letter, imposing civil
money penalties, suspending or delaying issuance of approvals, requiring product recall, imposing a total or partial shutdown of
production, withdrawal of approvals or clearances already granted, pursuing product seizures, consent decrees or other injunctive
relief, or criminal prosecution through the Department of Justice. The FDA can also require us to repair, replace or refund the
cost of products that we manufactured or distributed. Outside the US, regulatory agencies may exert a range of similar powers.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b>Competition</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We compete with many companies including, among others, large pharmaceutical
firms and specialized medical products companies, across all of our product lines. Many of these companies have substantially greater
financial resources, larger research and development staffs, more extensive marketing and manufacturing organizations, and more
experience in the regulatory processes than we have. We also compete with academic institutions, government agencies, and other
research organizations, which may be involved in the research and development and commercialization of products. Many of our competitors
also compete against us in securing relationships with collaborators for their research and development and commercialization programs.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We compete with other market participants primarily on the efficacy
of our products, our products&#8217; reputation for safety, our focus solely on HA-based products, and the breadth of our HA-based
product portfolio. Other factors that impact competition in our industry are the timing and scope of regulatory approvals, the
availability of raw material and finished product supply, marketing and sales capability, reimbursement coverage, product pricing,
and patent protection. Some of the principal factors that may affect our ability to compete in the HA development and commercialization
markets include:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The quality and breadth of our continued development of our technology portfolio;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our ability to complete successful clinical studies and obtain FDA marketing and foreign regulatory approvals prior to our
competitors;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The successful execution of our commercial strategies;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Our ability to recruit and retain skilled employees; and</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The availability of capital resources to fund strategic activities related to the significant expansion of our business or
product portfolio.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are aware of several companies that are
developing and/or marketing products utilizing HA for a variety of human applications. In some cases, competitors have already
obtained product approvals, submitted applications for approval or commenced human clinical studies, either in the United States
or in certain foreign countries. All of our products face substantial competition. There exist major worldwide competing products,
made from HA and other materials, for use in orthopedics, surgical adhesion prevention, advanced wound care, ENT, cosmetic dermatology,
and ophthalmic surgery. There is a risk that we will be unable to compete effectively against our current or future competitors.
Additionally, legislation and regulation aimed at curbing rising healthcare costs has resulted in a consolidation trend in the
healthcare industry to create larger companies, including hospitals, with greater market power. In turn, this has led to greater
and more intense competition in the provision of products and services to market participants. Important market makers, like group
purchasing organizations, have increased their negotiating leverage, and if these market makers demand significant price concessions
or if we are excluded as a supplier by these market makers, our product revenue could be adversely impacted. See also the sections
captioned &ldquo;<I>Risk Factors&mdash;Risks Related to Our Business and Industry&mdash;Substantial competition could materially
affect our financial performance</I>&rdquo; and <I>&ldquo;Risk Factors&mdash;Risks Related to Our Business and Industry&mdash;Our
business may be adversely affected if consolidation in the healthcare industry leads to demand for price concessions or if we are
excluded from being a supplier by a group purchasing organization or similar entity&rdquo;</I> for additional discussion of the
impact competition could have on our business and financial results.</P>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>Employees</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of December&nbsp;31, 2015, we had 107 employees, 20 of whom were
located outside the United States. We consider our relations with our employees to be good.&nbsp;None of our U.S. employees are
represented by labor unions, but most of the employees based in Italy are represented by unions, adding complexity and additional
risks to the wage and employment decision process.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Environmental Laws</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We believe that we are in compliance with all foreign, federal, state,
and local environmental regulations with respect to our manufacturing facilities and that the cost of ongoing compliance with such
regulations does not have a material effect on our operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b>Product Liability</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The testing, marketing, and sale of human health care products entails
an inherent risk of allegations of product liability, and we cannot assure that substantial product liability claims will not be
asserted against us. Although we have not received any material product liability claims to date and have coverage under our insurance
policy of $5.0 million per occurrence and $5.0 million in the aggregate, we cannot assure that if material claims arise in the
future, our insurance will be adequate to cover all situations. Moreover, we cannot assure that such insurance, or additional insurance,
if required, will be available in the future or, if available, will be available on commercially reasonable terms. Any product
liability claim, if successful, could have a material adverse effect on our business, financial condition, and results of operation.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Available Information</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our Annual Reports on Form&nbsp;10-K, including our consolidated
financial statements, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K and other information, including amendments
and exhibits to such reports, filed or furnished pursuant to the Securities Exchange Act of 1934, as amended, are available free
of charge in the &#8220;SEC Filings&#8221; section of our website located at http://www.anikatherapeutics.com, as soon as reasonably
practicable after the reports are filed with or furnished to the Securities and Exchange Commission (&#8220;SEC&#8221;). The information
on our website is not part of this Annual Report on Form&nbsp;10-K. Reports filed with the SEC may be viewed at www.sec.gov or
obtained at the SEC Public Reference Room at 100 F Street NE, Washington, D.C. 20549. Information regarding the operation of the
Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i1a"></a><b>ITEM 1A. RISK FACTORS</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our operating results and financial condition have varied in the
past and could vary significantly in the future depending on a number of factors. You should consider carefully the risks and uncertainties
described below, in addition to the other information contained in this Annual Report on Form 10-K, before deciding whether to
purchase our common stock. If any of the following risks actually occurs, our business, financial condition, results of operations,
and future prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline,
and you could lose part or all of your investment.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks Related to Our Business and Industry</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Failure to obtain, or any delay in obtaining, FDA or other U.S. and foreign governmental
approvals for our products may have a material adverse effect on our business, financial condition and results of operations.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">Several of our current products, and any future products we may develop,
will require clinical trials to determine their safety and efficacy for United States and international marketing approval by regulatory
bodies, including the FDA. Product development and approval within the FDA framework takes a number of years and involves the expenditure
of substantial resources. There can be no assurance that the FDA will accept submissions related to our new products, and, even
if submissions are accepted, there can be no guarantee that the FDA will grant approval for our new products, including CINGAL
or other line extensions, on a timely basis, if at all. In addition to regulations enforced by the FDA, we are subject to other
existing and future federal, state, local, and foreign regulations applicable to product approval, which may vary significantly
across jurisdictions. Additional approval of existing products may be required when changes to such products may affect the safety
and effectiveness, including for new indications for use, labeling changes, process or manufacturing changes, the use of a different
facility to manufacture, process or package the device, and changes in performance or design specifications. Failure to obtain
regulatory approvals of our products, including any changes to existing products, could have an adverse material impact on our
business, financial condition, and results of operations.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Even if granted, FDA and international regulatory approvals may be
subject to significant, unanticipated delays throughout the regulatory approval process. Internally, we make assumptions regarding
product approval timelines, both in the United States and internationally, in our business planning, and any delay in approval
could materially affect our competitive position in the relevant product market and our projections related to future business
results.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We cannot be certain that product approvals, both in the United States
and internationally, will not include significant limitations on the product indications, and other claims sought for use, under
which the products may be marketed. The relevant approval or clearance may also include other significant conditions of approval
such as post-market testing, tracking, or surveillance requirements. Any of these factors could significantly impact our competitive
position in relation to such products and could have a negative impact on the sales of such products.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b><i>Once obtained, we cannot guarantee that FDA or international
product approvals will not be withdrawn or that relevant agencies will not require other corrective action, and any withdrawal
or corrective action could materially affect our business and financial results.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Once obtained, marketing approval can be withdrawn by the FDA or
comparable foreign regulatory agencies for a number of reasons, including the failure to comply with ongoing regulatory requirements
or the occurrence of unforeseen problems following initial approval. Regulatory authorities could also limit or prevent the manufacture
or distribution of our products. Any regulatory limitations on the use of our products or any withdrawal or suspension of approval
or rescission of approval by the FDA or a comparable foreign regulatory agency could have a material adverse effect on our business,
financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Our operations and products are subject to extensive regulation, compliance with
which is costly and time consuming, and our failure to comply may result in substantial penalties, including recalls of our products.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The FDA and foreign regulatory bodies impose extensive regulations
applicable to our operations and products, including regulations governing product standards, packing requirements, labeling requirements,
quality system and manufacturing requirements, import restrictions, tariff regulations, duties, and tax requirements. We cannot
assure you that we will be able to achieve and maintain compliance required for FDA, CE marking, or other foreign regulatory approvals
for any or all of our operations and products or that we will be able to produce our products in a timely and profitable manner
while complying with applicable requirements.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Failure to comply with applicable regulatory requirements could result
in substantial penalties, including warning letters, fines, injunctions, civil penalties, seizure of products, total or partial
suspension of production, refusal to grant pre-market clearance or pre-market approval for devices or drugs, withdrawal of approvals,
and criminal prosecution. Additionally, regulatory authorities have the power to require the recall of our products. It also might
be necessary for us, in applicable circumstances, to initiate a voluntary recall per regulatory requirements of one or several
of our products. The imposition of any of the foregoing penalties, whether voluntarily or involuntary, could have a material negative
impact on our business, financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b><i>Any changes in FDA or international regulations related to
product approval, including those that apply retroactively, could adversely affect our competitive position and materially affect
our business and financial results.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">FDA and foreign regulations depend heavily on
administrative interpretation, and we cannot assure you that future interpretations made by the FDA or other regulatory bodies,
with possible retroactive effect, will not adversely affect us. Additionally, any changes, whether in interpretation or substance,
in existing regulations or policies, or any future adoption of new regulations or policies by relevant regulatory bodies, could
prevent or delay approval of our products. In the event our future, or current, products, including HA generally, are classified,
or re-classified, as human drugs, combination products, or biologics by the FDA or an applicable international regulatory body,
the applicable review process related to such products is typically substantially longer and substantially more expensive than
the review process to which they are currently subject as medical devices, which could materially impact our competitive position,
business, and financial results.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We are implementing a direct sales model to commercialize our CINGAL product, as
well as certain other future products, in the United States and we may face unforeseen difficulties and delays in implementing
this new model, which could affect our business and financial results.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">For the first time, we are implementing a direct
sales model to market and promote one of our products, CINGAL, in the United States, initially through a contract sales organization,
with the ultimate goal of transitioning the direct sales function into our company as part of a broader buildout of our commercial
capabilities. We may also use this direct model to commercialize other of our products in the United States in the future. Our
success in utilizing this sales model will initially depend in part on our ability to successfully develop and implement the necessary
internal and external resources to manage the contract sales organization and the sales of the product. Our longer term success
will depend on our ability to transition the direct sales function into our company and to manage all resources associated with
this function. We cannot assure you that there will not be unforeseen roadblocks or delays in finalizing the contracts related
to, and implementing, the relationship with the contract sales organization, nor we can we assure you that we will not face setbacks
in transitioning the direct sales function into our organization. The initial implementation timeline of this direct sales model
is also dependent on CINGAL obtaining FDA approval in a timely manner, of which there is no guarantee. Failure to timely implement
our direct sales model or to successfully manage the implementation or transition process could materially impact our competitive
position, business, and financial results.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b><i>Substantial competition could materially affect our financial
performance.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We compete with many companies, including
large pharmaceutical companies, specialized medical products companies, and healthcare companies. Many of these companies have
substantially greater financial resources, larger research and development staffs, more extensive marketing and manufacturing organizations,
and more experience in the regulatory process than us. We also compete with academic institutions, government agencies, and other
research organizations that may be involved in research, development, and commercialization of products similar to our own. Because
a number of companies are developing or have developed HA products for similar applications and have received FDA approval, the
successful commercialization of a particular product will depend in part upon our ability to complete clinical studies and obtain
FDA marketing and foreign regulatory approvals prior to our competitors, or, if regulatory approval is not obtained prior to our
competitors, to identify markets for our products that may be sufficient to permit meaningful sales of our products. For example,
we are aware of several companies that are developing and/or marketing products utilizing HA for a variety of human applications.
In some cases, competitors have already obtained product approvals, submitted applications for approval, or have commenced human
clinical studies, either in the United States or in certain foreign countries. There exist major competing products for the use
of HA in ophthalmic surgery. In addition, certain HA products made by our competitors for the treatment of osteoarthritis in the
knee received FDA approval before ours and have been marketed in the United States since 1997, as well as select markets in Canada,
Europe, and other countries. There can be no assurance that we will be able to compete against current or future competitors or
that competition will not have a material adverse effect on our business, financial condition, and results of operations.</P>


<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We may rely on third parties to support certain aspects of our clinical trials.
If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to
obtain regulatory approval or commercialize our products and our business could be substantially harmed.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We have hired experienced clinical development and regulatory staff,
and we have also retained the services of knowledgeable external service providers, including consultants and clinical research
organizations, to develop and supervise our clinical trials and regulatory processes. Despite our internal investment in staffing,
we will remain dependent upon these third party contract research organizations to carry out portions of our clinical and preclinical
research studies for the foreseeable future. As a result, we have had and will have less control over the conduct of the clinical
trials, the timing and completion of the trials, the required reporting of adverse events, and the management of data developed
through the trials than would be the case if we were relying entirely on our own staff. Outside parties may have staffing difficulties,
may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct
our trials. Failure by these third parties to comply with regulatory requirements or to meet timing expectations may require us
to repeat clinical or preclinical trials, which would delay the regulatory approval process, or require substantial unexpected
expenditures.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We are dependent upon marketing and distribution partners and the failure to maintain
strategic alliances on acceptable terms will have a material adverse effect on our business, financial condition and results of
operations.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">Our success will be dependent, in part, upon the efforts of our marketing
and distribution partners and the terms and conditions of our relationships with such partners. One partner, Mitek accounted for
72% of our product revenue in fiscal year 2015. We cannot assure you that our partners, including Mitek, will not seek to renegotiate
their current agreements on terms less favorable to us or terminate such agreements. A failure to renew these partnerships on terms
satisfactory to us, or at all, could result in a material adverse effect on our operating results.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We continue to seek to establish long-term distribution relationships
in regions and countries not covered by existing agreements, and we may need to obtain the assistance of additional marketing partners
to bring new and existing products to market and to replace certain marketing partners. There can be no assurance that we will
be able to identify or engage appropriate distribution or collaboration partners or effectively transition to any such partners.
The failure to establish strategic partnerships for the marketing and distribution of our products on acceptable terms and within
our planned timeframes could have a material adverse effect on our business, financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b><i>We must achieve market acceptance of our products in order
to be successful in the future. </i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our success will depend in part upon the acceptance of our existing
and future products by the medical community, hospitals and physicians and other health care providers, third-party payers, and
end-users. Such acceptance may depend upon the extent to which the medical community and end-users perceive our products as safer,
more effective, or cost-competitive than other similar products. Ultimately, for our new products to gain general market acceptance,
it may also be necessary for us to develop marketing partners or viable commercial strategies for the distribution of our products.
There can be no assurance that our new products will achieve significant market acceptance on a timely basis, or at all. Failure
of some or all of our future products to achieve significant market acceptance could have a material adverse effect on our business,
financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b><i>Our manufacturing processes involve inherent risks, and disruption
could materially adversely affect our business, financial condition and results of operations.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The operation of biomedical manufacturing plants involves many risks,
including the risks of breakdown, failure, or substandard performance of equipment, the occurrence of natural and other disasters,
and the need to comply with the requirements of directives of government agencies, including the FDA. In addition, we rely on a
single supplier for certain key raw materials and a small number of suppliers for a number of other materials required for the
manufacturing and delivery of our HA products. Although we believe that alternative sources for many of these and other components
and raw materials that we use in our manufacturing processes are available, we cannot be certain that the supply of key raw materials,
specifically HA, will continue be available at current levels or will be sufficient to meet our future needs. Any supply interruption
could harm our ability to manufacture our products until a new source of supply is identified and qualified. We also rely on a
single supplier for certain finished products, and if such manufacturer fails to meet production or delivery schedules, it could
have an adverse impact on our ability to sell such products. We may not be able to find a sufficient alternative supplier in a
reasonable time period, or on commercially reasonable terms, if at all, and our ability to produce and supply our products could
be impaired.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We are in the process of transferring the manufacturing of our HYAFF products from
Italy to our Bedford, MA facility, which carries inherent risks of supply interruption. </i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We are currently in the process of transferring the manufacturing
responsibilities for our HYAFF products from our current contract manufacturer in Italy to our facility in Bedford, MA. This process
requires us to take several steps including, but not limited to, building excess inventory of the products, finishing the necessary
construction at our Bedford facility to allow the transfer of equipment, removing our equipment from our contract manufacture&#8217;s
facility, properly packaging and storing the manufacturing equipment for transportation to the United States from Italy, installing
the equipment in the Bedford facility, and validating the equipment and achieving regulatory approval of the manufacturing processes
in accordance with all applicable law and regulations. There is no guarantee that any of these activities will not become delayed
or otherwise disrupted, which could lead to a supply interruption for the HYAFF products. Such an interruption could ultimately
have a material adverse effect on our business, financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Our Italian subsidiary, Anika Therapeutics S.r.l. (&#8220;Anika S.r.l.&#8221;)
is moving from its current facility in Abano Terme, Italy to a new facility in Padova, Italy, and there is no guarantee that this
facility move will not result in an interruption of our business.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Anika S.r.l. currently occupies warehousing,
research and development, and administrative space in Abano Terme, Italy. In October 2015, Anika S.r.l. entered into a build-to-suit
lease agreement to lease a new warehousing, research and development, and administrative facility in Padova, Italy. We expect that
we will move into this new facility in at the end of 2016. There is no guarantee that this move will be completed smoothly and
in a timely manner due to, among other things, unexpected construction delays or unexpected difficulties related to the lessor
achieving necessary permitting, and any delay has the potential to cause a disruption to our business activities. If there is a
business disruption or the move is delayed, this could ultimately have a material adverse effect on our business, financial condition,
and results of operations.</P>



<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We use raw materials derived from animal sources to produce certain of our products,
and there is no guarantee that we will be able to continue to utilize this source of material in the future.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our manufacturing processes and research and development efforts
for some of our ophthalmic and veterinary products involve products derived from animals. We procure our animal-derived raw materials
from a qualified vendor, who controls for contamination and has processes that effectively inactivate infectious agents; however,
we cannot assure you that we can completely eliminate the risk of transmission of infectious agents. Furthermore, regulatory authorities
could in the future impose restrictions on the use of animal-derived raw materials that could impact our business.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The utilization of animals in research and development and product
commercialization is subject to increasing focus by animal rights activists. The activities of animal rights groups and other organizations
that have protested animal based research and development programs or boycotted the products resulting from such programs could
cause an interruption in our manufacturing processes and research and development efforts. The occurrence of material operational
problems, including but not limited to the events described above, could have a material adverse effect on our business, financial
condition, and results of operations during the period of such operational difficulties and beyond.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b><i>Our financial performance depends on the continued sales growth
and increasing demand for our products and we may not be able to successfully manage the expansion of our operations.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our future success depends on substantial growth in product sales.
There can be no assurance that such growth can be achieved or, if achieved, sustained. There can be no assurance that, even if
substantial growth in product sales and the demand for our products is achieved, we will be able to:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Develop and maintain the necessary manufacturing capabilities;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Obtain the assistance of additional marketing partners or develop appropriate alternative sales strategies;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Attract, retain, and integrate required key personnel; and</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Implement the financial, accounting, and management systems needed to manage growing demand for our products.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our failure to successfully manage future growth could have a material
adverse effect on our business, financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i></I></B></P>

<P STYLE="font-size: 10pt; margin: 0"><B><I>We may face circumstances in the future that will result in impairment charges, including,
but not limited to, goodwill impairment and In-Process Research and Development (&ldquo;IPR&amp;D&rdquo;) charges.</I></B></P>



<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I></i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of December 31, 2015, we had long-lived assets, including goodwill,
of $59 million. If the fair value of any of our long-lived assets decreases as a result of an economic slowdown, a downturn in
the markets where we sell products and services, or a downturn in our financial performance or future outlook, we may be required
to record an impairment charge on such assets.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We are required to test intangible assets with indefinite life periods
for potential impairment annually and on an interim basis if there are indicators of a potential impairment. We also are required
to evaluate amortizable intangible assets and fixed assets for impairment if there are indicators of a possible impairment. Impairment
charges could have a negative impact on our results of operations and financial position, as well as on the market price of our
common stock.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Customer, vendor and employee uncertainty about the effects of any acquisitions
could harm us.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We and the customers of any companies we acquire may, in response
to the consummation of any acquisitions, delay or defer purchasing decisions. Any delay or deferral in purchasing decisions by
customers could adversely affect our business. Similarly, employees of acquired companies may experience uncertainty about their
future role until or after we execute our strategies with regard to employees of acquired companies. This may adversely affect
our ability to attract and retain key management, sales, marketing, and technical personnel following an acquisition.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We engage in acquisitions as a part of our growth strategy, which exposes us to
a variety of risks that could adversely affect our business operations.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our business strategy includes the acquisition of businesses, technologies,
services, or products that we believe are a strategic fit with our business. We may fund these acquisitions by utilizing our cash,
incurring debt, issuing additional shares of our common stock, or by other means. Completed acquisitions may expose us to a number
of risks and expenses, including unanticipated liabilities, amortization expenses related to intangible assets with definite lives,
or risks associated with entering new markets with which we have limited experience or where commercial alliances with experienced
partners or existing sales channels are not available. Whether or not completed, acquisitions may result in diversion of management
resources otherwise available for ongoing development of our business and significant expenditures.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We may not be able to realize the expected benefits of any completed
acquisitions, including synergies and cost savings from the integration of acquired businesses or assets with our existing operations
and technologies, as rapidly as expected, or at all. In addition, the integration and reorganization processes for our acquisitions
may be complex, costly, and time consuming and include unanticipated issues, expenses, and liabilities. We may have difficulty
in developing, manufacturing, and marketing the products of a newly acquired company in a manner that enhances the performance of
our combined businesses or product lines and allows us to realize value from expected synergies. Moreover, we may lose key clients
or employees of acquired businesses as a result of the change in ownership to us. Following an acquisition, we may not achieve
the revenue or net income levels that justify the acquisition. Acquisitions may also result in one-time charges, such as write-offs
or restructuring charges, impairment of goodwill or acquired In-Process Research and Development, which could adversely affect
our operating results. The failure to achieve the expected benefits of any acquisition may harm our business, financial condition,
and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>The acquisitions we have made or may make in the future may make us the subject
of lawsuits from either an acquired company&#8217;s stockholders, an acquired company&#8217;s previous stockholders or our current
stockholders.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We may be the subject of lawsuits from either an acquired company&#8217;s
stockholders, an acquired company&#8217;s previous stockholders, or our current stockholders. These lawsuits could result from
the actions of the acquisition target prior to the date of the acquisition, from the acquisition transaction itself, or from actions
after the acquisition. Defending potential lawsuits could cost us significant expense and distract management&#8217;s attention
from the operation of the business. Additionally, these lawsuits could result in the cancellation of or the inability to renew,
certain insurance coverage that would be necessary to protect our assets.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Attractive acquisition opportunities may not be available to us in the future.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We will consider the acquisition of other businesses. However, we
may not locate suitable acquisition targets or have the opportunity to make acquisitions of such targets on favorable terms in
the future, which could negatively impact the growth of our business. In order to pursue such opportunities, we may require significant
additional financing, which may not be available to us on favorable terms, if at all. The availability of such financing is limited
by the continued tightening of the global credit markets. We expect that our competitors, many of which have significantly greater
resources than we do, will compete with us to acquire compatible businesses. This competition could increase prices for acquisitions
that we would likely pursue.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Sales of our products are largely dependent upon third party reimbursement and
our performance may be harmed by health care cost containment initiatives.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In the United States and other foreign markets, health care providers,
such as hospitals and physicians, that purchase health care products, such as our products, generally rely on third party payers,
including Medicare, Medicaid, and other health insurance and managed care plans, to reimburse all or part of the cost of the health
care product. We generally depend upon the distributors of our products to secure reimbursement and reimbursement approvals. Reimbursement
by third party payers, both in the United States and internationally, may depend on a number of factors, including the payer&#8217;s
determination that the use of our products is clinically useful and cost-effective, medically necessary, and not experimental or
investigational. Since reimbursement approval is required from each payer individually, seeking such approvals can be a time consuming
and costly process which, in the future, could require us or our marketing partners to provide supporting scientific, clinical,
and cost-effectiveness data for the use of our products to each payer separately. Significant uncertainty exists as to the reimbursement
status of newly approved health care products, and any failure or delay in obtaining reimbursement approvals can negatively impact
sales of our new products.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In addition, third party payers are increasingly attempting to contain
the costs of health care products and services by limiting both coverage and the level of reimbursement for new therapeutic products
and by refusing, in some cases, to provide coverage for uses of approved products for disease indications for which the FDA, or
the applicable foreign regulatory agency, has granted marketing approval. Also, the U.S. Congress, certain state legislatures,
and certain foreign governments and regulatory agencies have considered reforms that may affect current reimbursement practices,
including controls on health care spending through limitations on the growth of Medicare and Medicaid spending. There can be no
assurance that third party reimbursement coverage will be available or adequate for any products or services developed by us. Outside
the United States, the success of our products is also dependent in part upon the availability of reimbursement and health care
payment systems. Domestic and international reimbursement laws and regulations may change from time to time. Lack of adequate coverage
and reimbursement provided by governments and other third party payers for our products and services, including continuing coverage
for MONOVISC and ORTHOVISC in the United States, and any change of classification by the Centers for Medicare and Medicaid Services
for ORTHOVISC and MONOVISC, could have a material adverse effect on our business, financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We may seek financing in the future, which could be difficult to obtain and which
could dilute your ownership interest or the value of your shares.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We had cash, cash equivalents, and investments of $138.5&nbsp;million
at December&nbsp;31, 2015. Our future capital requirements and the adequacy of available funds will depend, however, on numerous
factors, including:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Market acceptance of our existing and future products;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>



<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The success and sales of our products under various distributor agreements and other appropriate commercial strategies, including
the ability of our partners to achieve third party reimbursement for our products;</TD></TR></TABLE>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The successful commercialization of products in development;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Progress in our product development efforts;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The magnitude and scope of such product development efforts;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Any potential acquisitions of products, technologies, or businesses;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Progress with preclinical studies, clinical trials, and product approvals and clearances by the FDA and other agencies;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The cost and timing of our efforts to manage our manufacturing capabilities and related costs;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The cost of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights and the cost
of defending any other legal proceeding;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Competing technological and market developments;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The development of strategic alliances for the marketing of certain of our products;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The terms of such strategic alliances, including provisions (and our ability to satisfy such provisions) that provide upfront
and/or milestone payments to us; and</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The cost of maintaining adequate inventory levels to meet current and future product demand.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">To the extent funds generated from our operations, together with
our existing capital resources, are insufficient to meet future requirements, we will be required to obtain additional funds through
equity or debt financings, through strategic alliances with corporate partners and others, or through other sources. The terms of
any future equity financings may be dilutive to our investors and the terms of any debt financings may contain restrictive covenants,
which limit our ability to pursue certain courses of action. Our ability to obtain financing is dependent on the status of our
future business prospects as well as conditions prevailing in the relevant capital markets at the time we seek financing. No assurance
can be given that any additional financing will be made available to us or will be available on acceptable terms should such a
need arise.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We could become subject to product liability claims, which, if successful, could
materially adversely affect our business, financial condition, and results of operations.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The testing, marketing, and sale of human health care products entail
an inherent risk of allegations of product liability, and there can be no assurance that substantial product liability claims will
not be asserted against us. Although we have not received any material product liability claims to date and have an insurance policy
of $5.0 million per occurrence and $5.0 million in the aggregate to cover such product liability claims should they arise, there
can be no assurance that material claims will not arise in the future or that our insurance will be adequate to cover all situations.
Moreover, there can be no assurance that such insurance, or additional insurance, if required, will be available in the future
or, if available, will be available on commercially reasonable terms. Any product liability claim, if successful, could have a
material adverse effect on our business, financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Our business is dependent upon hiring and retaining qualified management and technical
personnel.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We are highly dependent on the members of our management and technical
staff, the loss of one or more of whom could have a material adverse effect on us. We have experienced a number of management
changes in recent years, and there can be no assurances that such management changes will not adversely affect our business. We
believe that our future success will depend in large part upon our ability to attract and retain technical and highly skilled managerial
and manufacturing personnel. We face significant competition for such personnel from competitive companies, research and academic
institutions, government entities, and other organizations. There can be no assurance that we will be successful in hiring or retaining
the personnel we require. The failure to hire and retain such personnel could have a material adverse effect on our business, financial
condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We are subject to environmental regulations and any failure to comply with applicable
laws could subject us to significant liabilities and harm our business.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We are subject to a variety of local, state, federal, and foreign
government regulations relating to the storage, discharge, handling, emission, generation, manufacture, and disposal of toxic or
other hazardous substances used in the manufacture of our products. Any failure by us to control the use, disposal, removal, or
storage of hazardous chemicals or toxic substances could subject us to significant liabilities, which could have a material adverse
effect on our business, financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>As our international sales and operations grow, we could become increasingly subject
to additional economic, political, and other risks that could harm our business.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Since we manufacture and sell our products worldwide, our business
is subject to risks associated with doing business internationally. During the years ended December 31, 2015, 2014, and 2013, 18%,
13%, and 23%, respectively, of our product sales were to international distributors. We continue to be subject to a variety of
risks, which could cause fluctuations in the results of our international and domestic operations. These risks include:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The impact of recessions and other economic conditions in economies, including Europe in particular, outside the United States;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Instability of foreign economic, political, and labor conditions;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Unfavorable labor regulations applicable to our European operations, such as severance and the unenforceability of non-competition
agreements in the European Union;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>The impact of strikes, work stoppages, work slowdowns, grievances, complaints, claims of unfair labor practices, or other collective
bargaining disputes;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Difficulties in complying with restrictions imposed by regulatory or market requirements, tariffs, or other trade barriers
or by U.S. export laws;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Imposition of government controls limiting the volume of international sales;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Longer accounts receivable payment cycles;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Potentially adverse tax consequences, including, if required or applicable, difficulties transferring funds generated in non-U.S.
jurisdictions to the United States in a tax efficient manner;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Difficulties in protecting intellectual property, especially in international jurisdictions;</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Difficulties in managing international operations; and</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td>Burdens of complying with a wide variety of foreign laws.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our success depends, in part, on our ability to anticipate and address
these risks. We cannot guarantee that these or other factors will not adversely affect our business or operating results.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Currency exchange rate fluctuations may have a negative impact on our reported
earnings.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Approximately 10% of our business during fiscal year 2015 was conducted
in functional currencies other than the U.S. dollar, which is our reporting currency. Thus, currency fluctuations among the U.S.
dollar and the other currencies in which we do business have caused and will continue to cause foreign currency transaction gains
and losses. Currently, we attempt to manage foreign currency risk through the matching of assets and liabilities. In the future,
we may undertake to manage foreign currency risk through additional hedging methods. We recognize foreign currency gains or losses
arising from our operations in the period incurred. We cannot guarantee that we will be successful in managing foreign currency
risk or in predicting the effects of exchange rate fluctuations upon our future operating results because of the variability of
currency exposure and the potential volatility of currency exchange rates.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b><i>A significant portion of our revenues are derived from a small
number of customers, the loss of which could materially adversely affect our business, financial condition and results of operations.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">We have historically derived the majority of our revenues from a small
number of customers who resell our products to end-users, and most of these customers are significantly larger companies than us.
For the year ended December&nbsp;31, 2015, five customers accounted for 84% of product revenue, with Mitek alone accounting for
72% of product revenue. We expect to continue to be dependent on a small number of large customers, especially Mitek, for the majority
of our revenues for the foreseeable future. The failure of these customers to purchase our products in the amounts they historically
have or in amounts that we expect would seriously harm our business.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In addition, if present and future customers terminate their purchasing
arrangements with us, significantly reduce or delay their orders, or seek to renegotiate their agreements on terms less favorable
to us, our business, financial condition, and results of operations will be adversely affected. If we accept terms less favorable
than the terms of the current agreements, such renegotiations may have a material adverse effect on our business, financial condition,
and/or results of operations. Furthermore, in any future negotiations we may be subject to the perceived or actual leverage that
these customers may have given their relative size and importance to us. Any termination, change, reduction, or delay in orders
could seriously harm our business, financial condition, and results of operations. Accordingly, unless and until we diversify and
expand our customer base, or develop alternative commercial strategies, our future success will significantly depend upon the timing
and size of future purchases by our largest customers, and the financial and operational success of these customers. The loss of
any one of our major customers or the delay of significant orders from such customers, even if only temporary, could reduce or
delay our recognition of revenues, harm our reputation in the industry, and reduce our ability to accurately predict cash flow,
and, as a consequence, it could seriously harm our business, financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Information security breaches or business system disruptions may adversely affect
our business. </i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We rely on our information technology infrastructure and management
information systems to effectively run our business. While we have not previously experienced a material information security breach
caused by illegal hacking, computer viruses, or acts of vandalism or terrorism, we may in the future be subject to such a breach.
Our security measures or those of our third-party service providers may not detect or prevent such breaches. Any such compromise
to our information security could result in an interruption in our operations, the unauthorized publication of our confidential
business or proprietary information, the unauthorized release of customer, vendor, or employee data, the violation of privacy,
or other laws and exposure to litigation, any of which could harm our business and operating results.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white"><b><i>Our business may be adversely affected if consolidation
in the healthcare industry leads to demand for price concessions or if we are excluded from being a supplier by a group purchasing
organization or similar entity.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">Because healthcare costs have risen significantly
over the past decade, numerous initiatives and reforms have been launched by legislators, regulators, and third-party payers to
curb these costs. As a result, there has been a consolidation trend in the healthcare industry to create larger companies, including
hospitals, with greater market power. As the healthcare industry consolidates, competition to provide products and services to
industry participants has become and may continue to become more intense. This may result in greater pricing pressures and the
exclusion of certain suppliers from important markets as group purchasing organizations, independent delivery networks, and large
single accounts continue to use their market power to consolidate purchasing decisions. If a group purchasing organization excludes
us from being one of their suppliers, our net sales could be adversely impacted. We expect that market demand, government regulation,
third-party reimbursement policies, and societal pressures will continue to change the worldwide healthcare industry, which may
exert further downward pressure on the prices of our products.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We experience quarterly sales volume variation, which makes our future results
difficult to predict and makes period-to-period comparisons potentially not meaningful.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">We experience quarterly fluctuations in our products sales as a result
of multiple factors, many of which are outside of our control. These quarterly fluctuations create uncertainty as to the volume
of sales that we may achieve in a given period. As a result, comparing our operating results on a period-to-period basis might
not be meaningful. You should not rely on our past results as an indication of our future performance. Our operating results could
be disproportionately affected by a reduction in revenue because a proportionately smaller amount of our expenses varies with our
revenue. As a result, our quarterly operating results are difficult to predict, even in the near term.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>Risks Related to Our Intellectual Property</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We may be unable to adequately protect our intellectual property rights, which
could have a material impact on our business and future financial results.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our efforts to enforce our intellectual property rights may not be
successful. We rely on a combination of copyright, trademark, patent, and trade secret laws, confidentiality procedures, and contractual
provisions to protect our proprietary rights. Our success will depend, in part, on our ability to obtain and enforce patents and
trademarks, to protect trade secrets, to obtain licenses to technology owned by third parties when necessary, and to conduct our
business without infringing on the proprietary rights of others. The patent positions of pharmaceutical, medical product, and biotechnology
firms, including ours, can be uncertain and involve complex legal and factual questions. There can be no assurance that any patent
applications will result in the issuance of patents or, if any patents are issued, that they will provide significant proprietary
protection or commercial advantage or will not be circumvented by others. In the event a third party has also filed one or more
patent applications for any of its inventions, we may have to participate in interference proceedings declared by the U.S. Patent
and Trademark Office to determine priority of invention, which could result in the failure to obtain, or the loss of, patent protection
for the inventions and the loss of any right to use the inventions. Even if the eventual outcome is favorable to us, such interference
proceedings could result in substantial cost to us, including, but not limited to, the diversion of management&#8217;s attention
away from our other operations. Filing and prosecution of patent applications, litigation to establish the validity and scope of
patents, assertion of patent infringement claims against others, and the defense of patent infringement claims by others can be
expensive and time consuming. There can be no assurance that, in the event that any claims with respect to any of our patents,
if issued, are challenged by one or more third parties, any court or patent authority ruling on such challenge will determine that
such patent claims are valid and enforceable. An adverse outcome in such litigation could cause us to lose exclusivity covered
by the disputed rights. If a third party is found to have rights covering products or processes used by us, we could be forced
to cease using the technologies or marketing the products covered by such rights, we could be subject to significant liabilities
to such third party, and we could be required to license technologies from such third party in order to continue production of
the products. Furthermore, even if our patents are determined to be valid, enforceable, and broad in scope, there can be no assurance
that competitors will not be able to design around such patents and compete with us using the resulting alternative technology.
We have a policy of seeking patent protection for patentable aspects of our proprietary technology. We intend to seek patent protection
with respect to products and processes developed in the course of our activities when we believe such protection is in our best
interest and when the cost of seeking such protection is not inordinate. However, no assurance can be given that any patent application
will be filed, that any filed applications will result in issued patents, or that any issued patents will provide us with a competitive
advantage or will not be successfully challenged by third parties. The protections afforded by patents will depend upon their scope
and validity, and others may be able to design around our patents.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We also rely upon trade secrets and proprietary know-how for certain
non-patented aspects of our technology. To protect such information, we require all employees, consultants, and licensees to enter
into confidentiality agreements limiting the disclosure and use of such information. There can be no assurance that these agreements
provide meaningful protection or that they will not be breached, that we would have adequate remedies for any such breach, or that
our trade secrets, proprietary know-how, and our technological advances will not otherwise become known to others. In addition,
there can be no assurance that, despite precautions taken by us, others have not and will not obtain access to our proprietary
technology. Further, there can be no assurance that third parties will not independently develop substantially equivalent or better
technology.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>There can be no assurance that we will not infringe upon the intellectual property
rights of others, which could have a significant impact on our business and financial results.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Other entities have filed patent applications for, or have been issued
patents concerning, various aspects of HA-related products or processes. There can be no assurance that the products or processes
developed by us will not infringe on the patent rights of others in the future. The cost of defending infringement suits is typically
large, and there is no guarantee that any future defense would be successful. In addition, infringement could lead to substantial
damages payouts or our inability to produce or market certain of our current or future products. As a result, any such infringement
may have a material adverse effect on our business, financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>Risks Related to Ownership of Our Common Stock</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b><i>Our stock price may be highly volatile, and we cannot assure
you that market making in our common stock will continue.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The market price of shares of our common stock may be highly volatile.
Factors such as announcements of new commercial products or technological innovations by us or our competitors, disclosure of results
of clinical testing or regulatory proceedings, government regulation and approvals, developments in patent or other proprietary
rights, public concern as to the safety of products developed by us, and general market conditions may have a significant effect
on the market price of our common stock. The trading price of our common stock could be subject to wide fluctuations in response
to quarter-to-quarter variations in our operating results, material announcements by us or our competitors, governmental regulatory
action, conditions in the health care industry generally or in the medical products industry specifically, or other events or factors,
many of which are beyond our control. In addition, the stock market has experienced extreme price and volume fluctuations, which
have particularly affected the market prices of many medical products companies and which often have been unrelated to the operating
performance of such companies. Our operating results in future quarters may be below the expectations of equity research analysts
and investors. In such an event, the price of our common stock would likely decline, perhaps substantially.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b><i>If securities or industry analysts do not publish or cease
publishing research or reports about us, our business, or our market, or if they adversely change their recommendations regarding
our stock, our stock price and trading volume could decline.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The trading market for our common stock is influenced by the research
and reports that securities or industry analysts may publish about us, our business, our market, or our competitors. No person
is under any obligation to publish research or reports on us, and any person publishing research or reports on us may discontinue
doing so at any time without notice. If adequate research coverage is not maintained on our company or if any of the analysts who
cover us downgrade our stock or publish inaccurate or unfavorable research about our business or provide relatively more favorable
recommendations about our competitors, our stock price would likely decline. If any analysts who cover us were to cease coverage
of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could
cause our stock price or trading volume to decline.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>We do not intend to pay dividends on our common stock in the foreseeable future.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We have never declared or paid any cash dividends on our common stock.
We currently intend to retain earnings, if any, for use in our business and do not anticipate paying cash dividends on our common
stock in the foreseeable future. Accordingly, investors are not likely to receive any dividends on their common stock in the foreseeable
future, and their ability to achieve a return on their investment will therefore depend on appreciation in the price of our common
stock.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Our charter documents contain anti-takeover provisions that may prevent or delay
an acquisition of our company.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Certain provisions of our Restated Articles of Organization and Amended
and Restated By-laws could have the effect of discouraging a third party from pursuing a non-negotiated takeover of us and preventing
certain changes in control. These provisions include a classified Board of Directors, advance notice to the Board of Directors
of stockholder proposals, limitations on the ability of stockholders to remove directors and to call stockholder meetings, and
the provision that vacancies on the Board of Directors be filled by vote of a majority of the remaining directors. In addition,
the Board of Directors adopted a ten-year Shareholders Rights Plan in April 2008. We are also subject to Chapter&nbsp;110F of the
Massachusetts General Laws which, subject to certain exceptions, prohibits a Massachusetts corporation from engaging in any of
a broad range of business combinations with any &#8220;interested stockholder&#8221; for a period of three years following the
date that such stockholder becomes an interested stockholder. All of these provisions, policies, and plans are reviewed periodically
by our Board of Directors. These provisions could discourage a third party from pursuing a takeover of us at a price considered
attractive by many stockholders, since such provisions could have the effect of preventing or delaying a potential acquirer from
acquiring control of us and our Board of Directors.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i1b"></a><b>ITEM 1B. UNRESOLVED STAFF COMMENTS</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">None.</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i2"></a><b>ITEM 2. PROPERTIES</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our corporate headquarters is located in Bedford, Massachusetts,
where we lease approximately 134,000 square feet of administrative, research and development, and manufacturing space. We entered
into this lease on January&nbsp;4, 2007, and the lease commenced on May&nbsp;1, 2007 for an initial term of ten and a half years.
We have an option under the lease to extend its terms for up to four periods beyond the original expiration date subject to the
condition that we notify the landlord that we are exercising each option at least one year prior to the expiration of the original
or then current term. The first three renewal options each extend the term an additional five years with the final renewal option
extending the term six years.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Anika S.r.l. currently leases approximately 28,000 square feet of
laboratory, warehouse, and office space in Abano Terme, Italy. The lease commenced on December 30, 2009 for an initial term of
six years, with the current lease being a six year lease that Anika may terminate at any time by providing six months&#8217; notice.
On October 9, 2015, Anika S.r.l. entered into a build-to-suit lease agreement for a new European headquarters facility, consisting
of approximately 33,000 square feet of general office, research and development, training, and warehousing space located in Padova,
Italy. The lease has an initial term of fifteen years, which is expected to commence during the fourth quarter of 2016. The lease
will automatically renew for up to three additional six-year terms, subject to certain terms and conditions. The Company has the
ability to early withdraw from this lease subject to certain financial penalties after six years and with no penalties after the
ninth year. The lease provides for an initial yearly rent of approximately $0.4 million.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">For the year ended December&nbsp;31, 2015, we had aggregate facility
lease expenses of approximately $1.3 million. We believe that the capacity of each of the properties we currently occupy is sufficient
to satisfy our current needs, as well as our needs for the foreseeable future. Upon Anika S.r.l.&#8217;s move into its new facility,
we believe that the property will be sufficient to satisfy its then-current needs, as well as its needs for the foreseeable future.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i3"></a><b>ITEM 3. LEGAL PROCEEDINGS</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">On July 7, 2010, Genzyme Corporation
filed a complaint against our company in the U.S. District Court for the District of Massachusetts seeking unspecified damages
and equitable relief. The complaint alleged that we infringed U.S. Patent No. 5,143,724 by manufacturing MONOVISC in the United
States for sale outside the United States and would infringe U.S. Patent Nos. 5,143,724 and 5,399,351&nbsp;if we manufactured and
sold MONOVISC in the United States. On March 7, 2014, we filed a joint motion with Genzyme to lift the stay in Genzyme&#8217;s
lawsuit against us and to dismiss with prejudice all of Genzyme&#8217;s claims. On March 10, 2014, the District Court granted the
motion to dismiss all of Genzyme&#8217;s claims against us with prejudice and the case was terminated.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 23; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We are also involved in various other legal proceedings arising in
the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, we do
not expect the resolution of these other legal proceedings to have a material adverse effect on our financial position, results
of operations, or cash flow.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i4"></a><b>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Not applicable.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="p2"></a><b>PART II</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i5"></a><b>ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Common Stock Information</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our common stock has traded on the NASDAQ Global Select Market since
November&nbsp;25, 1997, under the symbol &#8220;ANIK.&#8221; The following table sets forth, for the periods indicated, the high
and low sales prices of our common stock on the NASDAQ Global Select Market. These prices represent prices between dealers and
do not include retail mark-ups, markdowns, or commissions, and they may not necessarily represent actual transactions.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Year Ended December 31, 2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">First Quarter</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">45.35</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">37.05</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Second Quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">41.30</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">31.36</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Third Quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">39.24</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30.93</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Fourth Quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">43.82</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30.94</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>


<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Year Ended December 31, 2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">First Quarter</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">52.49</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">28.79</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Second Quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">51.40</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">35.62</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Third Quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">50.89</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">35.39</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Fourth Quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">43.24</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">34.16</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">At December&nbsp;31, 2015, the closing
price per share of our common stock was $38.16 as reported on the NASDAQ Global Select Market, and there were 146 holders of record
as of that date.&nbsp;We believe that the number of beneficial owners of our common stock at that date was substantially greater,
due to shares being held by intermediaries.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We have never declared or paid any cash dividends on our common stock.
We currently intend to retain earnings, if any, for use in our business and do not anticipate paying cash dividends on our common
stock in the foreseeable future. Payment of future dividends, if any, on our common stock will be at the discretion of our Board
of Directors after taking into account various factors, including our financial condition, operating results, anticipated cash
needs, and plans for expansion.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b>Performance Graph</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Set forth below is a graph comparing the total returns of our company,
the NASDAQ Composite Index, and the NASDAQ Biotechnology Index. The graph assumes $100 is invested on December 31, 2010 in our
common stock and each of the indices. Past performance is not indicative of future results.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="graph.jpg" alt=""></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec-10</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec-11</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec-12</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec-13</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec-14</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec-15</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; text-align: left; padding-left: 10pt">Anika Therapeutics, Inc.</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">100.00</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">146.93</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">149.03</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">572.11</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">610.79</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">572.11</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">NASDAQ Composite Index</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">100.00</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">98.20</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">113.82</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">157.44</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">178.53</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">188.75</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">NASDAQ Biotechnology Index</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">100.00</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">111.81</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">147.48</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">244.24</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">327.52</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">364.93</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><a name="i6"></a><b>ITEM 6. SELECTED FINANCIAL DATA</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 4.5pt 0pt 0; text-indent: 0.5in">The following selected consolidated financial data should
be read in conjunction with the Consolidated Financial Statements and the Notes thereto and the section captioned &#8220;<i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; included elsewhere in this Annual Report on
Form&nbsp;10-K. The Balance Sheet Data at December&nbsp;31, 2015 and 2014 and the Statement of Operations Data for each of the
three years ended December&nbsp;31, 2015, 2014, and 2013 have been derived from the audited Consolidated Financial Statements for
such years, included elsewhere in this Annual Report on Form&nbsp;10-K. The Balance Sheet Data at December&nbsp;31, 2013, 2012,
and 2011, and the Statement of Operations Data for each of the two&nbsp;years in the period ended December&nbsp;31, 2012 and 2011
have been derived from audited consolidated financial statements for such years not included in this Annual Report on Form 10-K.</p>

<p style="font-size: 10pt; margin: 0pt 4.5pt 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 4.5pt 0pt 0; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">Statements of Operations Data:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center">(in thousands, except per share data)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left">Product revenue</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">87,696</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">75,474</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">71,774</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">68,010</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">61,956</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Licensing, milestone and contract revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,303</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,121</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,307</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,348</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,822</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">92,999</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">105,595</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">75,081</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">71,358</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">64,778</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Cost of product revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,053</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,930</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,765</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">28,989</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26,784</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Product gross profit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">66,643</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">54,544</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">49,009</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">39,021</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">35,172</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Product gross margin</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">76%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">72%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">68%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">57%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">57%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total operating expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">44,865</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">44,148</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">42,474</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">51,643</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">50,811</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,758</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">38,319</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,575</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,757</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,467</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Diluted net income per common share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.01</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.51</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.39</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.82</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.62</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Diluted common shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,321</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,269</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,826</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,345</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,748</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>



<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">Balance Sheet Data:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center">(in thousands)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left">Cash, cash equivalents and investments</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">138,458</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">106,906</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">63,333</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">44,067</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">35,777</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Working capital*</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">159,155</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">131,863</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">84,650</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">60,900</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">47,680</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">235,748</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">192,808</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">156,042</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">142,069</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">132,844</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Long term debt</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,600</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,200</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Retained earnings</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">135,662</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">104,904</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">66,584</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">46,010</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">34,252</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stockholders' equity</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">210,848</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">178,098</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">135,634</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">108,925</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">94,763</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>



<p style="margin: 0">&nbsp;</p>

<p style="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">* In 2015, the Company adopted new accounting guidance related to the presentation of deferred income taxes, which has been applied above retrospectively. Current deferred tax assets and liabilities have been reclassified as non-current deferred tax assets and liabilities.</p>




<p style="font-size: 10pt; margin: 0pt 4.5pt 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><a name="i7"></a><b>ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>The following section contains statements that are not statements
of historical fact and are forward-looking statements within the meaning of the federal securities laws. These statements involve
known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievement to differ
materially from anticipated results, performance, or achievement, expressed or implied in such forward-looking statements. These
statements reflect our current views with respect to future events, are based on assumptions, and are subject to risks and uncertainties.
We discuss many of these risks and uncertainties at the beginning of this Annual Report on Form&nbsp;10-K and under the sections
captioned &#8220;Business&#8221; and &#8220;Risk Factors.&#8221; The following discussion should also be read in conjunction with
the consolidated financial statements and the Notes thereto appearing elsewhere in this Annual Report on Form 10-K.</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Management Overview</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We are a global, integrated orthopedic medicines company committed
to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing innovative and differentiated
therapeutic pain management solutions along the continuum of care, from palliative care to regenerative medicine. We have over
two decades of expertise developing, manufacturing, and commercializing our products, in markets across the globe, based on our
proprietary hyaluronic acid (&#8220;HA&#8221;) technology. Our orthopedic medicine portfolio is comprised of marketed (ORTHOVISC
and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by
replenishing depleted HA and aiding cartilage repair and regeneration.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our therapeutic offerings consist of products in the following areas:
Orthobiologics, Dermal, Surgical, Ophthalmic, and Veterinary. All of our products are based on HA, a naturally occurring, biocompatible
polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number
of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural
integrity of tissues, and the transport of molecules to and within cells.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our proprietary technologies for modifying the HA molecule allow
product properties to be tailored specifically to therapeutic use. Our patented technology chemically modifies HA to allow for
longer residence time in the body. We also offer products made from HA based on two other technologies: HYAFF, which is a solid
form of HA, and ACP gel, an autocross-linked polymer of HA.&nbsp;Our technologies are protected by an extensive portfolio of owned
and licensed patents.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Since our inception in 1992, we have utilized a commercial partnership
model for the distribution of our products to end users. Our strong, worldwide network of distributors has historically provided,
and continues to provide, a solid foundation for our revenue growth and territorial expansion. In 2015, we made the strategic decision
to commercialize our next generation viscosupplementation product, CINGAL, in the United States ourselves, initially through the
engagement of a contract sales organization. Ultimately, we intend to transition the entirety of the direct sales function into
our company as part of a broader buildout of our commercial capabilities. We believe that the combination of the direct and distribution
commercial models will maximize the revenue potential from our current and future product portfolio.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We began a strategic project in 2015 to move the manufacturing of
our HYAFF-based products, which currently are manufactured by a third party in Italy, to our Bedford, Massachusetts facility. Our
main purposes behind this strategic move are to improve the efficiency of our manufacturing process and to enhance our research
and development capabilities, with the aim of accelerating future product development. We expect to expend approximately $15 million
on this project over the course of the next 12 to 18 months.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following sections provide more information about our products:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt"><i>Orthobiologics</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">Our orthobiologics business contributed 84% of our product revenue for
the year ended December 31, 2015. Our orthobiologics products primarily consist of viscosupplementation and regenerative orthopedic
products. Viscosupplementation products include ORTHOVISC, ORTHOVISC <I>mini,</I> and MONOVISC, each of which is commercialized
in various territories worldwide, and CINGAL, which we plan to launch internationally in Canada and Europe in 2016. ORTHOVISC is
available in the United States, Canada, and some international markets for the treatment of osteoarthritis of the knee, and in
Europe and other international markets for the treatment of osteoarthritis in all joints. It has been marketed by us in the United
States since 2004 and internationally since 1996 through various distribution agreements. ORTHOVISC<I> mini</I> is available in
Europe and is designed for the treatment of osteoarthritis in small joints. MONOVISC is our single injection osteoarthritis treatment
indicated for all joints in Europe and certain international markets, and for the knee in the United States, Turkey, and Canada.
ORTHOVISC<I> mini</I> and MONOVISC both became available in certain international markets through our network of distributors during
the second quarter of 2008, and the commercial introduction of MONOVISC in the United States occurred in April 2014. CINGAL, our
second single-injection osteoarthritis product, received regulatory approval from Health Canada in November 2015, and we expect
the related commercial introduction of CINGAL in Canada to occur in the second quarter of 2016. We are currently seeking regulatory
approval of CINGAL in the United States and the European Union, and we expect to receive CE Mark approval in the European Union
by the end of April 2016.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; text-indent: 0.5in; margin: 0pt 0">We currently offer several orthopedic products
used in connection with regenerative medicine.&nbsp;The products currently available in Europe and certain international markets
include HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as
an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; and HYALOSS, HYAFF fibers used to mix
blood/bone grafts to form a paste for bone regeneration.&nbsp;We also offer HYALOGLIDE, an ACP gel used in tenolysis treatment
that, with additional clinical data, may demonstrate potential for flexor tendon adhesion prevention and for the treatment of adhesive
capsulitis prevention in the shoulder. These products are commercialized through a network of distributors, primarily in Europe,
the Middle East, and Korea.&nbsp;We believe that the U.S. market offers excellent expansion potential to increase revenue for these
products, and this will continue to be a focus area for us moving forward.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">Our strategy is to continue to add new products, to expand the indications
for use of both our current and any new products, and to expand our commercial reach. The orthobiologics area has been our fastest
growing area, growing from 58% of our product revenue in 2010 to 84% of our product revenue in 2015. We continue to seek new distribution
partnerships around the world, in concert with entering new markets with other appropriate sales strategies, and we expect total
orthobiologics product sales to increase in 2016 compared to 2015 based on sales to existing and new partners, as well as CINGAL
international product launches, including in Canada and Europe. Additionally, if we achieve FDA approval of CINGAL, we plan to
utilize a direct sales model to commercialize the product in the United States initially through the engagement of a contract sales
organization with the ultimate goal of transitioning the direct sales function to our company as part of a broader buildout of
our commercial capabilities.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt; text-indent: 0pt"><i>Dermal </i></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">Our dermal products contributed 2% to our product revenue for the year
ended December 31, 2015 and consist of advanced wound care products, which are based on the HYAFF technology, and aesthetic dermal
fillers. We offer products for the treatment of skin wounds ranging from burns to diabetic ulcers. The products cover a variety
of wound treatment solutions including debridement agents, advanced therapies, and scaffolds used as skin substitutes. Leading
products include HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection
with the regeneration of skin. Our dermal products are commercialized through a network of distributors, primarily in Europe, Latin
America, and the Middle East. Several of the products are also cleared for sale in the United States including HYALOMATRIX, HYALOFILL,
HYALOGRAN, and HYALOMATRIX 3D. We have a commercial partnership agreement with Medline Industries, Inc. to commercialize HYALOMATRIX
in the United States on an exclusive basis through 2019.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our initial aesthetic dermatology product is a dermal filler based
on our proprietary, chemically modified, cross-linked HA, and it is approved in certain European Union countries, Canada, the United
States, South Korea, and certain countries in South America. Internationally, this product is marketed under the ELEVESS trade
name. In the United States, the trade name is HYDRELLE, although the product is not currently marketed in the United States.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><i>Surgical</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our surgical group consists of products used to prevent surgical
adhesions and to treat ENT disorders. For the year ended December&nbsp;31, 2015, sales of surgical products contributed 7% of our
product revenue. HYALOBARRIER is a clinically proven post-operative adhesion barrier for use in the abdomino-pelvic area. The product
is currently commercialized in Europe, the Middle East, and certain Asian countries through a distribution network, but it is not
approved in the United States. INCERT, approved for sale in Europe, Turkey, and Malaysia, is a chemically modified, cross-linked
HA product used for the prevention of post-surgical spinal adhesions. There are no plans at this time to distribute INCERT in the
United States.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We also offer several products used in connection
with the treatment of ENT disorders.&nbsp;The lead products are MEROGEL, a woven fleece nasal packing, and MEROGEL INJECTABLE,
a thick, viscous hydrogel composed of cross-linked HA, a biocompatible agent that creates a moist wound-healing environment.&nbsp;We
partner with Medtronic for the worldwide distribution of these products.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Ophthalmic</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our ophthalmic business includes HA viscoelastic products used in
ophthalmic surgery. For the year ended December&nbsp;31, 2015, sales of ophthalmic products contributed 2% of our product revenue.
We previously manufactured the AMVISC product line for B&amp;L under the terms of a supply agreement that expired on December 31,
2014, and it was not renewed. Given that the ophthalmic franchise is not part of our core business, and that it has been steadily
diminishing for the past few years, we do not expect this event to have a material impact on our results going forward. Operating
margins under the B&amp;L agreement were low, and B&amp;L accounted for 3% of product revenue for the year ended 2014.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Veterinary</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">U.S.&nbsp;sales of HYVISC, our product for the treatment of equine
osteoarthritis, contributed 5% to product revenue for the year ended December&nbsp;31, 2015. We continue to look at other veterinary
applications and opportunities to expand geographic territories.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 28; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><i>Research and Development</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our research and development efforts primarily consist of the development
of new medical applications for our HA-based technology, the management of clinical trials for certain product candidates, the
preparation and processing of applications for regulatory approvals or clearances at all relevant stages of product development,
and process development and scale-up manufacturing activities for our existing and new products. Our development focus includes
products for tissue protection, repair, and regeneration. For the years ended December&nbsp;31, 2015, 2014 and 2013, these expenses
were $9.0 million, $8.1&nbsp;million, and $7.1&nbsp;million, respectively. We anticipate that we will continue to commit significant
resources to research and development, including in relation to clinical trials, in the future.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our second single-injection osteoarthritis
product under development is CINGAL, which is composed of our proprietary cross-linked HA material combined with an approved steroid
and is designed to provide both short- and long-term pain relief to patients. We completed the CINGAL phase III clinical trial
and associated statistical analysis during the fourth quarter of 2014. During the first half of 2015, we completed a CINGAL retreatment
study with patients who had participated in the phase III clinical trial and reported safety data related to the retreatment study.
On the regulatory front, we submitted an application for CE Mark approval of the product in December 2014, and we expect to receive
such approval by the end of April 2016. In May 2015, we also submitted an application for regulatory approval of CINGAL to Health
Canada, and we received notification of approval for CINGAL from Health Canada in early November 2015. After discussion with the
FDA related to the regulatory pathway for CINGAL, we conducted a formal meeting with the FDA&rsquo;s Office of Combination Products
to present and discuss our data in September 2015, and we submitted a formal request for designation with OCP a month later. In
its response to our formal request for designation, OCP assigned the product to CDER as the lead agency center for premarket review
and regulation. Since then, we have been in ongoing discussions with CDER to understand the requirements for submitting an NDA
for CINGAL, and preliminary indications from the FDA suggest that additional clinical work may be required. We will meet with the
FDA to collaboratively discuss this topic.</P>



<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We have research and development programs underway for new products
including for HYALOFAST, an innovative product for cartilage tissue repair, HYALOBONE, a bone void filler, and other early stage
regenerative medicine development programs. HYALOFAST received CE Mark approval in September 2009, and it is commercially available
in Europe and certain international countries. During the first quarter of 2015, we submitted an Investigational Device Exemption
(&#8220;IDE&#8221;) to the FDA, which was approved in July 2015. We are in the early stages of the phase III clinical trial for
HYALOFAST, and we enrolled our first patient in December 2015. Another of our products, HYALOSPINE, is an innovative adhesion prevention
gel for use after spinal surgery. We completed a HYALOSPINE pilot clinical study in 2012, submitted the CE Mark application in
September 2013, and received the CE Mark approval in January 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">In June 2015, we entered into an agreement with the Institute for Applied
Life Sciences at the University of Massachusetts Amherst to collaborate on research to develop a therapy for rheumatoid arthritis.
The purpose of this research is to develop a novel modality for the treatment of rheumatoid arthritis, and if successful, it is
expected to yield a potential product candidate that we could begin to move towards commercialization as early as 2017.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Summary of Critical Accounting Policies; Significant Judgments and Estimates</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our discussion and analysis of our financial condition and results
of operations are based upon our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, which
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the
reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities.
We monitor our estimates on an on-going basis for changes in facts and circumstances, and material changes in these estimates could
occur in the future. Changes in estimates are recorded in the period in which they become known. We base our estimates on historical
experience and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates
if past experience or other assumptions do not turn out to be substantially accurate.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 29; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We have identified the policies below as critical to our business
operations and the understanding of our results of operations. The impact and any associated risks related to these policies on
our business operations are discussed throughout this section captioned &#8220;<i>Management&#8217;s Discussion and Analysis of
Financial Condition and Results of Operations</i>&#8221; where such policies affect our reported and expected financial results.
For a detailed discussion on the application of these and other accounting policies, see Note&nbsp;2 to the consolidated financial
statements included elsewhere in this Annual Report on Form&nbsp;10-K.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Revenue Recognition - General</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We recognize revenue from product sales when all of the following
criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the seller's
price to the buyer is fixed or determinable; and collection from the customer is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Product Revenue</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">Revenue from product sales
is recognized when title and risk of loss have passed to the customer, which is typically upon shipment to the customer. Amounts
billed or collected prior to recognition of revenue are classified as deferred revenue. When determining whether risk of loss has
transferred to customers on product sales, or if the sales price is fixed or determinable, we evaluate both the contractual terms
and conditions of our distribution and supply agreements as well as our business practices. </font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">Product revenue also includes
royalties. Royalty revenue is based on our distributors&#8217; sales and is recognized in the same period our distributors record
their sale of products manufactured by us. On a quarterly basis we record royalty revenue based upon estimated or reported sales
results provided to us by our distributor customers. If necessary, we adjust our estimates based upon final sales data received
prior to issuing our quarterly unaudited or annual audited financial statements.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><i>Licensing, Milestone and Contract Revenue</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Licensing, milestone, and contract revenue consists of revenue recognized
on initial and milestone payments, as well as contractual amounts received from partners. Our business strategy includes entering
into collaborative license, development, and/or supply agreements with partners for the development and commercialization of our
products.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The terms of the agreements typically include non-refundable license
fees, funding of research and development, and payments based upon achievement of certain milestones. We adopted Accounting Standards
Update (&#8220;ASU&#8221;) 2009-13, <i>Revenue Recognition, </i>in January 2011, which amends ASC 605-25,<i> Multiple Element Arrangements</i>
to require the establishment of a selling price hierarchy for determining the allocable selling price of an item. Under ASC 605-25,
as amended by ASU 2009-13, in order to account for an element as a separate unit of accounting, the element must have objective
and reliable evidence of selling price of the undelivered elements. In general, non-refundable upfront fees and milestone payments
that do not relate to other elements are recognized as revenue over the term of the arrangement as we complete our performance
obligations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Inventories</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Inventories are stated at the lower of cost or market, with cost
being determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor,
and manufacturing overhead. Inventory costs associated with product candidates that have not yet received regulatory approval are
capitalized if we believe there is probable future commercial use and future economic benefit.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">Our policy is to write-down
inventory when conditions exist that suggest inventory may be in excess of anticipated demand or is obsolete based upon assumptions
about future demand for our products and market conditions. We regularly evaluate our ability to realize the value of inventory
based on a combination of factors including, but not limited to, historical usage rates, forecasted sales or usage, product end
of life dates, and estimated current or future market values. Purchasing requirements and alternative usage avenues are explored
within these processes to mitigate inventory exposure. </font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Goodwill and Acquired In-Process Research and Development</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white"><font style="background-color: white">Goodwill
is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable
assets on the date of acquisition. Acquired IPR&amp;D represents the fair value assigned to research and development assets that
we acquire that have not been completed at the date of acquisition or are pending regulatory approval in certain jurisdictions.
The value assigned to the acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially
viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. </font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 30; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Goodwill and IPR&amp;D are evaluated for impairment annually, or
more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors we consider important,
on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical
or projected future operating results, significant changes in our use of the acquired assets or the strategy for our overall business,
significant negative industry or economic trends, a significant decline in our stock price for a sustained period, or a reduction
of our market capitalization relative to net book value.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">To conduct impairment tests of goodwill, the fair value of the reporting
unit is compared to its carrying value. If the reporting unit&#8217;s carrying value exceeds its fair value, we record an impairment
loss to the extent that the carrying value of goodwill exceeds its implied fair value. We estimate the fair value for our reporting
unit using discounted cash flow valuation models which require the use of significant estimates and assumptions including but not
limited to, the risk free rate of return on an investment, the weighted average cost of capital, future revenue, operating margin,
working capital, and capital expenditure needs. Our annual assessment for impairment of goodwill as of November 30, 2015 indicated
that the fair value of our reporting unit exceeded the carrying value of the reporting unit.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">To conduct impairment tests of IPR&amp;D, the fair value of the IPR&amp;D
project is compared to its carrying value. If the carrying value exceeds its fair value, we record an impairment loss to the extent
that the carrying value of the IPR&amp;D project exceeds its fair value. We estimate the fair value for IPR&amp;D projects using
discounted cash flow valuation models, which require the use of significant estimates and assumptions, including but not limited
to, estimating the timing of and expected costs to complete the in-process projects, projecting regulatory approvals, estimating
future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount
rates. <font style="background-color: white">During the fourth quarter of 2015 we performed an impairment review of our IPR&amp;D
projects as we reassessed our R&amp;D strategy. We recorded an impairment charge of $0.7 million due to the decision to discontinue
further development efforts needed to commercialize this technology. </font>Our annual assessment for impairment of IPR&amp;D indicated
that the fair value of our other IPR&amp;D assets as of November 30, 2015 exceeded their respective carrying values.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Through December 31, 2015 there have not been any events or
changes in circumstances that indicate that the carrying value of goodwill or acquired intangible assets may not be
recoverable. We continue to monitor and evaluate the financial performance of our business, including the impact of general
economic conditions, to assess the potential for the fair value of the reporting unit to decline below its book value. There
can be no assurance that, at the time future impairment tests are completed, a material impairment charge will not be
recorded.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Long-Lived Assets</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Long-lived assets primarily include property and equipment, and intangible
assets with finite lives. Our intangible assets are comprised of purchased developed technologies, distributor relationships, patents,
and trade names. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line
basis over the intangible assets' useful lives, which range from approximately&nbsp;5&nbsp;to&nbsp;16&nbsp;years. We review long-lived
assets for impairment when events or changes in business circumstances indicate that the carrying amount of the assets may not
be fully recoverable or that the useful lives of those assets are no longer appropriate. Each impairment test is based on a comparison
of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its
estimated fair value based on a discounted cash flow analysis.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><i>Stock-Based Compensation</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We measure the compensation cost of award recipients&#8217; services
received in exchange for an award of equity instruments based on the grant-date fair value of the underlying award. That cost is
recognized over the period during which an employee is required to provide service in exchange for the award. For performance based
awards with financial achievement targets, we recognize expense using the graded vesting methodology based on the number of shares
expected to vest. Compensation cost associated with performance grants is estimated using the Black-Scholes valuation method multiplied
by the expected number of shares to be issued, which is adjusted based on the estimated probabilities of achieving the performance
goals. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related
share-based compensation expense that will be recorded in the period of the change. If the performance targets are not achieved,
no compensation cost is recognized and any previously recognized compensation cost is reversed. See Note&nbsp;13 to the consolidated
financial statements included elsewhere in this Annual Report on Form 10-K for a description of the types of stock-based awards
granted, the compensation expense related to such awards, and detail of equity-based awards outstanding. See Note 17 to such consolidated
financial statements for details related to the tax benefit recognized in the consolidated statement of operations for stock-based
compensation.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 31; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><i>Income Taxes</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our income tax expense includes U.S.&nbsp;and international income
taxes. Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effects
of these differences are reported as deferred tax assets and liabilities. Deferred tax assets are recognized for the estimated
future tax effects of deductible temporary differences and tax operating loss and credit carry-forwards. Changes in deferred tax
assets and liabilities are recorded in the provision for income taxes. We assess the likelihood that our deferred tax assets will
be recovered from future taxable income and, to the extent we believe that it is more likely than not that all or a portion of
deferred tax assets will not be realized, we establish a valuation allowance. To the extent we establish a valuation allowance
or increase this allowance in a period, we include an expense within the tax provision in the consolidated statement of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Results of Operations</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt"><b><i>Year ended December&nbsp;31, 2015 compared to year ended
December&nbsp;31, 2014</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="text-align: left; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">Statement of Operations Detail</p>



<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$
    Inc/(Dec)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%
    Inc/(Dec)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center">(in thousands, except percentages)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left; padding-left: 12px">Product revenue</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">87,696</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">75,474</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">12,222</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">16</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Licensing, milestone and contract revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,303</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,121</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(24,818</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(82</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Total revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">92,999</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">105,595</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(12,596</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(12</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"></td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Operating expenses:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"></td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Cost of product revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,053</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,930</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">123</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Research&nbsp;&amp; development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,987</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,144</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">843</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Selling, general&nbsp;&amp; administrative</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,825</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,074</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(249</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Total operating expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">44,865</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">44,148</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">717</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Income from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,134</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">61,447</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(13,313</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(22</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Interest income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">120</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">58</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">62</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">107</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Income before income taxes</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,254</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">61,505</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(13,251</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(22</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Provision for income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,496</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23,186</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,690</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(25</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 12px">Net income</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">30,758</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">38,319</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(7,561</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(20</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Product gross profit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">66,643</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">54,544</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">12,099</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Product gross margin</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">76%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">72%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>






<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Total revenue. </i>Total revenue for the year ended December&nbsp;31,
2015 decreased by $12.6 million to $93.0 million compared to the prior year. Total revenue decreased primarily due to the recognition
of approximately $29.7 million in milestone and contract revenue recognized in the year ended December 31, 2014 associated with
the Mitek MONOVISC Agreement, which was partially offset by $5 million of milestone revenue received in 2015 for the achievement
of a target MONOVISC U.S. end user sales threshold.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i></I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"><I>Product revenue by product line. </I>Product revenue for the year
ended December&nbsp;31, 2015 was $87.7 million, an increase of $12.2 million, or 16%, compared to the prior year. Product revenue
increases in our Orthobiologics, Dermal, and Veterinary franchises were partially offset by moderate decreases in revenue as a
result of the unfavorable impact from foreign currency exchange rate fluctuations. The increases were also offset by decreases
related to the B&amp;L supply agreement, which expired as expected at the end of 2014. Included in product revenue for the year
ended December 31, 2015 was approximately $1.8 million and $0.5 million of non-recurring revenue recorded in the second and third
quarter of 2015, respectively, related to a high end-user average selling price for MONOVISC products sold to our U.S. partner,
Mitek, prior to the fourth quarter of 2014. Products sold to Mitek after the third quarter of 2014 are not impacted by this arrangement,
which will not result in additional related revenue.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 32; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$
    Inc/(Dec)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%
    Inc/(Dec)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center">(in thousands, except percentages)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left; padding-left: 12px">Orthobiologics</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">73,247</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">61,957</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">11,290</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">18</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Dermal</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,266</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,334</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">932</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">70</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Surgical</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,812</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,855</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(43</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,371</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,328</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">43</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">87,696</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">75,474</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">12,222</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">Revenue from our orthobiologics franchises increased $11.3 million, or
18%, in 2015 compared to 2014. The growth in 2015 reflected a growing end-user demand, continued market penetration, increased
revenue from worldwide ORTHOVISC and worldwide MONOVISC sales, as well as the non-recurring product revenue discussed in the prior
section. Domestic ORTHOVISC and MONOVISC end user sales increased 24% in 2015 compared to 2014. These increases were partially
offset by decreases in product sales to Mitek as a result of its planned reduction in inventory, which was completed during the
third quarter of 2015. International viscosupplementation product revenue in 2015 increased 42% compared to 2014. The increase
in international revenue was driven primarily by increased sales of MONOVISC and ORTHOVISC in 2015, as compared to 2014, resulting
from growing end-user demand. We expect orthobiologics revenue to continue to grow in 2016, led by increased MONOVISC revenue in
the United States, the expected commercial launch of CINGAL in Canada and Europe, as well as overall revenue growth from our viscosupplementation
products both domestically and internationally.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">Dermal revenue increased $0.9 million, or 70%, in
2015 compared to 2014. The increase as compared to 2014 primarily reflects revenue from the agreement we entered into in July 2014
with Medline Industries, Inc. to commercialize HYALOMATRIX in the United States on an exclusive basis through 2019. We expect advanced
wound care revenue to increase in 2016 compared to 2015 primarily due increased end user demand and geographic expansion, particularly
in the U.S., European, and Latin American markets.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">Sales of our surgical&nbsp;products decreased slightly in 2015 as compared
to 2014. The decrease of surgical product revenue was primarily due to the unfavorable impact from foreign currency exchange rate
fluctuations compared with the same periods in the prior year. Our Surgical franchise consists primarily of our anti-adhesion and
ENT products. Our anti-adhesion products include INCERT and HYALOBARRIER. Our leading ENT product is MEROGEL.&nbsp;We are partnered
with Medtronic for worldwide distribution of these ENT products.&nbsp;We expect surgical product revenue to decrease moderately
in 2016 compared to 2015 primarily <FONT STYLE="background-color: white">due to continued unfavorable foreign currency exchange
rates and releveling of inventory by our U.S. ENT commercial partner</FONT>.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">Other product revenue includes revenues from ophthalmic and veterinary
products. The other product revenue decreased in 2015 from 2014 due to an increase in veterinary revenue, partially offset by a
decrease in ophthalmic revenue. We expect other revenue to decrease in 2016 as compared to 2015,<FONT STYLE="background-color: white">
primarily driven by lower veterinary revenue</FONT>.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Licensing, milestone, and contract revenue. </i>Licensing, milestone,
and contract revenue for the year ended December&nbsp;31, 2015 was $5.3 million, compared to $30.1 million for 2014. The year over
year decrease was primarily the result of the recognition of licensing and milestone revenue for the year ended December 31, 2014
of $27.5 million for milestone payments <font style="background-color: white">related to development obligations under the Mitek
MONOVISC Agreement. It also included the recognition of approximately $2.2 million unamortized upfront payments previously received
in December 2011. The FDA&#8217;s approval of our MONOVISC product during the first quarter in 2014 completed the delivery of development
obligations under the Mitek MONOVISC Agreement, and it resulted in the immediate recognition of a $17.5 million milestone payment,
as well as the full recognition of prior deferred revenue in that quarter. During the second quarter of 2014, a $5.0 million milestone
payment associated with the first commercial sale of MONOVISC in the United States was also earned, received, and recognized as
revenue. We also received a unique J-Code from the Centers for Medicare and Medicaid Services for MONOVISC during the fourth quarter
of 2014 and, a</font>s a result, we collected a milestone payment of $5.0 million which was fully earned and recognized as revenue.
For the year ended December 31, 2014, we recognized a total of $29.7 million in milestone revenue related to MONOVISC. During the
fourth quarter of 2015, we collected and fully recognized revenue for a milestone payment of $5.0 million as a result of U.S. MONOVISC
annual end-user sales exceeding $50 million. <font style="background-color: white">We expect that our licensing, milestone, and
contract revenue will decrease in 2016 compared to 2015 in large part due to milestone achievements by us in 2015 in relation to
our commercial agreement with Mitek for MONOVISC in the United States.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 33; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Product gross profit and margin. </i>Product gross profit for
the year ended December&nbsp;31, 2015 was $66.6 million, or 76% of product revenue, compared with $54.5 million, or 72% of product
revenue, for the year ended December&nbsp;31, 2014. The increase in product gross profit was primarily due to improved manufacturing
efficiencies, as well as improvements in the overall product sales mix compared to the prior year, with increased sales of our
higher-margin orthobiologics products as a percentage of our total product sales.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i></I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"><I>Research and development. </I>Research and development expenses for
the year ended December&nbsp;31, 2015 increased by $0.8 million, or 10%, as compared to the prior year, mainly due to a <FONT STYLE="background-color: white">$0.7
million expense resulting from an impairment charge related to IPR&amp;D that was recorded in connection with our acquisition of
Anika S.r.l. The charge resulted from a decision to discontinue development of the acquired Hemostatic Patch in-process development
project.&nbsp;</FONT> Research and development expense as a percentage of total revenue was 10% and 8% for the years ended 2015
and 2014, respectively. Research and development spending is expected to increase in 2016 and thereafter compared to 2015 as we
further develop new products and initiate new clinical trials based on our existing technology assets, including HYALOFAST, as
well as increased development activities for other products in the pipeline.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Selling, general, and administrative. </i>Selling, general, and
administrative expenses for the year ended December&nbsp;31, 2015 decreased by $249 thousand, or 2%, as compared to 2014. The decrease
was <font style="background-color: white">primarily a result of the full amortization of certain intangible assets on December
31, 2014, certain former employee termination and related expenses in 2014, as well as beneficial impact from foreign currency
exchange rate fluctuations</font>. We expect selling, general, and administrative expenses for 2016 will increase to reflect the
support required to grow our business both domestically and internationally.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Income taxes. </i>Provisions for income taxes were $17.5 million
and $23.2 million for the years ended December 31, 2015 and 2014, respectively. The decrease in the effective tax rate in 2015
of 1.4%, as compared to 2014, is primarily due to an increased benefit from domestic production activities.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">A reconciliation of the U.S.&nbsp;federal statutory tax rate to the
effective tax rate for the periods ending December&nbsp;31 is as follows:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Statutory federal income tax rate</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">35.0</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">35.0</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State tax expense, net of federal benefit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.8</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.9</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Permanent items, including nondeductible expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.3</td><td style="font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.1</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State investment tax credit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.1</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Federal, state and foreign research and development credits</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.4</td><td style="font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.7</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Foreign rate differential</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.1</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.2</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Domestic production deduction</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2.9</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1.7</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Effective income tax rate</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">36.3</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">37.7</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of December 31, 2015, we had net operating losses (&#8220;NOL&#8221;)
for income tax purposes in Italy of $6.3 million with no expiration date. In connection with the preparation of the financial statements,
we performed an analysis to ascertain if it was more likely than not that we would be able to utilize, in future periods, the net
deferred tax assets associated with our NOL carry-forward. We have concluded that the positive evidence outweighs the negative
evidence and, thus, that the deferred tax assets not otherwise subject to a valuation allowance are realizable on a &#8220;more
likely than not&#8221; basis. As such, we have not recorded a valuation allowance at December 31, 2015 or 2014.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The 2012 through 2015 tax years remain subject to examination by
the Internal Revenue Service (&#8220;IRS&#8221;) and other taxing authorities for U.S. federal and state purposes. The 2011 through
2015 tax years remain subject to examination by the applicable governmental authorities in Italy.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 34; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Net income. </i>For the year ended December&nbsp;31, 2015, net
income was $30.8 million, or $2.01 per diluted share, compared to $38.3, or $2.51 per diluted share, for the same period in the
prior year. The decrease in net income and diluted earnings per share was primarily a result of the approximately $29.7 million
in milestone and contract revenue recognized for the year ended December 31, 2014 associated with our U.S. license agreement for
MONOVISC.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Year ended December&nbsp;31, 2014 compared to year ended December&nbsp;31, 2013</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="text-align: left; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">Statement of Operations Detail</p>



<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$
    Inc/(Dec)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%
    Inc/(Dec)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center">(in thousands, except percentages)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left; padding-left: 12px">Product revenue</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">75,474</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">71,774</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">3,700</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">5</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Licensing, milestone and contract revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,121</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,307</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">26,814</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">811</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Total revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">105,595</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">75,081</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,514</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">41</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Operating expenses:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Cost of product revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,930</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,765</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,835</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(8</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Research&nbsp;&amp; development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,144</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,060</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,084</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Selling, general&nbsp;&amp; administrative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,074</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,936</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,138</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Restructuring credits</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(287</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">287</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(100</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Total operating expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">44,148</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">42,474</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,674</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Income from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">61,447</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">32,607</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">28,840</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">88</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Interest income (expense), net</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">58</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(127</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">185</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(146</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Income before income taxes</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">61,505</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">32,480</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">29,025</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">89</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Provision for income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23,186</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,905</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,281</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">95</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 12px">Net income</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">38,319</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">20,575</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,744</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">86</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Product gross profit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">54,544</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">49,009</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,535</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Product gross margin</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">72%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">68%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>




<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Total revenue. </i>Total revenue for the year ended December&nbsp;31,
2014 increased by $30.5 million to $105.6 million. The increase in product and total revenue was primarily due to the U.S. MONOVISC
commercial launch in April 2014 and milestone revenue from our U.S. distributor for MONOVISC, resulting from the product&#8217;s
FDA approval, patent litigation resolution, commercial launch, and the achievement of a unique reimbursement code from the Centers
for Medicare and Medicaid Services in 2014.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Product revenue by product line. </i>Product revenue for the year
ended December&nbsp;31, 2014 was $75.5 million, an increase of $3.7 million, or 5%, compared to the prior year.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$
    Inc/(Dec)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%
    Inc/(Dec)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center">(in thousands, except percentages)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left; padding-left: 12px">Orthobiologics</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">61,957</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">55,956</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">6,001</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">11</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Dermal</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,334</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,817</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(483</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(27</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Surgical</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,855</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,446</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">409</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,328</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,555</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,227</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(26</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">75,474</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,774</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,700</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table>



<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Revenue from our orthobiologics franchises increased $6.0 million,
or 11%, in 2014 compared to 2013. The improvement in orthobiologics product revenue was due primarily to increases in domestic
MONOVISC and&nbsp;ORTHOVISC revenue. This increase reflects MONOVISC U.S. product launch in April 2014 and Mitek&#8217;s continued
market penetration. International viscosupplementation product revenue in 2014 decreased 23% compared to 2013. The decrease in
international revenue was driven primarily by decreased sales of ORTHOVISC in 2014, as compared to 2013, resulting from increased
price competition.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Dermal revenue decreased $0.5 million, or 27%, in 2014 compared to
2013. The decrease was primarily due to decreases in advanced wound care products revenue, which totaled $1.2 million in 2014,
as compared to $1.6 million in 2013. This decrease was driven by order timing and lower revenue in Argentina as a result of the
country&#8217;s recent financial crisis.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 35; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Sales of our surgical&nbsp;products increased $0.4 million, or 8%,
in 2014 as compared to 2013. The increase was primarily due to the addition of line extension products in Korea to utilize an expanded
treatment indication. Our Surgical franchise consists primarily of anti-adhesion and ENT products. Our anti-adhesion products include
INCERT and HYALOBARRIER. Our leading ENT product is MEROGEL.&nbsp;We are partnered with Medtronic for worldwide distribution of
these ENT products.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Other revenue decreased $2.2 million, or 26%, compared to other revenue
in 2013. The decrease was primarily attributable to the reduced contractual minimum purchase commitment in the latest B&amp;L supply
agreement, which expired as expected at the end of 2014.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Licensing, milestone, and contract revenue. </i>Licensing, milestone,
and contract revenue for the year ended December&nbsp;31, 2014 was $30.1 million, compared to $3.3 million for 2013. Licensing
and milestone <font style="background-color: white">included a $17.5 million milestone payment resulting from the resolution of
the patent litigation with Genzyme and the FDA approval of MONOVISC, and it also included the recognition of approximately $2.2
million remaining in the unamortized upfront payment previously received in December 2011. These payments were related to our development
obligations under the Mitek MONOVISC Agreement. The FDA&#8217;s approval of our MONOVISC product during the quarter ended March
31, 2014 completed the delivery of our development obligations under the Mitek MONOVISC Agreement, and resulted in the immediate
recognition of the $17.5 million milestone payment, as well as the full recognition of prior deferred revenue in the first quarter
of 2014. During the second quarter of 2014, a $5.0 million milestone payment associated with the first commercial sale of MONOVISC
in the </font>United States<font style="background-color: white"> was earned, received, and recognized as revenue. We also received
a unique J-Code from CMS for MONOVISC during the fourth quarter of 2014 and, a</font>s a result, we collected a milestone payment
of $5.0 million, which was fully earned and recognized as revenue. For the year ended December 31, 2014, we recognized a total
of $29.7 million in milestone revenue related to MONOVISC.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Product gross profit and margin. </i>Product gross profit for
the year ended December&nbsp;31, 2014 was $54.5 million, or 72% of product revenue, compared with $49.0 million, or 68% of product
revenue, for the year ended December&nbsp;31, 2013. The increase in product gross profit was primarily due to favorable revenue
mix, improved manufacturing efficiencies, as well as improvements in the overall product sales mix compared to the prior year,
with increased sales of our higher-margin orthobiologics products as a percentage of our total product sales.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Research and development. </i>Research and development expenses
for the year ended December&nbsp;31, 2014 increased by $1.1 million, or 15%, as compared to the prior year, mainly due to the CINGAL
phase III clinical trial. Research and development expense as a percentage of total revenue was 8% and 9% for the years ended 2014
and 2013, respectively.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Selling, general, and administrative. </i>Selling, general, and
administrative expenses for the year ended December&nbsp;31, 2014 increased by $2.1 million, or 17%, as compared to 2013. This
increase was primarily due to a legal dispute settlement payment received in 2013, increases in external professional fees, and
increased headcount related expenses in 2014.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i></I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"><I>Restructuring credits. </I>On December 28, 2012, we announced a
strategic shift involving the closure of our tissue engineering facility in Abano Terme, Italy due to the inability to meet
strict regulatory standards, established by the EMA, which became effective January 1, 2013. As a result of the plan, we
recorded restructuring and associated impairment charges in the fourth quarter 2012 of approximately $2.5 million. Of the
total restructuring and associated impairment charges, approximately $1.6 million related to the abandonment and noncash
impairment of assets. The remaining $0.9 million related to cash payments that occurred in 2013, primarily for employee
termination costs. The restructuring plan was completed in 2013, with a $0.3 million benefit to the statement of operations
for the year ended December 31, 2013, based on actual expenses and payment settlements.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Interest income (expense), net. </i>Net interest income was $58
thousand for the year ended December&nbsp;31, 2014, as compared to interest expense of $127 thousand in the same period ended 2013.
On November 29, 2013, we terminated our credit agreement entered into on January 31, 2008 with lenders for which Bank of America,
N.A. served as administrative agent. In connection with the termination, we pre-paid in full the entire outstanding debt balance
of $8.4 million, and we did not incur any pre-payment penalties. This termination resulted in the change from net interest expense
in 2013 to net interest income in 2014. Interest income is primarily from our short-term investment holdings.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 36; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Income taxes. </i>Provisions for income taxes were $23.2 million
and $11.9 million for the years ended December 31, 2014 and 2013, respectively. The increase in the effective tax rate in 2014
of 1.0%, as compared to 2013, is primarily due to a decreased benefit from domestic production activities.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">A reconciliation of the U.S.&nbsp;federal statutory tax rate to the
effective tax rate for the periods ending December&nbsp;31 is as follows:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Statutory federal income tax rate</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">35.0</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">35.0</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State tax expense, net of federal benefit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.9</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.8</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Permanent items, including nondeductible expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.1</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.2</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State investment tax credit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.1</td><td style="font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.1</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Federal, state and foreign research and development credits</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.7</td><td style="font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.5</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Foreign rate differential</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.2</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.1</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Domestic production deduction</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1.7</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2.4</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Effective income tax rate</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">37.7</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">36.7</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; color: Red">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of December 31, 2014, we had net operating losses (&#8220;NOL&#8221;)
for income tax purposes in Italy of $8.3 million with no expiration date. In connection with the preparation of the financial statements,
we performed an analysis to ascertain if it was more likely than not that we would be able to utilize, in future periods, the net
deferred tax assets associated with our NOL carry-forward. We have concluded that the positive evidence outweighs the negative
evidence and, thus, that the deferred tax assets not otherwise subject to a valuation allowance are realizable on a &#8220;more
likely than not&#8221; basis. As such, we have not recorded a valuation allowance at December 31, 2014 or 2013.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>Net income. </i>For the year ended December&nbsp;31, 2014, net
income was $38.3 million, or $2.51 per diluted share, compared to $20.6 million, or $1.39 per diluted share, for the same period
in the prior year. The primary drivers for this increase in net income were an increase in gross profit due to increased milestone
and licensing revenue, a more favorable product mix, and the improved manufacturing efficiencies at our Bedford, Massachusetts
manufacturing facility.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Concentration of Risk</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We have historically derived the majority of our revenues from a
small number of customers, most of whom resell our products to end-users and most of whom are significantly larger companies than
us. For the year ended December 31, 2015, five customers accounted for 84% of product revenue, with Mitek alone accounting for
72% of product revenue. We expect to continue to be dependent on a small number of large customers, especially Mitek, for the majority
of our revenues for the foreseeable future, even with our implementation of a direct sales model for CINGAL in the United States.
The failure of these customers to purchase our products in the amounts they historically have or in amounts that we expect would
seriously harm our business.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In addition, if present and future customers terminate their purchasing
arrangements with us, significantly reduce or delay their orders, or seek to renegotiate their agreements on terms less favorable
to us, our business, financial condition, and results of operations will be adversely affected. If we accept terms less favorable
than the terms of the current agreements, such renegotiations may have a material adverse effect on our business, financial condition,
and/or results of operations. Furthermore, in any future negotiations we may be subject to the perceived or actual leverage that
these customers may have given their relative size and importance to us. Any termination, change, reduction, or delay in orders
could seriously harm our business, financial condition, and results of operations. Accordingly, unless and until we diversify and
expand our customer base, our future success will significantly depend upon the timing and size of future purchases by our largest
customers and the financial and operational success of these customers. The loss of any one of our major customers or the delay
of significant orders from such customers, even if only temporary, could reduce or delay our recognition of revenues, harm our
reputation in the industry, and reduce our ability to accurately predict cash flow, and, as a consequence, it could seriously harm
our business, financial condition, and results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 37; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">See Note 16, <i>Revenue by Product Group, by Significant Customer
and by Geographic region; Geographic Information</i>, to the consolidated financial statements included elsewhere in this Annual
Report on Form 10-K for information regarding significant customers.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Liquidity and Capital Resources </b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We require cash to fund our operating expenses and to make capital
expenditures. We expect that our requirements for cash to fund these uses will increase as our operations expand. Historically
we have generated positive cash flow from operations, which, together with our available cash, investments, and debt, have met
our cash requirements. Cash, cash equivalents and investments totaled $138.5 million and $106.9 million, and working capital totaled
$159.2 million and $131.9 million, at December 31, 2015 and December 31, 2014, respectively.&nbsp;We believe that we have adequate
financial resources to support our business for at least the next twelve months.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Cash provided by operating activities was $39.1 million, $40.0 million
and $25.2 million for 2015, 2014, and 2013, respectively. The decrease in cash provided by operations was due primarily to decreased
net income compared to the same period last year, which reflected $29.7 million in milestone and contract revenue associated with
our U.S. license agreement for MONOVISC. Cash provided by operations was also <font style="background-color: white">impacted by
an increase in net working capital requirements as compared to the same period in 2014 related to higher accounts receivable, inventory
purchases and the timing of sales during the year, which was partially offset by higher levels of accounts payable at December
31, 2015.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Cash used in investing activities was $30.2 million, $8.3 million,
and $253 thousand for 2015, 2014, and 2013, respectively. The increase in cash used in investing activities in 2015, as compared
to the same period in the prior year, is a result of purchases of investments and increased capital purchases associated with our
Bedford, Massachusetts headquarters and manufacturing facility.&nbsp;We expect an increase in investing activities in 2016 as a
result of our on-going project to establish additional manufacturing capabilities at the Bedford, Massachusetts facility to manufacture
our HYAFF-based products, which currently are manufactured by a third party in Italy. At December 31, 2015, we expended approximately
$9 million for this project. We expect to expend approximately $15.0 million on this project over the course of the next twelve
to eighteen months.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Cash provided by financing activities was $1.9 million and $5.3 million
for 2015 and 2014, respectively, whereas cash used in financing activities was $5.7 million in 2013. The decrease in cash provided
by financing activities compared to the same period in the prior year was attributable to the lower tax benefits and cash received
in regards to employees&#8217; exercise of equity awards.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Contractual Obligations and Other Commercial Commitments</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The table below summarizes our non-cancelable operating leases, purchase
commitments and contractual obligations related to future periods which are not reflected in our consolidated balance sheet at
December&nbsp;31, 2015. Purchase commitments relate primarily to non-cancellable inventory commitments and capital expenditures
entered in the normal course of business:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Payments due by period (in thousands)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Less than</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">More than</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">1 year</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">1 - 3 years</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">3 - 5 years</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">5 years</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Operating Leases <font style="font-size: 10pt; font-weight: normal; font-style: normal"><sup>(1)</sup></font></td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">10,403</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">1,540</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">2,618</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">2,668</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">3,577</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1pt">Purchase Commitments <font style="font-size: 10pt; font-weight: normal; font-style: normal"><sup>(2)</sup></font></td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">16,601</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">16,249</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">318</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">34</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27,004</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,789</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,936</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,702</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,577</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">(1)</font></td>
    <td style="width: 94%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Included in this line is a lease we entered into on January&nbsp;4, 2007, pursuant to which we lease our corporate headquarters facility, which consists of approximately 134,000 square feet of general office, research and development, and manufacturing space located in Bedford, Massachusetts. The lease has an initial term of ten and one-half years, and commenced on May&nbsp;1, 2007. We have an option under the lease to extend its terms for up to four periods, ranging in length from 5 to 6 years, beyond the original expiration date subject to the condition that we notify the landlord that we are exercising each option at least one year prior to the expiration of the original or current term thereof. The first three renewal options each extend the term an additional five years with the final renewal option extending the term six years.&nbsp;Also included in this line is a lease entered into pursuant to which Anika S.r.l. leases its Italian facility, which consists of approximately 28,000 square feet of space. The lease commenced on December 30, 2009 for a period of six years with certain extension options. See the section captioned &#8220;<i>Properties</i>&#8221; for additional information regarding these leases. On October 9, 2015, Anika S.r.l, entered into a build-to-suit lease agreement for a new European headquarters facility consisting of approximately 33,000 square feet of general office, research and development, training, and warehousing space located in Padova, Italy. This lease has an initial term of fifteen years, which is expected to commence during the fourth quarter of 2016. The lease will automatically renew for up to three additional six-year terms, subject to certain terms and conditions. The lease provides for an initial yearly rent of approximately $0.4 million. See the section captioned &#8220;<i>Item 2&#8212;Properties</i>&#8221; in this Annual Report on Form 10-K for additional discussion regarding these leases.</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td></tr></table>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; width: 6%"><font style="font-size: 10pt">(2)</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; width: 94%"><font style="font-size: 10pt">Included in this line is approximately $15 million related to our on-going project to establish additional manufacturing capabilities at the Bedford, Massachusetts facility.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 38; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->


<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>Accounting for Off-Balance Sheet Arrangements</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We do not use special purpose entities or other off-balance sheet
financing techniques, except for operating leases as disclosed in the contractual obligations table above, that we believe have
or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, or capital resources.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Recent Accounting Pronouncements</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">A discussion of recent accounting pronouncements
is included in Note&nbsp;2 to the consolidated financial statements in this Annual Report.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><a name="i7a"></a><b>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Primary Market Risk Exposures</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We manage our investment portfolio in accordance with our investment
policy. The primary objectives of our investment policy are to preserve principal, maintain a high degree of liquidity to meet
operating and other needs, and obtain competitive returns subject to prevailing market conditions without significantly increasing
risk. To achieve this objective, we maintain our portfolio of cash equivalents and investments in a variety of high quality securities,
including money market funds, corporate bonds and bank certificates of deposits. The investments are classified as available-for-sale
and consequently are recorded at fair value with unrealized gains or losses reported as a separate component of accumulated other
comprehensive income. Our portfolio of cash equivalents and investments is subject to interest rate fluctuations, changes in credit
quality of the issuer and other factors.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Foreign Exchange Risk</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our primary market risk exposures are in the area of currency exchange
rate risk. We have two major supplier contracts denominated in foreign currencies. Unfavorable fluctuations in exchange rates would
have a negative impact on our financial statements. The impact of currency exchange rate fluctuation for the two contracts on our
financial statements was immaterial in 2015. Currently, we attempt to manage foreign currency risk through the matching of assets
and liabilities. In the future, we may undertake to manage foreign currency risk through additional hedging methods. We recognize
foreign currency gains or losses arising from our operations in the period incurred.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">A significant portion of Anika S.r.l.&#8217;s
revenue, and all operating expenses, are denominated in Euros, which leaves us vulnerable to foreign exchange risk.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 39; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><a name="i8"></a><b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>ANIKA THERAPEUTICS,&nbsp;INC. AND SUBSIDIARIES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 91%; padding-right: 5.4pt; padding-left: 19.8pt; text-decoration: none; text-indent: -19.8pt"><a href="#report">Report
    of Independent Registered Public Accounting Firm</a></td>
    <td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><a href="#report">41</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 19.8pt; text-decoration: none; text-indent: -19.8pt"><a href="#bs">Consolidated Balance
    Sheets as of December&nbsp;31, 2015 and 2014</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><a href="#bs">42</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 19.8pt; text-decoration: none; text-indent: -19.8pt"><a href="#ci">Consolidated Statements
    of Operations and Comprehensive Income for the Years Ended December&nbsp;31, 2015, 2014 and 2013</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><a href="#ci">43</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 19.8pt; text-decoration: none; text-indent: -19.8pt"><a href="#se">Consolidated Statements
    of Stockholders&#8217; Equity for the Years Ended December&nbsp;31, 2015, 2014 and 2013</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><a href="#se">44</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 19.8pt; text-decoration: none; text-indent: -19.8pt"><a href="#cf">Consolidated Statements
    of Cash Flows for the Years Ended December&nbsp;31, 2015, 2014 and 2013</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><a href="#cf">45</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 19.8pt; text-decoration: none; text-indent: -19.8pt"><a href="#notes">Notes to Consolidated
    Financial Statements</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><a href="#notes">46</a></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 40; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="report"></a><b>Report of Independent Registered Public Accounting Firm</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">To<b>&nbsp;</b>the Board of Directors and Stockholders of Anika Therapeutics, Inc.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In our opinion, the accompanying consolidated balance sheets and
the related consolidated statements of operations and comprehensive income, of stockholders' equity, and of cash flows present
fairly, in all material respects, the financial position of Anika Therapeutics, Inc. and its subsidiaries as of December 31, 2015
and December 31, 2014 and the results of their operations and their cash flows for each of the three years in the period ended
December 31, 2015 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion,
the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2015,
based on criteria established in Internal Control - Integrated Framework (2013) as issued by the Committee of Sponsoring Organizations
of the Treadway Commission (COSO). The Company's management is responsible for these financial statements, for maintaining effective
internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting,
included in Management's Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to
express opinions on these financial statements and on the Company's internal control over financial reporting based on our integrated
audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements
are free of material misstatement and whether effective internal control over financial reporting was maintained in all material
respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating
the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding
of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the
design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other
procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As discussed in Note 2 to the consolidated financial statements,
the Company changed the manner in which it classifies deferred taxes in 2015 and 2014 due to the adoption of Accounting Standards
Update 2015-17, Balance Sheet Classification of Deferred Taxes.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">A company&#8217;s internal control over financial reporting is a
process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control
over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial
statements.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Boston, Massachusetts</p>

<p style="font-size: 10pt; margin: 0pt 0">March 10, 2016</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 41; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><a name="bs"></a>Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">Consolidated Balance Sheets</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">(in thousands, except share
data and per share data)</p>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">ASSETS</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Current assets:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 24px">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">110,707</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">100,156</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,751</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,750</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Accounts receivable, net of reserves of $167 and $147 at December 31, 2015 and December 31, 2014, respectively</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,652</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,152</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Inventories</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,938</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,407</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Prepaid expenses and other current assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,385</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,371</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Total current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">176,433</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">137,836</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Property and equipment, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">40,108</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">31,669</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Long-term deposits and other</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">69</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">69</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Intangible assets, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,656</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,895</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Goodwill</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,482</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,339</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 12px">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">235,748</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">192,808</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Current liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,302</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1,201</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Accrued expenses and other current liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,778</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,772</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Income taxes payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,198</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 36px">Total current liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,278</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,973</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Other long-term liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">781</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">894</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Long-term deferred revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">66</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">102</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Deferred tax liability</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,775</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,741</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Commitments and contingencies (Note 12)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Stockholders&#8217; equity:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Common stock, $.01 par value; 30,000,000 shares authorized, 15,036,808 and 14,851,703 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">150</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">149</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Additional paid-in-capital</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">81,685</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">77,540</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Accumulated other comprehensive loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(6,649</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,495</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Retained earnings</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">135,662</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">104,904</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 36px">Total stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210,848</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">178,098</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 12px">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">235,748</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">192,808</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">The accompanying notes are an integral part of these consolidated
financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 42; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><a name="ci"></a>Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">Consolidated Statements of Operations and Comprehensive Income</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">(in thousands, except per
share data)</p>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left; padding-left: 12px">Product revenue</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">87,696</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">75,474</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">71,774</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Licensing, milestone and contract revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,303</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,121</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,307</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Total revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">92,999</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">105,595</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">75,081</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Operating expenses:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Cost of product revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,053</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,930</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,765</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Research&nbsp;&amp; development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,987</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,144</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,060</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Selling, general&nbsp;&amp; administrative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,825</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,074</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,936</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Restructuring credits</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(287</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Total operating expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">44,865</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">44,148</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">42,474</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Income from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,134</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">61,447</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">32,607</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Interest income (expense), net</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">120</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">58</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(127</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Income before income taxes</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,254</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">61,505</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">32,480</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Provision for income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,496</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23,186</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,905</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 12px">Net income</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">30,758</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">38,319</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">20,575</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Basic net income per share:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.06</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.61</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.46</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Basic weighted average common shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,934</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,678</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,087</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Diluted net income per share:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.01</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.51</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.39</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Diluted weighted average common shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,321</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,269</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,826</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">30,758</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">38,319</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">20,575</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Other comprehensive income (loss):</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Foreign currency translation adjustment</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,154</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,796</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">956</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Comprehensive income</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">28,604</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">35,523</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">21,531</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>




<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">The accompanying notes are an integral part of these consolidated
financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 43; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><a name="se"></a>Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">Consolidated Statements of Stockholders' Equity</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">(in thousands, except share data)</p>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="stockholders-equity"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Accumulated</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Stock</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">Total</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br>
&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;<br>
&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br>
Shares</td>
    <td nowrap style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;<br>
&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$.01 Par<br>
Value</td>
    <td nowrap style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;<br>
&nbsp;</td>
    <td colspan="3" nowrap style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Additional Paid<br>
in Capital</td>
    <td nowrap style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;<br>
&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Retained<br>
Earnings</td>
    <td nowrap style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;<br>
&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Comprehensive<br>
Loss</td>
    <td nowrap style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;<br>
&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stockholders'<br>
Equity</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left">Balance, December 31, 2012</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 5%; font-size: 10pt; text-align: right">13,866,060</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 5%; font-size: 10pt; text-align: right">139</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 5%; font-size: 10pt; text-align: right">65,431</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 5%; font-size: 10pt; text-align: right">46,010</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 5%; font-size: 10pt; text-align: right">(2,655</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 5%; font-size: 10pt; text-align: right">108,925</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Issuance of common stock for equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">423,248</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,050</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,054</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Tax benefit related to equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">857</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">857</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,268</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,268</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,575</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,575</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Other comprehensive income</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">956</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">956</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Balance, December 31, 2013</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">14,289,308</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">143</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,606</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">66,585</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(1,699</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">135,635</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Issuance of common stock for equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">696,169</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,048</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,055</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Tax benefit related to equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,626</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,626</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,607</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,607</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Retirement of common stock for minimum tax withholdings</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(133,774</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(6,347</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(6,348</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">38,319</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">38,319</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Other comprehensive loss</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,796</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,796</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Balance, December 31, 2014</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">14,851,703</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">149</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">77,540</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">104,904</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(4,495</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">178,098</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Issuance of common stock for equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">185,105</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,073</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,074</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Tax benefit related to equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">847</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">847</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,225</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,225</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,758</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,758</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Other comprehensive loss</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,154</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,154</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Balance, December 31, 2015</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,036,808</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">150</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">81,685</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">135,662</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(6,649</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">210,848</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">The accompanying notes are an integral part of these consolidated
financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 44; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><a name="cf"></a>Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">Consolidated Statements of Cash Flows</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">(in thousands)</p>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the years ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Cash flows from operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; text-align: left; padding-left: 24px">Net income</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">30,758</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">38,319</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">20,575</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Adjustments to reconcile net income to net cash provided by operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Depreciation and amortization</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,775</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,706</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,772</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,225</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,607</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,268</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Deferred income taxes</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(747</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">815</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,206</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Provision for doubtful accounts</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">38</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">238</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Provision for inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">210</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">378</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">171</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Gain on sale of assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(126</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Tax benefit from equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(847</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(9,626</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(857</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Non-cash impairment charges for IPR&amp;D</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">697</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Restructuring credits</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(161</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Changes in operating assets and liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 72px">Accounts receivable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,996</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">898</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,411</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 72px">Inventories</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,939</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,974</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,823</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 72px">Prepaid expenses, other current and long-term assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">89</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">585</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">307</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 72px">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,625</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(750</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">623</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 72px">Accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(199</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,189</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(377</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 72px">Deferred revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(15</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,014</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,795</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 72px">Income taxes payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,484</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,436</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">152</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 72px">Other long-term liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(94</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(213</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(419</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Net cash provided by operating activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,064</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,978</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,165</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">&nbsp;</td><td style="font-size: 10pt; color: red; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; color: red; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Cash flows from investing activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Proceeds from maturity of investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">24,250</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Purchase of investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(45,251</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(26,750</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Purchase of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(9,225</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,553</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(441</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 36px">Proceeds from sale of assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">188</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Net cash used in investing activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(30,226</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,303</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(253</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">&nbsp;</td><td style="font-size: 10pt; color: red; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; color: red; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Cash flows from financing activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Principal payments on debt</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(9,600</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Proceeds from exercise of equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,074</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,055</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,054</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 36px">Tax benefit from equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">847</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,626</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">857</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 36px">Minimum tax withholdings on share-based awards</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,349</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Net cash provided by financing activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,921</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,332</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,689</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">&nbsp;</td><td style="font-size: 10pt; color: red; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; color: red; font-weight: bold; text-align: right">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Exchange rate impact on cash</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(208</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(184</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">43</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">&nbsp;</td><td style="font-size: 10pt; color: red; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; color: red; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; color: red; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Increase in cash and cash equivalents</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,551</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">36,823</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">19,266</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Cash and cash equivalents at beginning of period</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">100,156</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">63,333</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">44,067</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 24px">Cash and cash equivalents at end of period</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">110,707</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100,156</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">63,333</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Supplemental disclosure of cash flow information:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 36px">Cash paid for income taxes</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">12,724</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">13,778</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,842</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 36px">Cash paid for interest</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">126</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 24px">Non-cash Investing Activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 36px">Purchases of property and equipment included in accounts payable and accrued expenses</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,949</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">52</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">364</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">The accompanying notes are an integral part of these consolidated
financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 45; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="notes"></a><b>Anika Therapeutics,&nbsp;Inc. and Subsidiaries</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Notes to Consolidated Financial Statements</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>1. Nature of Business</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Anika Therapeutics, Inc. is a global, integrated orthopedic medicines
company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing
innovative and differentiated therapeutic pain management solutions along the continuum of care, from palliative care to regenerative
medicine. The Company has over two decades of expertise developing, manufacturing and commercializing more than 20 products, in
markets across the globe, based on the Company&#8217;s proprietary hyaluronic acid technology. The Company&#8217;s orthopedic medicine
portfolio is comprised of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to
alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">The Company is subject to risks common to
companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors
of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing
and new products, and compliance with FDA and foreign regulations and approval requirements, as well as the ability to grow the
Company&#8217;s business through appropriate commercial strategies.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>2. Summary of Significant Accounting Policies</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: -0.55in; margin: 0pt 0 0pt 0.55in"><i>Use of Estimates</i></p>

<p style="font-size: 10pt; text-indent: -0.55in; margin: 0pt 0 0pt 0.55in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The preparation of financial statements in conformity with generally
accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those
estimates.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: -0.55in; margin: 0pt 0 0pt 0.55in"><i>Principles of Consolidation</i></p>

<p style="font-size: 10pt; text-indent: -0.55in; margin: 0pt 0 0pt 0.55in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The accompanying consolidated financial statements include the accounts
of Anika Therapeutics,&nbsp;Inc. and its wholly owned subsidiaries, Anika Securities,&nbsp;Inc. (a Massachusetts Securities Corporation),
and Anika Therapeutics S.r.l. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period
amounts have been reclassified to conform to the current period presentation. There was no impact on operating income.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Foreign Currency Translation</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">The functional
currency of our foreign subsidiary is the Euro. Assets and liabilities of the foreign subsidiary are translated using the exchange
rate existing on each respective balance sheet date. Revenues and expenses are translated using the monthly average exchange rates
prevailing throughout the year. The translation adjustments resulting from this process are included as a component of accumulated
currency translation adjustment which resulted in a loss from foreign currency translation of $2.2 million and $2.8 million for
the years ended December 31, 2015 and 2014, respectively. The translation adjustments resulted in a gain from foreign currency translation
of $1.0 million for the year ended December 31, 2013. </font></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">The Company recognized a loss
from foreign currency transactions of $0.4 million and $0.6 million during the years ended December 31, 2015 and 2014, respectively
and a gain from foreign currency transactions of $259 thousand during the year ended December 31, 2013. </font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Fair Value Measurements</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Fair value is defined as the price that would be received from selling
an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. When
determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers
the principal or most advantageous market in which it would transact and consider assumptions that market participants would use
when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of non-performance. The accounting standard
establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 46; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">A financial instrument&#8217;s categorization within the fair value
hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs that
may be used to measure fair value are:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 27pt"></td><td style="width: 9pt">&#8226;</td><td>Level 1 &#8211; Valuation is based upon quoted prices for identical instruments traded in active markets. Level 1 instruments
include securities traded on active exchange markets, such as the New York Stock Exchange.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 27pt"></td><td style="width: 9pt">&#8226;</td><td>Level 2 &#8211; Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical
or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions
are directly observable in the market.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 27pt"></td><td style="width: 9pt">&#8226;</td><td>Level 3 &#8211; Valuation is generated from model-based techniques that use significant assumptions not observable in the market.
These unobservable assumptions reflect our own estimates of assumptions market participants would use in pricing the instrument.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company&#8217;s financial assets have been classified as Level&nbsp;2.
The Company&#8217;s financial assets (which include cash equivalents and investments) have been initially valued at the transaction
price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable
data.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Allowance for Doubtful Accounts</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company maintains an allowance for doubtful accounts for estimated
losses resulting from the inability of our customers to make required payments, and are included in general and administrative
expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance for doubtful accounts,
management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer credit-worthiness,
current economic conditions, accounts receivable aging trends, and changes in our customer payment terms. A summary of activity
in the allowance for doubtful accounts is as follows (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">Balance, beginning of the year</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">147</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">593</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">337</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Amounts provided</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">38</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">238</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Amounts written off</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(377</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Translation adjustments</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(15</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(69</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Balance, end of the year</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">167</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">147</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">593</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Revenue Recognition - General</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company recognizes revenue when all of the following criteria
are met: persuasive evidence of an arrangement exists, risk of loss has passed or services have been rendered, the seller's price
to the buyer is fixed or determinable, and collection from the customer is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Product Revenue</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">Revenues from product sales
are recognized when title and risk of loss have passed to the customer, which is typically upon shipment to the customer. Amounts
billed or collected prior to recognition of revenue are classified as deferred revenue. When determining whether risk of loss has
transferred to customers on product sales, or if the sales price is fixed or determinable, the Company evaluates both the contractual
terms and conditions of its distribution and supply agreements as well as its business practices. </font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">Product revenue also includes
royalties. Royalty revenue is based on our distributors&#8217; sales and recognized in the same period our distributors record
their sale of products manufactured by us. On a quarterly basis the Company records royalty revenue based upon sales provided to
us by our distributor customers. </font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white"></font></p>

<!-- Field: Page; Sequence: 47; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">Pursuant to the Health Care
and Education Reconciliation Act of 2010, in conjunction with the Patient Protection and Affordable Care Act, a medical device
excise tax (&#8220;MDET&#8221;) became effective on January 1, 2013 for sales of certain medical devices. Some of our product sales
are subject to the provisions of the MDET. The Company has elected to recognize any amounts related to the MDET under the gross
method as allowed under ASC 605-45. For the periods ended December 31, 2015 and 2014, amounts included in revenues and costs of
goods sold for the MDET were immaterial. On December 18, 2015, President Obama signed the Consolidated Appropriations Act of 2016,
which suspends the 2.3 percent MDET beginning on January 1, 2016, with the suspension ending on December 31, 2017.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><i>Licensing, Milestone, and Contract Revenue</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Licensing, milestone, and contract revenue consist of revenue recognized on initial and
milestone payments, as well as contractual amounts received from partners. The Company&#8217;s business strategy includes entering
into collaborative license, development and/or supply agreements with partners for the development and commercialization of the
Company&#8217;s products. Under the milestone method, the Company recognizes a consideration that is contingent upon the achievement
of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive
in its entirety. A milestone is considered substantive when it meets all of the following criteria:</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">1.</td><td>The consideration is commensurate with either the entity&#8217;s performance to achieve the milestone or the enhancement of
the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#8217;s performance to achieve the
milestone,</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">2.</td><td>The consideration relates solely to past performance, and</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">3.</td><td>The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">A milestone is defined as an event (i) that can only be achieved
based in whole or in part on either the entity&#8217;s performance or on the occurrence of a specific outcome resulting from the
entity&#8217;s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the
event will be achieved and (iii) that would result in additional payments being due to the Company. Non substantive milestones
are recognized when there are no further obligations by the Company.</p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The terms of the agreements typically include non-refundable license
fees, funding of research and development and payments based upon achievement of certain milestones. The Company adopted ASU 2009-13,
<i>Revenue Recognition, </i>in January 2011, which amends ASC Subtopic 605-25,<i> Multiple Element Arrangements</i> (&#8220;ASC
605-25&#8221;) to require the establishment of a selling price hierarchy for determining the allocable selling price of an item.
Under ASC 605-25, as amended by ASU 2009-13, in order to account for an element as a separate unit of accounting, the element must
have objective and reliable evidence of selling price of the undelivered elements. In general, non-refundable up-front fees and
milestone payments that do not relate to other elements are recognized as revenue over the term of the arrangement as the Company
completes its performance obligations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Cash and Cash Equivalents </i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company <font style="background-color: white">considers only
those investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase
to be cash equivalents. The Company&#8217;s cash equivalents consist of money market funds and bank certificates of deposit with
an original maturity of less than 90 days.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Investments</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company&#8217;s investments consist of bank certificates of deposit
with an original maturity of more than 90 days. The Company has designated all investments as available-for-sale and therefore,
such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income.
For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains
and losses on the sale of investments are recorded in interest income (expense), net. Interest is recorded when earned. Investments
with original maturities greater than approximately three months and remaining maturities less than one year are classified as
short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. The
Company considers securities with maturities of three months or less from the purchase date to be cash equivalents.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 48; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">All of the Company&#8217;s investments are subject to a periodic
impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost
basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the extent and
length of time the investment's fair value has been lower than its cost basis, the financial condition and near-term prospects
of the investee, extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company&#8217;s
intent to sell the security, and whether or not the Company will be required to sell the security prior the expected recovery of
the investment's amortized cost basis. During the years ended&nbsp;December&nbsp;31, 2015 and 2014, the Company did not record
any other-than-temporary impairment charges on its available-for-sale securities because the Company does not intend to sell the
securities and it is not more likely than not that the Company will be required to sell these securities before the recovery of
their amortized cost basis.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Concentration of Credit Risk and Significant Customers</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company has no significant off-balance sheet risks related to
foreign exchange contracts, option contracts, or other foreign hedging arrangements. The Company&#8217;s cash equivalents and investments
are held with two major international financial institutions.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company, by policy, routinely assesses the financial strength
of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of December&nbsp;31, 2015 and 2014, DePuy Mitek, represented 60%
and 52%, respectively, of the Company&#8217;s accounts receivable balance, no other single customer accounted for more than 10%
of accounts receivable in either period.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Inventories</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Inventories are stated at the lower of cost or market, with cost
being determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor
and manufacturing overhead. Inventory costs associated with product candidates that have not yet received regulatory approval are
capitalized if the Company believes there is probable future commercial use and future economic benefit.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">The Company&#8217;s policy
is to write-down inventory when conditions exist that suggest inventory may be in excess of anticipated demand or is obsolete based
upon assumptions about future demand for the Company&#8217;s products and market conditions. The Company regularly evaluates the
ability to realize the value of inventory based on a combination of factors including, but not limited to, historical usage rates,
forecasted sales or usage, product end of life dates, and estimated current or future market values. Purchasing requirements and
alternative usage avenues are explored within these processes to mitigate inventory exposure. </font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">When recorded, inventory write-downs
are intended to reduce the carrying value of inventory to its net realizable value. Inventory </font>of $14.9 million<font style="background-color: white">
and $12.4 million as of December 31, 2015 and 2014, respectively, is stated net of inventory reserves of approximately $0.9 million
and $0.9 million, respectively. If actual demand for the Company&#8217;s products deteriorates, or market conditions are less favorable
than those projected, additional inventory write-downs may be required.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Property and Equipment</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">Property and equipment are recorded at cost and depreciated using the
straight-line method over their estimated useful lives. Equipment and software are typically amortized over two to ten years, and
furniture and fixtures over five to seven years. Leasehold improvements are amortized over the shorter of their useful lives or
the remaining terms of the related leases. Maintenance and repairs are charged to expense when incurred; additions and improvements
are capitalized. When an item is sold or retired, the cost and related accumulated depreciation is relieved, and the resulting
gain or loss, if any, is recognized in income. Construction-in-process is stated at cost, which includes the cost of construction
and other direct costs attributable to the construction. Construction-in-process is not depreciated until such time as the relevant
assets are completed and put into use. Construction-in-process at December 31, 2015 and 2014 primarily represents the costs of
building, leasehold improvements, machinery and equipment under installation.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 49; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><i>Goodwill and Acquired Intangible Assets</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white"><font style="background-color: white">Goodwill
is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable
assets on the date of acquisition. Acquired IPR&amp;D represents the fair value assigned to research and development assets that
we acquire that have not been completed at the date of acquisition or are pending regulatory approval in certain jurisdictions.
The value assigned to the acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially
viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. </font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Goodwill and IPR&amp;D are evaluated for impairment annually or more
frequently if events or changes in circumstances indicate that the asset might be impaired. Factors the Company considers important,
on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical
or projected future operating results, significant changes in the Company&#8217;s use of the acquired assets or the strategy for
its overall business, significant negative industry or economic trends, a significant decline in our stock price for a sustained
period, or a reduction of our market capitalization relative to net book value.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">To conduct impairment tests of goodwill, the fair value of the reporting
unit is compared to its carrying value. If the reporting unit&#8217;s carrying value exceeds its fair value, we record an impairment
loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value for
its reporting unit using discounted cash flow valuation models which require the use of significant estimates and assumptions, including
but not limited to, risk free rate of return on an investment, weighted average cost of capital, future revenue, operating margin,
working capital, and capital expenditure needs. The Company&#8217;s annual assessment for impairment of goodwill as of November
30, 2015 indicated that the fair value of our reporting unit exceeded the carrying value of the reporting unit.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">To conduct impairment tests of IPR&amp;D, the fair value of the IPR&amp;D
project is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss
to the extent that the carrying value of the IPR&amp;D project exceeds its fair value. The Company estimates the fair value for
IPR&amp;D projects using discounted cash flow valuation models, which require the use of significant estimates and assumptions,
including but not limited to, estimating the timing of and expected costs to complete the in-process projects, projecting regulatory
approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing
appropriate discount rates. <font style="background-color: white">During the fourth quarter of 2015 the Company performed an impairment
review of its IPR&amp;D projects as it reassessed its R&amp;D strategy. The Company recorded an impairment charge of $0.7 million
due to the decision to discontinue further development efforts needed to commercialize this technology. </font>The Company&#8217;s
annual assessment for impairment of IPR&amp;D indicated that the fair value of our other IPR&amp;D assets as of November 30, 2015
exceeded their respective carrying values.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><i>Long-Lived Assets</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Long-lived assets primarily include property and equipment, and intangible
assets with finite lives. The Company&#8217;s intangible assets are comprised of purchased developed technologies, distributor
relationships, patents and trade names. These intangible assets are carried at cost, net of accumulated amortization. Amortization
is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately&nbsp;5&nbsp;to&nbsp;16&nbsp;years.
The Company reviews long-lived assets for impairment when events or changes in business circumstances indicate that the carrying
amount of the assets may not be fully recoverable or that the useful lives of those assets are no longer appropriate. Each impairment
test is based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the
asset is written down to its estimated fair value based on a discounted cash flow analysis.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><i>Research and Development</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Research and development costs consist primarily of salaries and
related expenses for personnel and fees paid to outside consultants and outside service providers, including costs associated with
licensing, milestone, and contract revenue. Research and development costs are expensed as incurred.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Stock-Based Compensation</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company measures the compensation cost of award recipients&#8217;
services received in exchange for an award of equity instruments based on the grant date fair value of the underlying award. That
cost is recognized over the period during which an employee is required to provide service in exchange for the award. See Note&nbsp;13
for a description of the types of stock-based awards granted, the compensation expense related to such awards, and detail of equity-based
awards outstanding.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 50; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">For performance based awards with financial achievement targets,
the Company recognizes expense using the graded vesting methodology based on the number of shares expected to vest. Compensation
cost associated with these grants was estimated using the Black-Scholes valuation method multiplied by the expected number of shares
to be issued, which is adjusted based on the estimated probabilities of achieving the performance goals. Changes to the probability
assessment and the estimated shares expected to vest will result in adjustments to the related share-based compensation expense
that will be recorded in the period of the change. If the performance targets are not achieved, no compensation cost is recognized,
and any previously recognized compensation cost is reversed. The Company recorded approximately $0.4 million related to performance
based awards in 2015. There was no expense recognized on performance based awards in 2014 as satisfaction of the performance conditions
were not considered probable.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Income Taxes</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&rsquo;s income tax expense includes
U.S.&nbsp;and international income taxes. Certain items of income and expense are not reported in tax returns and financial statements
in the same year. The tax effects of these timing differences are reported as deferred tax assets and liabilities. Deferred tax
assets are recognized for the estimated future tax effects of deductible temporary differences, tax operating losses, and tax credit
carry-forwards (including investment tax credits). Changes in deferred tax assets and liabilities are recorded in the provision
for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income
and, to the extent it believes that it is more likely than not that all or a portion of deferred tax assets will not be realized,
the Company establishes a valuation allowance to reduce the deferred tax assets to the appropriate valuation. To the extent the
Company establishes a valuation allowance or increases or decreases this allowance in a given period, it includes the related tax
expense or tax benefit within the tax provision in the consolidated statement of operations in that period.</P>




<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Comprehensive Income</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Comprehensive income consists of net income and other comprehensive
income (loss), which includes foreign currency translation adjustments, and unrealized gains and losses on available-for-sale securities.
For the purposes of comprehensive income disclosures, the Company does not record tax provisions or benefits for the net changes
in the foreign currency translation adjustment, as it intends to indefinitely reinvest undistributed earnings of its foreign subsidiary.
Accumulated other comprehensive income (loss) is reported as a component of stockholders' equity and, for the years ended December
31, 2015 and 2014, comprehensive income was comprised solely of cumulative translation adjustments.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Segment Information</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Operating segments, as defined under U.S. GAAP, are components of
an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision
maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s chief
operating decision maker is its Chief Executive Officer. Based on the criteria established by ASC 280, <i>Segment Reportin</i>g,
the Company has one reportable operating segment, the results of which are disclosed in the accompanying consolidated financial
statements.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Subsequent Events</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Events occurring subsequent to December&nbsp;31, 2015 have been evaluated
for potential recognition or disclosure in the consolidated financial statements. See Note 19 <i>Subsequent Events</i>, to the
consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information regarding subsequent events.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><i>Recent Accounting Pronouncements</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white"><font style="background-color: white">In
May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;)
No. 2014-09, &#8220;Revenue from Contracts with Customers.&#8221; ASU 2014-09 supersedes the revenue recognition requirements in
&#8220;Topic 605, Revenue Recognition&#8221; and requires entities to recognize revenue in a way that depicts the transfer of promised
goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange
for those goods or services.&nbsp;</font>&nbsp;In July 2015, the FASB issued a deferral of ASU 2014-09 of one year making it effective
for annual reporting periods beginning on or after December 15, 2017 while also providing for early adoption not to occur before
the original effective date. The Company is assessing the appropriate method for implementing ASU 2014-09, as well as the impact
the adoption of ASU 2014-09 will have on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 51; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">In July 2015, the FASB issued ASU No. 2015-11,&nbsp;Inventory
(Topic 330) &#8220;Simplifying the Measurement of Inventory.&#8221;<i>&nbsp;</i>ASU 2015-11 more closely aligns the measurement
of inventory in US GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies
using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value,
where net realizable value is the estimated selling prices in the ordinary course of business less reasonably predictable costs
of completion, disposal, and transportation. The provisions of ASU 2015-11 are effective for annual and interim periods beginning
after December 15, 2016. ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of
an interim or annual reporting period. The adoption of this amendment is not expected to have a material impact on the Company&#8217;s
financial position or results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In November 2015 FASB issued ASU No. 2015-17, Income Taxes (Topic
740) Balance Sheet Classification of Deferred Taxes. ASU 2015-17 requires entities to present deferred tax assets and deferred
tax liabilities as noncurrent in a classified balance sheet. The ASU simplifies the current guidance, which requires entities to
separately present deferred tax assets and deferred tax liabilities as current and noncurrent in a classified balance sheet. The
guidance in ASU 2015-17 is required for annual reporting periods beginning after December 15, 2016, including interim periods within
the reporting period. We early adopted the provisions of this ASU during the fourth quarter of fiscal year 2015 and applied it
retrospectively. The adoption of ASU 2015-17 resulted in the reclassification of $2.3 million of current deferred tax assets to
a reduction in noncurrent deferred tax liabilities as of December 31, 2015. We retrospectively adjusted the December 31, 2014 consolidated
balance sheet and related disclosures to reflect the reclassification of $1.2 million of current deferred tax assets to a reduction
in noncurrent deferred tax liabilities. Adoption of this standard did not impact results of operations, retained earnings, or cash
flows in the current or previous interim and annual reporting periods.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">In February 2016, the FASB issued &ldquo;Leases (Topic 842)&rdquo; (ASU
2016-02). This new standard amends existing leasing accounting requirements. The most significant change will result in the recognition
of lease assets and lease liabilities by lessees for virtually all leases. The new guidance will also require significant additional
disclosures about the amount, timing and uncertainty of cash flows from leases. ASU 2016-02 is effective for fiscal years and interim
periods beginning after December 15, 2018. Upon adoption, entities are required to recognize and measure leases at the beginning
of the earliest period presented using a modified retrospective approach. Early adoption is permitted, and a number of optional
practical expedients may be elected to simplify the impact of adoption. We are currently evaluating the impact of adopting this
guidance.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>3. Investments</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">All of the Company&#8217;s
investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component
of accumulated other comprehensive income, net of related income taxes. The Company held corporate debt securities of $2.0 million
at December 31, 2015 and bank certificates of deposits of $25.8 million and $6.8 million at December 31, 2015 and 2014, respectively.
There were no unrealized gains or losses on the Company&#8217;s available-for-sale securities at December 31, 2015 or 2014.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>4. Fair Value Measurements</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">The Company&#8217;s investments are all
classified within Level 2 of the fair value hierarchy. The Company&#8217;s investments classified within Level 2 of the fair value
hierarchy are valued based on matrix pricing compiled by third party pricing vendors, using observable market inputs such as interest
rates, yield curves, and credit risk.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The fair value hierarchy of the Company&#8217;s
cash equivalents and investments at fair value is as follows (in thousands):</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 52; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting<br> Date Using</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quoted Prices in<br> Active Markets<br> for Identical Assets<br> (Level 1)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant Other<br> Observable Inputs<br> (Level 2)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant<br> Unobservable Inputs<br> (Level 3)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cash equivalents:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; text-align: left">Money market funds</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">61,385</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">61,385</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bank certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">250</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">250</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total cash equivalents</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">61,635</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">61,635</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,001</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,001</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bank certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,750</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,750</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27,751</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27,751</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>




<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting<br> Date Using</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quoted Prices in<br> Active Markets<br> for Identical Assets<br> (Level 1)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant Other<br> Observable Inputs<br> (Level 2)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant<br> Unobservable Inputs<br> (Level 3)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cash equivalents:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; text-align: left">Money market funds</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">69,552</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">69,552</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bank certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,000</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,000</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total cash equivalents</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">72,552</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">72,552</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Bank certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,750</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,750</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>




<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">The Company did not have any transfers between Level 1 and Level 2 or transfers in or
out of Level 3 of the fair value hierarchy during the years ended December 31, 2015 and 2014.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>5. Earnings per Share (&#8220;EPS&#8221;) </b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">Basic EPS is calculated by dividing net income by the weighted average number of shares
outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding
for purposes of calculating basic earnings per share. Diluted EPS is calculated by dividing net income by the weighted average
number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, stock appreciation rights (&#8220;SAR&#8217;s&#8221;),
restricted shares, and restricted stock units using the treasury stock method.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following table provides share information used in the calculation
of the Company's basic and diluted earnings per share (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">Shares used in the calculation of basic earnings per share</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">14,934</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">14,678</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">14,087</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Effect of dilutive securities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 24px">Stock options, SARs, and RSAs</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">387</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">591</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">739</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Diluted shares used in the calculation of earnings per share</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,321</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,269</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">14,826</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Stock options to purchase 197,691 shares, 129,540 shares, and 21,326
shares for 2015, 2014, and 2013, respectively, were excluded from the computation of diluted EPS as their effect would have been
anti-dilutive.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">At December&nbsp;31, 2015, 2014, and 2013, 62,825 shares, 30,700
shares, and 52,339 shares of issued and outstanding unvested restricted stock, respectively, were excluded from the basic earnings
per share.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 53; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>6. Inventories</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Inventories consist of the following (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Raw materials</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">5,780</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">6,162</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Work-in-process</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,656</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,041</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,502</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,204</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 24px">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">14,938</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">12,407</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>7. Property&nbsp;and Equipment</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Property and equipment is stated at cost and consists of the following
(in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; color: Red"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 12px">Equipment and software</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">24,512</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">24,176</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Furniture and fixtures</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,240</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Leasehold improvements</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,622</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,589</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Construction in progress</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,274</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">559</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">&nbsp;&nbsp;Subtotal</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">64,648</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">53,620</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(24,540</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(21,951</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 12px">&nbsp;&nbsp;Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">40,108</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">31,669</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; color: Red">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Depreciation expense was $2.7 million, $2.6
million, and $2.7 million for the years ended December&nbsp;31, 2015, 2014, and 2013, respectively.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>8. Acquired Intangible Assets, Net</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In November 2007, in connection with the termination of the agreement
with Galderma which originally granted to Galderma the worldwide rights to commercialize, distribute, and market the ELEVESS product,
the Company reacquired the worldwide rights and control of the future development and marketing of ELEVESS. The intangible asset
realized during this process was the ELEVESS trade name.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On December 30, 2009, in connection with the acquisition of Anika
S.r.l., the Company purchased various intangible assets.&nbsp;The Company finalized the purchase price allocation relative to this
acquisition during the fourth quarter of 2010.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">The Company recorded an
impairment charge totaling $0.7 million to write-off in-process research and development that was recorded in connection with
our acquisition of Anika S.r.l. Subsequent to an evaluation in the fourth quarter of the ongoing research and development
efforts surrounding the Hemostatic Patch IPR&amp;D project, the Company determined it would discontinue further development
efforts needed to commercialize this technology. As a result of this decision, an impairment charge was recorded. These
amounts are included in research and development expenses on our consolidated statements of operations.</font> Through
December 31, 2015, there have not been any events or changes in circumstances that indicate that the carrying value of the
other acquired intangible assets may not be recoverable. The Company continues to monitor and evaluate the financial
performance of its business including the impact of general economic conditions, to assess the potential for the fair value
of the reporting unit to decline below its book value.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In January 2015 the Company received CE Mark approval for HYALOSPINE
which is an innovative adhesion prevention gel for use after spinal surgery, and was a component of the IPR&amp;D intangible assets
initially identified. As a result of this approval the Company has reclassified $400 thousand from IPR&amp;D to developed technology
and began amortization on the HYALOSPINE asset.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 54; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Amortization expense was $1.1 million, $2.1 million, and $2.1 million
for the years ended December&nbsp;31, 2015, 2014, and 2013, respectively. Amortization expense on intangible assets is expected
to be approximately $1.0 million in 2016, $0.9 million annually through 2020 and approximately $3.8 million in aggregate thereafter.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Intangible assets consist of the following (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2014</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross Value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Current Period Completed Projects</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Abandonment</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated Currency Translation Adjustment</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated Amortization</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Useful Life</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-size: 10pt; text-align: left">Developed technology</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">16,700</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">400</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(3,215</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(5,926</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">7,959</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">9,410</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 4%; font-size: 10pt; text-align: center">15</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">In-process research &amp; development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,503</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(400</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(697</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,307</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,099</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,653</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: center">Indefinite</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Distributor relationships</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,700</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(415</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,285</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: center">5</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Patents</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(194</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(333</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">473</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">581</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: center">16</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Elevess trade name</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,000</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(875</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">125</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">251</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">9</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.25pt; padding-left: 10pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">28,903</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(697</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(5,131</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(11,419</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,656</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">14,895</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: center">&nbsp;</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><b>&nbsp;</b></p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>9. Goodwill</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company completed its annual impairment review as of November
30, 2015 and concluded that no impairment in the carrying value exists as of that date with respect to goodwill. Through December
31, 2015, there have not been any events or changes in circumstances that indicate that the carrying value of goodwill may not
be recoverable. Changes in the carrying value of goodwill were as follows (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Balance, beginning</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">8,339</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">9,444</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Effect of foreign currency adjustments</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(857</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,105</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance, ending</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,482</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,339</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>10. Accrued Expenses</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Accrued expenses consist of the following (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 12px">Compensation and related expenses</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">3,082</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">2,792</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Facility construction costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">415</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Research grants</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">381</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">539</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Clinical trial costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">252</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">508</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Professional fees</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">210</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">554</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">438</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">379</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,778</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,772</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>





<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>11. <font style="background-color: white">Deferred Revenue</font></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In December 2003, the Company entered into the Mitek ORTHOVISC Agreement
with Ortho Biotech Products,&nbsp;L.P., a member of the Johnson&nbsp;&amp; Johnson family of companies, to market ORTHOVISC in
the U.S. In mid-2005, the agreement was assigned to Mitek. Under the Mitek ORTHOVISC Agreement, Mitek performs sales, marketing,
and distribution functions, and Mitek licenses the right to further develop and commercialize ORTHOVISC, as well as other new products
for the treatment of pain associated with osteoarthritis based on the Company&#8217;s viscosupplementation technology. In support
of the license, the Mitek ORTHOVISC Agreement provides that Mitek will fund post-marketing clinical trials for new indications
of ORTHOVISC. The Company received an initial payment of $2.0 million upon entering into the Mitek ORTHOVISC Agreement, a milestone
payment of $20.0 million in February 2004 as a result of obtaining FDA approval of ORTHOVISC, and a milestone payment of $5.0 million
in December 2004 for planned upgrades to our manufacturing operations. The Company evaluated the terms of the Mitek ORTHOVISC Agreement
and determined that the upfront fee and milestone payments did not meet the conditions to be recognized separately from the supply
agreement. These payments were recognized into revenue as all of the performance obligations were met.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 55; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In December 2011, the Company entered into a fifteen-year licensing
agreement (the &#8220;Mitek MONOVISC Agreement&#8221;) with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics,
Inc., to exclusively market MONOVISC in the U.S. The Company received an upfront payment of $2.5 million in December 2011. This
non-refundable upfront payment did not have standalone value without Anika&#8217;s completion of development obligations, which
included obtaining regulatory approval of the product and resolving the related patent litigation. As a result, the Company recognized
the upfront payment over the development obligation period. During the first quarter of 2014, the Company received FDA approval
of MONOVISC and resolved the patent lawsuit with Genzyme Corporation. As a result of the full delivery of its development obligations
under this agreement, the Company recognized approximately $2.2 million, which represented the remaining balance of deferred revenue
relating to the initial $2.5 million payment. In the first quarter of 2014, the Company also received a milestone payment of $17.5
million as a result of achieving FDA approval for MONOVISC and resolving the patent litigation with Genzyme. This milestone payment
was fully recognized as revenue during the three months ended March 31, 2014. On April 15, 2014 the first U.S. commercial sale
of MONOVISC was made by our commercial partner, Mitek. Under the terms of the Mitek MONOVISC Agreement, the Company earned and
collected a milestone payment of $5 million, which was fully recognized as revenue in the second quarter of 2014. On November 10,
2014, the Center for Medicare &amp; Medicaid Services ("CMS") assigned a unique Healthcare Common Procedure Coding System
("HCPCS") code, or J-Code, to MONOVISC. The issuance of this code by CMS set national Medicare reimbursement rates for
the product. The new J-Code became effective on January 1, 2015. As a result of CMS assigning the J-Code, the Company collected
a milestone payment of $5.0 million, which was fully recognized as revenue in the fourth quarter of 2014. During the fourth quarter
of 2015, the Company collected and fully recognized revenue for a milestone payment of $5.0 million as a result of U.S. MONOVISC
annual end-user sales exceeding $50 million. For the year ended December 31, 2015 and 2014, the Company recognized a total of $5.0
million and $29.7 million in milestone revenue related to MONOVISC, respectively.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>12. Commitments and Contingencies</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><i>Leasing Arrangements</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company&#8217;s headquarters facility is located in Bedford,
Massachusetts, where the Company leases approximately 134,000 square feet of administrative, manufacturing, and R&amp;D space.
This lease was entered into on January&nbsp;4, 2007, and the lease commenced on May&nbsp;1, 2007 for an initial term of ten and
one-half years. The Company has an option under the lease to extend its terms for up to four additional periods beyond the original
expiration date subject to the condition that the Company notify the landlord that the Company is exercising each option at least
one year prior to the expiration of the original or then current term. The first three renewal options each extend the term an
additional five years, while the final renewal option extends the term by six years. The Company&#8217;s administrative and R&amp;D
personnel moved into the Bedford facility in November of 2007. The Bedford facility was fully validated and approved by applicable
regulatory authorities in 2012.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Anika S.r.l., leases approximately 28,000 square feet of laboratory,
warehouse and office space in Abano Terme, Italy. The lease commenced on December 30, 2009 for an initial term of six (6) years,
with options to extend, which the Company has not exercised as of December 31, 2015 and is currently renting this facility under
a six year lease that Anika may terminate at any time by providing six months&#8217; notice. The Company expects to exit this facility
in late 2016.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On October 9, 2015, Anika S.r.l, entered into a build-to-suit lease
agreement with Consorzio Zona Industriale E Porto Fluviale di Padova (&#8220;ZIP&#8221;), as landlord, pursuant to which Anika
S.r.l. will lease a new Eurpoean headquarters facility, consisting of approximately 33,000 square feet of general office, research
and development, training, and warehousing space located in Padova, Italy. The Lease has an initial term of fifteen years, which
is expected to commence during the fourth quarter of 2016 once construction of the facility is completed. The Lease will automatically
renew for up to three additional six-year terms, subject to certain terms and conditions. The Company has the ability to withdraw
from this lease subject to certain financial penalties after six years and with no penalties after the ninth year. Beginning on
the commencement date, the Lease provides for an initial yearly rent of approximately $0.4 million.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 56; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Construction of the new facility is expected to begin in the first
quarter of 2016 and is expected to be completed in late 2016. During the period of construction the Company is considered the deemed
owner of the facility and as a result at December 31, 2015 has recorded a construction-in-process asset of&nbsp;approximately $0.2
million, and an offsetting facility lease obligation of approximately $30 thousand associated with the new facility.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Rental expense in connection with the various facility leases totaled
$1.3 million for the year ended December 31, 2015, and $1.4 million, for the years ended December&nbsp;31, 2014 and 2013, respectively.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company&#8217;s future lease commitments as of December&nbsp;31,
2015 are as follows (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; text-align: left; padding-left: 12px">2016</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">1,540</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">2017</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,309</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">2018</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,309</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">2019</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,319</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">2020 and thereafter</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,926</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,403</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Warranty and Guarantor Arrangements</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In certain of our contracts, the Company warrants to its customers
that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product.
The Company may also warrant that the products it manufactures do not infringe, violate or breach any U.S. patent or intellectual
property rights, trade secret, or other proprietary information of any third party. On occasion, the Company contractually indemnifies
its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties
or any actual or alleged defect in any product caused by the negligence or acts or omissions of the Company. The Company maintains
a products liability insurance policy that limits its exposure to these risks. Based on the Company&#8217;s historical activity,
in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements
is immaterial. The Company has no accrued warranties at December 31, 2015 or 2014, respectively, and has no history of claims paid.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Legal Proceedings</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">On July 7, 2010, Genzyme Corporation
filed a complaint against the Company in the United States District Court for the District of Massachusetts seeking unspecified
damages and equitable relief. The complaint alleged that the Company infringed U.S. Patent No. 5,143,724 by manufacturing MONOVISC
in the United States for sale outside the United States and would infringe U.S. Patent Nos. 5,143,724 and 5,399,351&nbsp;if the
Company manufactured and sold MONOVISC in the United States. On March 7, 2014, Genzyme and the Company filed a joint motion to
lift the stay in Genzyme&#8217;s lawsuit against the Company and to dismiss with prejudice all of Genzyme&#8217;s claims. On March
10, 2014, the District Court granted the motion to dismiss all of Genzyme&#8217;s claims against the Company with prejudice, and
the case was terminated.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company is involved in various other legal proceedings arising
in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, the
Company does not expect the resolution of these other legal proceedings to have a material adverse effect on our financial position,
results of operations, or cash flow.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>13. Equity Incentive Plan </b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Anika Therapeutics,&nbsp;Inc. Stock Option and Incentive Plan,
as amended, (the &#8220;2003 Plan&#8221;) provides for grants of nonqualified and incentive stock options, common stock, restricted
stock, restricted stock units, and SAR&#8217;s to employees, directors, officers, and consultants. The 2003 Plan was originally
approved by the Board of Directors on April 4, 2003, approved by the Company&#8217;s shareholders on June 4, 2003, and reserved
1,500,000 shares of common stock for grant pursuant to its terms. There are 1,251,635 shares available for future grant at December&nbsp;31,
2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On May 29, 2009, the Board of Directors approved changes to the 2003
Plan and adopted the Amended and Restated 2003 Stock Option and Incentive Plan (the &#8220;Amended 2003 Plan&#8221;) to increase
the number of shares available to grant by 850,000.&nbsp;The Amended 2003 Plan was approved by the Company&#8217;s shareholders
on June 5, 2009, and it resulted in a total of 2,350,000 shares of common stock being reserved for issuance under the Amended 2003
Plan.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 57; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">At the 2011 Annual Meeting of Stockholders on June 7, 2011, the shareholders
of the Company approved the Anika Therapeutics, Inc. Second Amended and Restated Stock Option and Incentive Plan (the &#8220;2003
Plan&#8221;), which, among other things, increased the number of shares reserved for issuance under the Company&#8217;s predecessor
stock option and incentive plan by 800,000 to 3,150,000 shares. Pursuant to this amendment and restatement to the 2003 Plan approved
by our shareholders, each share award issued after June 7, 2011 other than options or stock appreciation rights will reduce the
number of total shares available for grant by 1.9&nbsp;shares.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">At the 2013 Annual Meeting of Stockholders on June 18, 2013, the
shareholders of the Company approved an additional amendment to the Amended 2003 Plan, which, among other things, increased the
number of shares reserved for issuance under the Company&#8217;s stock option and incentive plan by 650,000 to 3,800,000 shares.
Pursuant to this amendment and restatement to the 2003 Plan approved by our shareholders, each share award issued after June 18,
2013 other than options or stock appreciation rights will reduce the number of total shares available for grant by 1.5&nbsp;shares</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company may satisfy the awards upon exercise, or upon fulfillment
of the vesting requirements for other equity-based awards, with either newly-issued shares or shares reacquired by the Company.
Stock-based awards are granted with an exercise price equal to the market price of the Company&#8217;s stock on the date of grant.
Awards contain service conditions or service and performance conditions, and they generally become exercisable ratably over one
to four years.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company estimates the fair value of stock options and SAR&#8217;s
using the Black-Scholes valuation model. Fair value of restricted stock is measured by the grant-date price of the Company&#8217;s
shares. Key input assumptions used to estimate the fair value of stock options and SAR&#8217;s include the exercise price of the
award, the expected award term, the expected volatility of the Company&#8217;s stock over the option&#8217;s expected term, the
risk-free interest rate over the award&#8217;s expected term, and the Company&#8217;s expected annual dividend yield.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company uses historical data on the exercise of stock options
and other factors to evaluate and estimate the expected term of share-based awards. The Company also evaluates actual forfeiture
rates periodically and adjusts the expected forfeiture rate assumption within the model accordingly. The expected volatility assumption
is evaluated against the historical volatility of the Company&#8217;s common stock over a four year average, and it is adjusted
if there are material swings in historical volatility. The risk-free interest rate assumption is based on U.S. Treasury interest
rates at the time of grant.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The fair value of each stock option and SAR award during 2015, 2014,
and 2013 was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Risk free interest rate</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">1.15%</td>
    <td style="font-size: 10pt; text-align: center"> -</td>
    <td style="font-size: 10pt; text-align: center">1.46%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">1.16%</td>
    <td style="font-size: 10pt; text-align: center"> -</td>
    <td style="font-size: 10pt; text-align: center">1.39%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">0.61%</td>
    <td style="font-size: 10pt; text-align: center"> -</td>
    <td style="font-size: 10pt; text-align: center">1.02%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected volatility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">53.15%</td>
    <td style="font-size: 10pt; text-align: center"> -</td>
    <td style="font-size: 10pt; text-align: center">54.65%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">53.28%</td>
    <td style="font-size: 10pt; text-align: center"> -</td>
    <td style="font-size: 10pt; text-align: center">57.05%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">53.60%</td>
    <td style="font-size: 10pt; text-align: center"> -</td>
    <td style="font-size: 10pt; text-align: center">57.60%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected life (years)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">4.5</td>
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">4.0</td>
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: right">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">4.0</td>
    <td style="font-size: 10pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; width: 55%">Expected dividend yield</td><td style="font-size: 10pt; width: 1%">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center; width: 5%">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center; width: 4%">0.00%</td>
    <td style="font-size: 10pt; text-align: center; width: 5%">&nbsp;</td><td style="font-size: 10pt; width: 1%">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center; width: 5%">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center; width: 4%">0.00%</td>
    <td style="font-size: 10pt; text-align: center; width: 5%">&nbsp;</td><td style="font-size: 10pt; width: 1%">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center; width: 5%">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center; width: 4%">0.00%</td>
    <td style="font-size: 10pt; text-align: center; width: 5%">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company recorded $2.2 million, $1.6 million, and $1.3 million
of share-based compensation expense for the years ended December&nbsp;31, 2015, 2014, and 2013, respectively, for stock options,
SAR&#8217;s, and restricted stock awards. The Company presents the expenses related to stock-based compensation awards in the same
expense line items as cash compensation paid to each of its employees.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 58; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Combined stock options and SAR&#8217;s activity under our plans is
summarized as follows for the years ended December&nbsp;31, 2015 and 2014, respectively:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br> Average<br> Exercise<br> Price Per<br> Share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br> Average<br> Exercise<br> Price Per<br> Share</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left">Options and SAR's outstanding at beginning of year</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">851,287</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">14.85</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">1,513,326</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">9.14</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">111,625</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">39.25</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">179,240</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">35.62</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(85,349</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">19.77</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(53,325</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">23.73</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Expired</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(8,825</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">20.03</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(24,292</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9.87</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Exercised</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(106,478</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">10.96</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(763,662</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">7.95</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Options and SAR's outstanding at end of year</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">762,260</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">18.75</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">851,287</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">14.85</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>




<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Of the 762,260 options and SAR&#8217;s outstanding at December 31,
2015, 734,301 are vested or are expected to vest, with a weighted-average exercise price of approximately $17.88 as well as an
aggregate intrinsic value of approximately $15 million related to these awards. The weighted average remaining contractual term
of the vested and expected to vest options and SAR&#8217;s was 6.7 years as of December&nbsp;31, 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of December 31, 2015, total unrecognized compensation costs related
to non-vested options and SAR&#8217;s was approximately $2.6 million and is expected to be recognized over a weighted average period
of 2.5 years.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">There were 140,023 incentive stock options exercisable at December
31, 2015 with a weighted-average exercise price of $9.52 and a weighted-average remaining contractual term of 5.6 years for these
awards.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">There were 225,620 non-qualified stock options exercisable at December
31, 2015 with a weighted-average exercise price of $12.27 and a weighted-average remaining contractual term of 6.3 years.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">There were 56,220 SAR&#8217;s exercisable at December 31, 2015 with
a weighted-average exercise price of $8.30 and a weighted-average remaining contractual term of 2.9 years for these awards.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The aggregate intrinsic value of stock options and SAR&#8217;s fully
vested at December&nbsp;31, 2015 and 2014 was $11.6 million and $12.0 million, respectively. The aggregate intrinsic value of stock
options and SAR&#8217;s outstanding at December&nbsp;31, 2015 and 2014 was $15.2 million and $21.7 million, respectively.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The total intrinsic value of options and SAR&#8217;s exercised was
$3.1 million and $26.7 million for the years ended December&nbsp;31, 2015 and 2014, respectively. <font style="background-color: white">During
the second quarter of 2014, the Company acquired, and subsequently retired, 133,774 common shares related to an employee SAR&#8217;s
exercise to meet minimum statutory tax withholding requirements.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The total fair value of options and SAR&#8217;s vested during the
years ended December&nbsp;31, 2015 and 2014 was approximately $1.1 million for both periods.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company received $1.1 million and $2.1 million for exercises
of stock options during the years ended December&nbsp;31, 2015 and 2014, respectively.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 59; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The restricted stock activity for the years ended December&nbsp;31,
2015 and 2014 is as follows:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><b></b></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br> Average<br> Grant Date<br> Fair Value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br> Average<br> Grant Date<br> Fair Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left">Nonvested at Beginning of year</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">109,614</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">23.91</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">79,591</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">11.93</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">81,080</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">37.84</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">60,098</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">32.02</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(10,635</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">32.02</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(7,500</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">25.46</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Expired</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Vested/Released</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(29,675</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">19.31</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(22,575</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">10.01</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Nonvested at end of year</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">150,384</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">34.29</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">109,614</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">23.91</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>




<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; color: Red">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The total fair value of restricted stock and
restricted stock units vested during the year ended December 31, 2015 and 2014 was $1.2 million and $0.8 million.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>14. Shareholder Rights Plan</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On April&nbsp;4, 2008, the Board of Directors of the Company adopted
a Shareholder Rights Plan (the &#8220;2008 Plan&#8221;) that replaced the Company&#8217;s former Shareholder Rights Plan. Under
the 2008 Plan, the Rights generally become exercisable if:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 0.75in">(1)&nbsp;A person becomes an &#8220;Acquiring Person&#8221;
by acquiring 15% or more of the Company&#8217;s common stock, or</p>

<p style="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 0.75in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: -13.5pt; margin: 0pt 0 0pt 49.5pt">(2)&nbsp;A person commences a tender offer that would
result in that person owning 15% or more of the Company&#8217;s common stock.</p>

<p style="font-size: 10pt; text-indent: -13.5pt; margin: 0pt 0 0pt 49.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In the event that a person becomes an &#8220;Acquiring Person,&#8221;
each holder of a Right (other than the Acquiring Person) would be entitled to acquire a number of shares of preferred stock equivalent
to shares of the Company&#8217;s common stock having a value of twice the exercise price of the Right. If, after any such event,
the Company enters into a merger or other business combination transaction with another entity, each holder of a Right would then
be entitled to purchase, at the then-current exercise price, shares of the acquiring company&#8217;s common stock having a value
of twice the exercise price of the Right.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The current exercise price per Right is $75.00. The Rights may be
redeemed in whole, but not in part, at a price of $0.01 per Right (payable in cash, shares of the Company&#8217;s common stock
or other consideration deemed appropriate by the Board of Directors) by the Board of Directors only until the earlier of :</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">(1)&nbsp;The time at which any person becomes an &#8220;Acquiring
Person,&#8221; or</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">(2)&nbsp;The Expiration Date.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At any time after any person becomes an
&ldquo;Acquiring Person,&rdquo; the Board of Directors may, at its option, exchange all or any part of the then outstanding and
exercisable Rights for shares of the Company&rsquo;s common stock at an exchange ratio specified in the 2008 Plan. Notwithstanding
the foregoing, the Board of Directors generally will not be empowered to affect such exchange at any time after any person becomes
the beneficial owner of 50% or more of the Company&rsquo;s common stock.</P>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the establishment of
the 2008 Plan, the Board of Directors approved the creation of Preferred Stock of the Company designated as Series&nbsp;B Junior
Participating Cumulative Preferred Stock with a par value of $0.01 per share. The Board also reserved 175,000 shares of preferred
stock for issuance upon exercise of the Rights. Until a Right is exercised, the holder will have no rights as a stockholder of
the Company, beyond those as an existing stockholder, including the right to vote or to receive dividends.</P>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>15. Employee Benefit Plan</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">U.S. employees are eligible to participate in the Company&#8217;s
401(k) savings plan. Employees may elect to contribute a percentage of their compensation to the plan, and the Company will make
matching contributions up to a limit of 5% of an employee&#8217;s eligible compensation. In addition, the Company may make annual
discretionary contributions. The Company made matching contributions of approximately $350 thousand, $350 thousand, and $362 thousand,
for the years ended December&nbsp;31, 2015, 2014, and 2013, respectively.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 60; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>16. Revenue by Product Group, by Significant Customer and by Geographic Region; Geographic
Information</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Product revenue by product group is as follows (in thousands, except
percentages):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="23" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of Product Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of Product Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of Product Revenue</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; font-size: 10pt; text-align: left; padding-left: 12px">Orthobiologics</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">73,247</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">84</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">61,957</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">82</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">55,956</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">78</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Dermal</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,266</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,334</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,817</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Surgical</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,812</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,855</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,446</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,371</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,328</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,555</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">87,696</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">75,474</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,774</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Product revenue by significant customers as a percent of product
revenues is as follows:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of Product Revenue<br> Years Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left; padding-left: 12px">Mitek</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">72</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">72</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">63</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Boehringer</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Medtronic</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Nordic Pharma</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Pharmascience</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 12px">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">84</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">84</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">76</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table></div>




<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Total revenue by geographic location based on the location of the
customer in total and as a percentage of total revenue are as follows (in thousands, except percentages):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;<b></b></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="23" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br> Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br> Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br> Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br> Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br> Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br> Revenue</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Geographic Location:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 22%; font-size: 10pt; text-align: left; padding-left: 12px">United States</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">76,621</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">82</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">92,259</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">87</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">58,490</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">78</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 12px">Europe</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,756</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,215</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,412</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,622</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,121</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,179</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">92,999</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">105,595</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">75,081</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table></div>




<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company recorded licensing, milestone, and contract revenue of
$5.3 million, $30.1 million and $3.3 million for the years ended December&nbsp;31, 2015, 2014, and 2013, respectively. Substantially
all licensing, milestone, and contract revenue was derived in the United States for each year presented.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Net long-lived assets, consisting of net property and equipment,
are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area
in a reasonable time period and because they are relatively illiquid. Net tangible long-lived assets by principal geographic areas
were as follows (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 12px">United States</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">39,732</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">31,059</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Italy</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">376</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">610</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">40,108</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">31,669</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>




<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 61; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>17. Income Taxes</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Income Tax Expense</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The components of the Company&#8217;s income before income taxes
and our provision for (benefit from) income taxes consist of the following (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Income (loss) before income taxes</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; padding-left: 20pt">Domestic</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">48,608</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">63,232</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">33,061</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 20pt">Foreign</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(354</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,727</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(581</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,254</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">61,505</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">32,480</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Provision for (benefit from) income taxes:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Current provision:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; padding-left: 20pt">Federal</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">14,572</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">18,301</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">8,024</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 20pt">State</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,635</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,895</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,581</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 20pt">Foreign</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">249</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">192</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">94</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18,456</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,388</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,699</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred provision:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 20pt">Federal</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(370</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,153</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,375</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 20pt">State</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(33</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">122</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">115</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 20pt">Foreign</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(557</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(477</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(284</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(960</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">798</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,206</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total provision</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,496</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">23,186</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,905</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Deferred Tax Assets and Liabilities</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Significant components of the Company&#8217;s deferred tax assets
and liabilities consist of the following (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt">Net operating loss carry forward, foreign</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">1,567</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">2,292</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,043</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">755</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Foreign currency exchange</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">762</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">353</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accrued expenses and other</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">510</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">527</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Inventory reserve</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">547</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">334</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Tax credit carry forward</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">46</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Deferred tax assets</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,429</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,307</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred tax liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt">Acquisition-related Intangibles</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(3,738</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(4,827</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,466</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,221</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(11,204</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(12,048</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(6,775</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(7,741</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td></tr>
</table></div>




<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 62; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><i>Tax Rate</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The reconciliation between the U.S. federal statutory rate and our
effective rate is summarized as follows:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">Statutory federal income tax rate</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">35.0</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">35.0</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">35.0</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State tax expense, net of federal benefit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.8</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.9</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.8</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Permanent items, including nondeductible expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.3</td><td style="font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.1</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.2</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State investment tax credit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.1</td><td style="font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.1</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Federal, state and foreign research and development credits</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.4</td><td style="font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.7</td><td style="font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.5</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Foreign rate differential</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.1</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.2</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.1</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Domestic production deduction</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2.9</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1.7</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2.4</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Effective income tax rate</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">36.3</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">37.7</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">36.7</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of December 31, 2015, the Company had NOL&#8217;s for income tax
purposes in Italy of $6.3 million with no expiration date.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Accounting for Uncertainty in Income Taxes</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company had no unrecognized tax benefits for the years ended
December 31, 2015 and 2014, respectively. A reconciliation of the beginning and ending amount of our unrecognized tax benefits
is summarized as follows (in thousands):</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended <br>
December 31, 2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; text-align: left">Unrecognized tax benefit, beginning of year</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">56</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Tax positions related to current year</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Tax positions related to prior years</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Statute expirations</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(56</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Unrecognized tax benefit, end of year</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">In the normal course of business,
Anika and its subsidiaries may be periodically examined by various taxing authorities. The Company files income tax returns in
the U.S.&nbsp;federal jurisdiction, in certain U.S. states, and in Italy. The associated tax filings remain subject to examination
by applicable tax authorities for a certain length of time following the tax year to which those filings relate. The 2012 through
2015 tax years remain subject to examination by the IRS and other taxing authorities for U.S. federal and state tax purposes. The
2011 through 2015 tax years remain subject to examination by the appropriate governmental authorities for Italy. </font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white"></FONT></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"><FONT STYLE="background-color: white">The Company does not anticipate
experiencing any significant increases or decreases in our unrecognized tax benefits within the twelve months following December
31, 2015.</FONT></P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="background-color: white"></font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company incurred expenses related to stock-based compensation
in 2015, 2014, and 2013 of $2.2 million, $1.6 million, and $1.3 million, respectively. Accounting for the tax effects of certain
stock-based awards requires that the Company establish a deferred tax asset as the compensation expense is recognized for financial
reporting prior to recognizing the related tax deduction upon exercise of the awards. The gross tax benefit recognized in the consolidated
statement of operations related to stock-based compensation totaled $1.1 million, $3.1 million, and $2.0 million in 2015, 2014,
and 2013, respectively.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Upon the settlement of certain stock-based awards (i.e., exercise,
vesting, forfeiture, or cancellation), the actual tax deduction is compared with cumulative financial reporting compensation cost
and any excess tax deduction related to these awards is considered a windfall tax benefit. Such benefits are tracked in a &#8220;windfall
tax benefit pool&#8221; to offset any future tax deduction shortfalls, and they will be recorded as increases to additional paid-in
capital in the period when the tax deduction reduces income taxes payable. The Company follows the with-and-without approach for
the direct effects of windfall/shortfall items and to determine the timing of the recognition of any related benefits. The Company
recorded a net windfall of $0.9 million, $9.6 million and $0.9 million in 2015, 2014, and 2013, respectively.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt"></p>

<!-- Field: Page; Sequence: 63; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt"><b>18. Quarterly Financial Data (Unaudited)</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1pt solid"><b>Year 2015</b></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quarter ended<br> December 31,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quarter ended<br> September 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quarter ended<br> June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quarter ended<br> March 31,</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left">Product revenue</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">25,607</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">23,676</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">22,898</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">15,515</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,894</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">23,681</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,904</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,520</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cost of product revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,290</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,176</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,274</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,313</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Gross profit on product revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">19,317</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">18,500</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,624</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,202</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">11,042</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,380</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7,820</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">3,516</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Per common share information:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Basic net income per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.74</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.56</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.52</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.24</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic common shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,965</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,967</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,961</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,905</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Diluted net income per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.72</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.55</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.51</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.23</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Diluted common shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,353</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,316</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,336</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,330</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1pt solid"><b>Year 2014</b></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quarter ended<br> December 31,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quarter ended<br> September 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quarter ended<br> June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quarter ended<br> March 31,</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left">Product revenue</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">17,880</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">21,975</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">21,267</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">14,352</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">23,255</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,055</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26,275</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">34,010</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cost of product revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,511</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,725</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,333</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,361</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Gross profit on product revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,369</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,250</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,934</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,991</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7,816</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">6,171</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9,302</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">15,030</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Per common share information:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Basic net income per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.53</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.42</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.63</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.04</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic common shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,801</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,759</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,688</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,461</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Diluted net income per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.51</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.40</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.60</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.97</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Diluted common shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,278</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,435</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,493</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,499</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>





<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p></div><p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>19. Subsequent Events</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On February 26, 2016, the Company entered into an accelerated stock
repurchase agreement with Morgan Stanley &amp; Co. LLC (&#8220;Morgan Stanley&#8221;) pursuant to a Fixed Dollar Accelerated Share
Repurchase Transaction ("ASR Agreement") to purchase $25.0 million of shares of its common stock. Pursuant to the terms
of the ASR Agreement, the Company paid Morgan Stanley&nbsp;$25.0 million&nbsp;in cash and received an initial delivery of 377,155
shares&nbsp;of the Company&#8217;s common stock on&nbsp;February 29, 2016. The total number of shares to be repurchased will be
based generally on the daily volume-weighted average share prices of the Company&#8217;s common stock during the term of the transaction.
At settlement, Morgan Stanley may be required to deliver additional shares of common stock to the Company, or, under certain circumstances,
the Company may be required to deliver shares of its common stock or may elect to make a cash payment to Morgan Stanley. Final
settlement of the ASR Agreement is expected to be completed in&nbsp;the third quarter of 2016, although the settlement may be accelerated
at Morgan Stanley&#8217;s option or extended, in either case subject to certain terms and conditions.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 64; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><a name="i9"></a><b>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">None.</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i9a"></a><b>ITEM 9A. CONTROLS AND PROCEDURES</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 8%">(a)</td>
    <td style="width: 84%">Evaluation of disclosure controls and procedures.</td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As required by Rule&nbsp;13a-15 under the Securities Exchange Act
of 1934 (&#8220;Exchange Act&#8221;), we carried out an evaluation under the supervision and with the participation of our management,
including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure
controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the chief executive officer
and chief financial officer have concluded that our disclosure controls and procedures are effective as of December 31, 2015 to
ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls
and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed
by our company in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including
our chief executive officer and chief financial officer, or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure. On an on-going basis, we review and document our disclosure controls and procedures, and
our internal control over financial reporting, and we may from time to time make changes aimed at enhancing their effectiveness
and ensuring that our systems evolve with our business.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 8%">(b)</td>
    <td style="width: 84%">Changes in internal controls over financial reporting.</td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">There were no changes in our internal control over financial reporting
during the fourth quarter of fiscal year 2015 that have materially affected, or that are reasonably likely to materially affect,
our internal controls over financial reporting.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Management&#8217;s Report on Internal Control over Financial Reporting</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our management is responsible for establishing and maintaining adequate
internal control over financial reporting as defined in Rules&nbsp;13a-15(f) and 15d-15(f) under the Exchange Act. Our internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Because of its inherent limitations, internal control over financial
reporting can provide only reasonable assurance, and it may not prevent or detect misstatements. Also, projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our management assessed the effectiveness of our internal control
over financial reporting as of December&nbsp;31, 2015. In making this assessment, management used the criteria set forth by the
Committee of Sponsoring Organizations of the Treadway Commission in<i> Internal Control&#8212;Integrated Framework</i> as issued
in 2013.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Based on our assessment and those criteria, our management believes
that our company maintained effective internal control over financial reporting as of December&nbsp;31, 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The effectiveness of our internal control over financial reporting
as of December&nbsp;31, 2015 has been audited by PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm,
as stated in their report which is included elsewhere in this Annual Report on Form 10-K.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i9b"></a><b>ITEM 9B. OTHER INFORMATION</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">None.</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 65; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="p3"></a><b>PART III</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i10"></a><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The information required under this item is incorporated herein by
reference to our definitive proxy statement pursuant to Regulation&nbsp;14A, which proxy statement will be filed with the SEC not
later than 120&nbsp;days after the close of our fiscal year ended December&nbsp;31, 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i11"></a><b>ITEM 11. EXECUTIVE COMPENSATION</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The information required under this item is incorporated herein by
reference to our definitive proxy statement pursuant to Regulation&nbsp;14A, which proxy statement will be filed with the SEC not
later than 120&nbsp;days after the close of our fiscal year ended December&nbsp;31, 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i12"></a><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The information required under this item and Item&nbsp;5 of this
Annual Report on Form&nbsp;10-K under the heading &#8220;Equity Compensation Plan Information&#8221; is incorporated herein by
reference to our definitive proxy statement pursuant to Regulation&nbsp;14A, which proxy statement will be filed with the SEC not
later than 120&nbsp;days after the close of our fiscal year ended December&nbsp;31, 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i13"></a><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The information required under this item is incorporated herein by
reference to our definitive proxy statement pursuant to Regulation&nbsp;14A, which proxy statement will be filed with the SEC not
later than 120&nbsp;days after the close of our fiscal year ended December&nbsp;31, 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i14"></a><b>ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The information required under this item is incorporated herein by
reference to our definitive proxy statement pursuant to Regulation&nbsp;14A, which proxy statement will be filed with the SEC not
later than 120&nbsp;days after the close of our fiscal year ended December&nbsp;31, 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="p4"></a>PART IV</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="i15"></a><b>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%">(a)</td>
    <td style="width: 91%">Documents filed as part of Form&nbsp;10-K.</td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 11%">&nbsp;</td>
    <td style="width: 11%">(1)</td>
    <td style="width: 78%">Financial Statements</td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 89%; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">Report of Independent Registered Public Accounting Firm</td>
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">41</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">Consolidated Balance Sheets</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">42</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">Consolidated Statements of Operations and Comprehensive Income</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">43</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">Consolidated Statements of Stockholder&#8217;s Equity</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">44</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">Consolidated Statements of Cash Flows</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">45</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">Notes to Consolidated Financial Statements</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">46-64</td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 11%">&nbsp;</td>
    <td style="width: 11%">(2)</td>
    <td style="width: 78%">Schedules</td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Schedules have been omitted as all required information has been
disclosed in the financial statements and related footnotes.</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 66; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 11%">&nbsp;</td>
    <td style="width: 11%">(3)</td>
    <td style="width: 78%">Exhibits</td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The list of Exhibits filed as a part of this Annual Report on Form&nbsp;10-K
is set forth in the Exhibit Index (b)&nbsp;below.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: top; padding-right: 2.9pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 2.9pt; padding-left: 2.9pt">&nbsp;</td>
    <td rowspan="2" style="vertical-align: bottom; padding-right: 1.45pt; padding-left: 1.45pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Filed</b><br>
<b>with this</b><br>
<b>Form 10-K</b></p></td>
    <td colspan="3" style="vertical-align: bottom; padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Incorporated by Reference</b></p></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 2.9pt; padding-left: 2.9pt; text-align: center">
        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt"><b>Exhibit Number</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Description</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Form</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Filing Date</b><br>
<b>with SEC</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Exhibit Number</b></p></td></tr>
<tr style="vertical-align: top">
    <td style="width: 10%; padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="width: 50%; padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">&nbsp;</td>
    <td style="width: 8%; padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="width: 8%; padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="width: 17%; padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="width: 7%; padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt"><i>Restated Articles of Organization, as amended, of Anika Therapeutics, Inc. (with date of filing with Secretary of State of the Commonwealth of Massachusetts):</i></td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">3.1a</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(a)	Restated Articles of Organization (April 29, 1993)</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">March 13, 2015</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">3.1a</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">3.1b</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(b)	Certificate of Correction (November 10, 1993)</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">March 13, 2015</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">3.1b</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">3.1c</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(c)	Certificate of Vote of Directors Establishing a Series of a Class of Stock (May 18, 1995)</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">March 13, 2015</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">3.1c</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">3.1d</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(d)	Articles of Amendment (January 9, 1997) </td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-QSB</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">January 14, 1997</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">3.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">3.1e</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(e)	Certificate of Vote of Directors Establishing a Series of a Class of Stock (April 7, 1998)</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">March 13, 2015</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">3.1e</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">3.1f</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(f)	Articles of Amendment (June 3, 1998)</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-QSB</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">August 13, 1998</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">3.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">3.1g</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(g)	Articles of Amendment (April 4, 2008)</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">March 9, 2009</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">3.7</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">3.2</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Amended and Restated Bylaws of Anika Therapeutics, Inc.</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-Q</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">August 14, 2002</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">3.6</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">4.1</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Shareholder Rights Agreement, dated as of April 7, 2008, between Anika Therapeutics, Inc. and American Stock Transfer &amp; Trust Company</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-A12B</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">April 7, 2008</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">4.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">10.1</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Lease, dated January 3, 2007, between Anika Therapeutics, Inc. and Farley White Wiggins, LLC, relating to 32 Wiggins Avenue, Bedford, Massachusetts</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">January 10, 2007</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">10.2</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Lease Agreement, dated December 30, 2009, between Fidia Farmaceutici S.p.A. and Fidia Advanced Biopolymers S.r.l., relating to Via Ponte della Fabbrica 3/A and 3/B Abano Terme, Padua, Italy</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">January 6, 2010</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.2</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">10.3</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Translation of Lease Agreement, dated October 9, 2015, between Anika Therapeutics S.r.l. and Consorzio Zona Industriale E Porto Fluviale di Padova relating to Land Registry of the Municipality of Padova, Page 148, cadastral map 516 and 517</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">October 14, 2015</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt"><i>Credit Agreement with Bank of America, N.A.:</i></td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">10.4a</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(a)	Credit Agreement, dated as of January 31, 2008, among Anika Therapeutics, Inc., Anika Securities, Inc. and Bank of America, N.A., as administrative agent</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">February 6, 2008</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">10.4b</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(b)	Consent and First Amendment, dated as of December&nbsp;30, 2009, by and among Anika Therapeutics, Inc., Anika Securities, Inc. and Bank of America, N.A., as administrative agent</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">January 6, 2010</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.4</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">10.4c</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(c)	Pledge Agreement on a Quota of Fidia Advanced Biopolymers S.r.l., dated March 12, 2010, by Anika Therapeutics, Inc. in favor of Bank of America, N.A., as agent bank</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-Q</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">May 10, 2010</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">10.5</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Sale and Purchase Agreement, dated December 30, 2009, by and between Fidia Farmaceutici S.p.A. and Anika Therapeutics, Inc.</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">January 6, 2010</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">2.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center"></td></tr></table>

<!-- Field: Page; Sequence: 67; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"><tr><td style="vertical-align: top; padding-right: 2.9pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 2.9pt; padding-left: 2.9pt">&nbsp;</td>
    <td rowspan="2" style="vertical-align: bottom; padding-right: 1.45pt; padding-left: 1.45pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Filed</b><br>
<b>with this</b><br>
<b>Form 10-K</b></p></td>
    <td colspan="3" style="vertical-align: bottom; padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Incorporated by Reference</b></p></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 2.9pt; padding-left: 2.9pt; text-align: center">
        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt"><b>Exhibit Number</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Description</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Form</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Filing Date</b><br>
<b>with SEC</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Exhibit Number</b></p></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center; width: 10%">10.6</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; width: 50%">Tolling Agreement, dated December 30, 2009, between Fidia Farmaceutici S.p.A. and Fidia Advanced Biopolymers S.r.l</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center; width: 8%">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify; width: 8%">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; width: 17%">January 6, 2010</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right; width: 7%">10.3</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">10.7</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Registration Rights Agreement, dated December 30, 2009, between Anika Therapeutics, Inc. and Fidia Farmaceutici S.p.A.</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">January 6, 2010</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">*10.8</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">License Agreement, dated as of December 21, 2011, by and between Anika Therapeutics, Inc. and DePuy Mitek, Inc.</td>
    <td style="padding-right: 1.45pt; padding-bottom: 3pt; padding-left: 1.45pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">December 22, 2011</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt"><i>2003 Stock Option and Incentive Plan:</i></td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.9a</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(a)	Second Amended and Restated 2003 Stock Option and Incentive Plan (adopted April 5, 2011)</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">June 10, 2011</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.9b</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(b)	Amendment to Second Amended and Restated 2003 Stock Option and Incentive Plan (adopted April&nbsp;11, 2013)</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">June 21, 2013</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.9c</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(c)	Form of Incentive Stock Option Agreement </td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">October 5, 2004</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.3</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.9d</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(d)	Form of Non-Qualified Stock Option Agreement for Non-Employee Directors</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">October 5, 2004</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.4</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.9e</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(e)	Form of Performance Share Award Agreement</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">February 6, 2008</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.3</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.9f</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(f)	Form of Restricted Deferred Stock Unit Award Agreement for Non-Employee Directors</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">March 9, 2009</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.25</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.9g</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(g)	Form of Restricted Stock Award Agreement for Employees </td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">March 12, 2008</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.27</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.9h</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(h)	Form of Stock Appreciation Right Agreement for Employees</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-Q</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">May 9, 2006</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.9i</td>
    <td style="padding-bottom: 3pt; padding-left: 15.3pt; text-indent: -15.3pt">(i)	Form of Stock Appreciation Right Agreement for Non-Employee Directors</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-Q</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">May 9, 2006</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.2</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.10</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Anika Therapeutics, Inc. Senior Executive Incentive Compensation Plan</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">February 6, 2008</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.2</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.11</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Anika Therapeutics, Inc. Non-Employee Director Compensation Policy</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">March 12, 2008</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.28</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.12a</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Employment Agreement, dated March 22, 2010, between Anika Therapeutics, Inc. and Sylvia Cheung</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">May 5, 2014</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.42</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.12b</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Amendment No. 1 to the Employment Agreement, dated December 8, 2010, by and between Anika Therapeutics, Inc. and Sylvia Cheung</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">May 5, 2014</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.43</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.13a</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Employment Agreement, dated September 10, 2009, between Anika Therapeutics, Inc. and Frank J. Luppino</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">September 14, 2009</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.13b</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Amendment No. 1 to Employment Agreement, dated December 1, 2010, by and between Anika Therapeutics, Inc. and Frank J. Luppino</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">March 16, 2011</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.35</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.14a</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Employment Agreement, dated September 10, 2009, between Anika Therapeutics, Inc. and William J. Mrachek</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">September 14, 2009</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.2</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.14b</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Amendment No. 1 to Employment Agreement, dated December 1, 2010, by and between Anika Therapeutics, Inc. and William J. Mrachek</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">March 16, 2011</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.36</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.15</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Employment Agreement, dated October 17, 2008, between Anika Therapeutics, Inc. and Kevin Quinlan</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">October 22, 2008 </td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.2</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.16a</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Employment Agreement, dated October 17, 2008, between Anika Therapeutics, Inc. and Charles H. Sherwood, Ph.D.</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">October 22, 2008 </td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.16b</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Amendment No. 1 to Employment Agreement, dated December 8, 2010, by and between Anika Therapeutics, Inc. and Charles H. Sherwood, Ph.D.</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">March 16, 2011</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.33</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center"></td></tr></table>

<!-- Field: Page; Sequence: 68; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"><tr><td style="vertical-align: top; padding-right: 2.9pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 2.9pt; padding-left: 2.9pt">&nbsp;</td>
    <td rowspan="2" style="vertical-align: bottom; padding-right: 1.45pt; padding-left: 1.45pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Filed</b><br>
<b>with this</b><br>
<b>Form 10-K</b></p></td>
    <td colspan="3" style="vertical-align: bottom; padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Incorporated by Reference</b></p></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 2.9pt; padding-left: 2.9pt; text-align: center">
        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt"><b>Exhibit Number</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Description</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Form</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Filing Date</b><br>
<b>with SEC</b></p></td>
    <td style="padding-right: 2.9pt; padding-left: 2.9pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: Black 0.5pt solid"><b>Exhibit Number</b></p></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center; width: 10%">&#8224;10.17</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; width: 50%">Separation Agreement, effective November 26, 2014, by and between Anika Therapeutics, Inc. and Carol Barnett </td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center; width: 8%">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify; width: 8%">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; width: 17%">March 13, 2015</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right; width: 7%">10.16</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.18</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Separation Agreement, effective November 7, 2014, by and between Anika Therapeutics, Inc. and John W. Sheets</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">10-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">March 13, 2015</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.17</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&#8224;10.19</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Consulting Agreement, effective December 8, 2015, by and between Anika Therapeutics, Inc. and John C. Moran</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">8-K</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">December 9, 2015</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">10.1</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">21.1</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">List of Subsidiaries of Anika Therapeutics, Inc.</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">X</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">23.1</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Consent of PricewaterhouseCoopers<font style="font-size: 10pt"> LLP</font></td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">X</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">31.1</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Certification of Principal Executive Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">X</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">31.2</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">X</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">**32.1</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">X</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">***101</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">The following materials from the Annual Report on Form 10-K of Anika Therapeutics, Inc. for the fiscal year ended December&nbsp;31, 2015, formatted in xBRL:&nbsp;&nbsp;(i)&nbsp;Consolidated Balance Sheets as of December 31, 2015 and December 31, 2014; (ii) Consolidated Statements of Operations for the Years Ended December 31, 2015, December 31, 2014, and December 31, 2013; (iii) Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December&nbsp;31, 2015, December 31, 2014, and December 31, 2013; (iv) Consolidated Statements of Cash Flows for the Years Ended December 31, 2015, December 31, 2014, and December 31, 2013; and (v)&nbsp;Notes to Consolidated Financial Statements</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: center">X</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt">&nbsp;</td>
    <td style="padding-right: 2.9pt; padding-bottom: 3pt; padding-left: 2.9pt; text-align: right">&nbsp;</td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8224;</td>
    <td style="width: 95%; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: justify">Management contract or compensatory plan or arrangement.</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">*</td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: justify">Certain portions of this document have been omitted pursuant to a confidential treatment request filed with the Securities and Commission. The omitted portions have been filed separately with the Commission.</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">**</td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: justify">The certification attached as Exhibit 32.1 that accompanies this Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Anika Therapeutics, Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">***</td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: justify">Pursuant to Rule 406T of Regulation S-T, XBRL (Extensible Business Reporting Language) information is deemed not filed or a part of a registration statement or prospectus for purposes of sections&nbsp;11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section&nbsp;18 of the Securities Exchange Act of 1934 and otherwise is not subject to liability under these sections.</td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 69; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --> -</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="sign"></a><b>SIGNATURES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="margin-top: 0; margin-bottom: 0"><font style="font-size: 10pt">ANIKA THERAPEUTICS,&nbsp;INC.</font></p>
                                                                      <p style="margin-top: 0; margin-bottom: 0">&nbsp;</p></td></tr>
<tr style="vertical-align: top">
    <td style="width: 38%; padding-right: 5.4pt; padding-left: 19.8pt; text-indent: -19.8pt"><font style="font-size: 10pt">Date: March 10, 2016</font></td>
    <td style="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">By:</font></td>
    <td style="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0"><u>/s/ CHARLES H. SHERWOOD, PH.D.</u></p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0">Charles H. Sherwood, Ph.D.</p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0"><i>President and Chief Executive Officer</i></p></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>SIGNATURES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 38%; padding-right: 5.4pt; padding-left: 26.1pt; text-align: center"><font style="font-size: 10pt"><b>Signature</b></font></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-bottom: 1.1pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt"><b>Title</b></font></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-bottom: 1.1pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt"><b>Date</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 26.1pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-bottom: 1.1pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-bottom: 1.1pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt"><u>/s/ CHARLES H. SHERWOOD, PH.D.&nbsp;</u></p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">Charles H. Sherwood, Ph.D.</p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">&nbsp;</p></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; margin: 0pt 0 0pt 26.1pt">President and Chief Executive Officer <BR>
Director&nbsp;</p>
        <p style="font-size: 10pt; margin: 0pt 0 0pt 26.1pt"><i>(Principal Executive Officer)</i></p>
        <p style="font-size: 10pt; margin: 0pt 0 0pt 26.1pt">&nbsp;</p></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">March 10, 2016</font></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt"><u>/s/ SYLVIA CHEUNG&nbsp;</u></p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">Sylvia Cheung</p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">&nbsp;</p></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; margin: 0pt 0 0pt 26.1pt">Chief Financial Officer&nbsp;</p>
        <p style="font-size: 10pt; margin: 0pt 0 0pt 26.1pt"><i>(Principal Accounting Officer)</i></p>
        <p style="font-size: 10pt; margin: 0pt 0 0pt 26.1pt">&nbsp;</p></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">March 10, 2016</FONT></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt"><u>/s/ JOSEPH L. BOWER&nbsp;</u></p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">Joseph L. Bower</p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">&nbsp;</p></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 26.1pt"><font style="font-size: 10pt">Director</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">March 10, 2016</FONT></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt"><u>/s/ RAYMOND J. LAND&nbsp;</u></p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">Raymond J. Land</p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">&nbsp;</p></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 26.1pt">
        Director</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">March 10, 2016</FONT></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt"><u>/s/ GLENN R. LARSEN, PH.D.&nbsp;</u></p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">Glenn R. Larsen</p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">&nbsp;</p></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 26.1pt"><font style="font-size: 10pt">Director</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">March 10, 2016</FONT></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt"><u>/s/ JEFFERY S. THOMPSON&nbsp;</u></p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">Jeffery S. Thompson</p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">&nbsp;</p></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 26.1pt"><font style="font-size: 10pt">Director</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">March 10, 2016</FONT></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt"><u>/s/ STEVEN E. WHEELER&nbsp;</u></p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">Steven E. Wheeler</p>
        <p style="font-size: 10pt; text-indent: -19.8pt; margin: 0pt 0 0pt 26.1pt">&nbsp;</p></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 26.1pt"><font style="font-size: 10pt">Director</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">March 10, 2016</FONT></td></tr>
</table>
<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">70</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
